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Since 1991 our research group and others have investigated children with short stature 
who were born small for gestational age (SGA), both before and during treatment with 
biosynthetic growth hormone (GH). Because of these efforts and the positive results, 
GH treatment was licensed for short SGA children in 2005. However, many questions 
remained unanswered, for instance about the association between low birth weight and 
the risk to develop type 2 diabetes mellitus (DM) or cardiovascular disease (CVD) in 
adulthood and the effect of GH treatment on such associations.
 This doctoral thesis describes studies that evaluated metabolic and cardiovascular 
risk factors in short children born SGA and the association of these risk factors with family 
history, preterm birth, GH treatment, serum insulin-like growth factor binding protein-2 
(IGFBP-2) levels and genetic polymorphisms. This first chapter describes definitions, 
prevalence and etiologies of SGA, and clinical and endocrinological aspects associated 
with SGA. Finally, the aims of the study and outline of this thesis are described.
1. SMAll for GeStAtionAl AGe (SGA)
1.1 Definition of SGA
The term “small for gestational age” (SGA) describes the size of an infant at birth. SGA 
children can be born either preterm or term. In order to determine whether a child is born 
SGA, one needs accurate information on gestational age, birth weight, birth length and an 
appropriate reference population to calculate standard deviation scores for birth weight 
and/or birth length (1). SGA is defined as a birth weight and / or length at least 2 standard 
deviations (SDS) below the mean for gestational age (2). In the Dutch multicenter studies 
from which the data in this thesis are derived, the neonatal growth chart from Usher and 
McLean was used as the reference (3). Segregation of SGA children from their peers is 
somewhat arbitrary but < - 2 SD was selected because it likely encompasses the majority 
of patients with disordered fetal growth (2).
 SGA birth can be the consequence of intrauterine growth retardation (IUGR) but 
fetal growth may also have been insufficient from the beginning of gestation without 
the occurrence of fetal growth deceleration. A child with IUGR late in gestation will not 
necessarily be born SGA. These different fetal growth patterns are shown in Figure 1. To 
diagnose IUGR at least two ultrasound measurements are necessary. Because detailed 
information on fetal growth does often not exist, it is better to refer to an infant with a low 
birth weight or low birth length for gestational age as SGA rather than IUGR. 
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1.2 Prevalence and etiology of SGA
By definition, approximately 2.3% of all live-born neonates are born SGA. In 2007, 181,336 
infants were live-born in the Netherlands (Central Bureau of Statistics, Voorburg, the 
Netherlands). According to the definition, 4171 of them were born SGA. 
  SGA might be the result of various etiologies but in 40% of the infants born SGA 
the underlying mechanism remains unclear. Nevertheless it is important to try to identify 
the underlying cause because this may have consequences for prognosis and treatment. 
Fetal growth restriction can originate from a number of fetal, maternal, placental, and 
+2 SD
0 SD
-2 SD
LGA
AGA
SGA
gestation    birth
SGA and IUGR
IUGR but not SGA
SGA but not IUGR
Figure 1. Fetal growth chart showing various intrauterine growth patterns
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demographic factors (4, 5).
 Fetal factors include chromosomal disorders (e.g. Down syndrome, Turner syndrome), 
congenital defects (e.g. cardiac abnormalities, Potter syndrome), metabolic diseases, 
and genetic disorders (e.g. achondroplasia, Bloom syndrome).
 Maternal factors include age (very young or older age), tobacco smoking, alcohol 
abuse, use of therapeutic (e.g. anticonvulsants, anticoagulants) or illicit drugs (e.g. 
heroin, cocaine) and maternal medical conditions, such as infection (e.g. Toxoplasmosis, 
Rubella, Cytomegalovirus, Herpes virus, Malaria, HIV, Trypanosomiasis), hypertension, 
renal disease, diabetes mellitus, collagen vascular diseases (e.g. systemic lupus 
erythematosus), cyanotic heart disease, chronic anemia, or chronic pulmonary disease.
 Placental factors are associated with problems in placental perfusion resulting in 
reduced fetal oxygenation. These include structural abnormalities of the placenta (e.g. 
single umbilical artery, velamentous umbilical cord insertion, bilobate placenta, placental 
hemangiomas, infarcts or focal lesions), maternal or fetal thrombophilia, and suboptimal 
implantation site.
 Demographic factors include maternal and paternal height and race, parity (e.g. 
nulliparity or grand multiparity), previous delivery of SGA infants and multiple gestation, 
particularly in case of shared fetal circulation.
2. CliniCAl And endoCrinoloGiCAl ASpeCtS ASSoCiAted witH SGA
2.1 Short stature
SGA is a common cause of short stature in childhood and adulthood, accounting for 22% 
of all cases (6). Most children born SGA show spontaneous catch-up growth to a normal 
height above – 2 SD. However, 10-15% of them do not and remain short (7, 8). Catch-
up growth is most pronounced during the first 6 months and is usually completed in the 
first 2 years of life. In premature infants catch-up growth may take longer (7, 9). The 
difference between preterm and full-term SGA children in the timing of catch-up growth 
was explained by differences in the distance between height SDS at the age of 2 years 
and target height SDS and by differences between height SDS at the age of 2 years and 
birth length SDS (9). The difference in length of gestation had no effect on the timing of 
catch-up growth (7, 9). By the age of 8 years, 91% of the SGA born children had reached 
a height > - 2 SDS (9). The risk of having a short height as an adult (< - 2 SD) is five times 
higher for children with a low birth weight and seven times higher for those with a low 
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birth length in comparison with children with a normal birth size (8). Without catch-up 
growth, SGA born children reached a mean adult height of 161.9 (± 8.0) cm for boys and 
147.6 (± 7.0) cm for girls, significantly below the target heights of these children (10). 
Short children who are born SGA without signs of catch-up growth at the age of 3 years 
are not likely to catch-up to a normal height later on. These children should be referred 
to a pediatrician with expertise in endocrinology (2).
2.2 Growth hormone, insulin-like growth factors and IGF-binding proteins
Postnatal growth and development are coordinated by genetic and environmental 
influences and numerous growth factors (11). The growth hormone-insulin-like 
growth factor-I (GH-IGF-I) axis (Figure 2) plays an important role in these growth 
processes. GH is secreted by the pituitary gland under control of the hypothalamic 
hormones GH-releasing hormone (GHRH) and somatostatin, as well as ghrelin, 
a hormone mainly produced in the stomach (12). GHRH and ghrelin bind to their 
receptors in the pituitary and stimulate GH secretion. Somatostatin inhibits GH 
release. Most of the anabolic actions of GH are mediated by insulin-like growth factor-I 
(IGF-I), but GH has also many cellular effects that are independent of IGF-I (11). 
 The IGF system consists of IGF-I, IGF-II and insulin and three closely related 
membrane-bound receptors. IGF-I and IGF-II show structural and functional similarity with 
insulin because they share approximately 50% of their aminoacids, and have important 
anabolic and metabolic effects. IGF-I is present as circulating IGF-I produced by the liver 
and as extra-hepatic IGF-I produced by local tissues and acting in a autocrine/paracrine 
way (13). 
 The majority of circulating IGF-I is bound to IGF binding proteins (IGFBPs), of which 
six classes have been identified. IGFBP-3 is the most important carrier protein of IGF-I 
and binds 70-95% of IGF-I as a binary complex or as a ternary complex together with 
the acid-labile subunit (ALS) (14). IGFBP-3 and ALS are both regulated by GH. IGFBP-2 
is the second most abundant protein in serum and binds both IGF-I and IGF-II (15). 
Apart from its role in regulating the amount of free IGF-I, IGFBP-2 is also thought to 
prevent adipogenesis by impairing adipocyte differentiation (16). In addition, IGFBP-2 is 
inversely associated with insulin levels (17-19) and HOMA insulin resistance (20) but it 
is not clear whether the effect of IGFBP-2 on glucose homeostasis is adiposity related 
or independent from fat mass. Less than 1% of IGF-I is unbound and circulates in its 
free form. An influence of free IGF-I on short-term metabolic changes and on long-term 
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Figure 2. Physiology of the GH-IGF-IGFBP axis. Adapted from Holt (12)
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changes like linear growth has been described and therefore free IGF-I is thought to be 
the biological active form (21, 22).
 The mechanism underlying persistent short stature in SGA children is still unknown 
but disturbances in the GH / insulin-like growth factor-I (IGF-I)-axis may play a role. A 
significant number of short SGA children show a reduced spontaneous GH secretion 
during a 24-hour GH-profile and/or low GH peaks during GH provocation tests (23-27). 
Serum IGF-I and IGFBP-3 levels were also lower in short SGA children than in healthy 
controls with a normal height (28-30). These observations have led to the first GH studies 
in short SGA children. 
2.3 Thyroid hormones
Studies concerning thyroid hormone levels in SGA children were very limited. Short SGA 
children were reported to have higher TSH levels compared to SGA children with catch-
up growth (31), but the gestational age of these children was not mentioned. In another 
study in which only SGA children born at term were included, these results could not be 
replicated (32). One paper suggested that not SGA, but preterm birth is associated with 
higher TSH levels (33). However, this was studied in SGA children with catch-up growth to 
a normal height. There were no data on thyroid hormone levels in term and preterm SGA 
children with persistent short stature.
2.4 Type 2 Diabetes Mellitus and Cardiovascular disease
2.4.1 Historical data and hypotheses
Epidemiological studies reported an inverse association between birth weight and risk 
for hypertension, cardiovascular disease (CVD) and type 2 diabetes mellitus (DM) in adult 
life (34-36). Reduced insulin sensitivity plays an important role in the pathogenesis of 
these disorders (37, 38) but the exact mechanism underlying these associations is still 
unknown. In the past years several hypotheses have been proposed.
 Fetal origins of adult disease hypothesis: In 1989 Barker et al. were the first to 
report an inverse association between birth weight and death rates from ischaemic heart 
disease (39). Based on these observations they formulated their fetal origins hypothesis. 
This hypothesis states that events during pregnancy cause fetal malnutrition and this 
fetal malnutrition leads to permanent endocrine and metabolic alterations in the fetus 
(34, 35). This is called re-programming (Figure 3). In utero the fetus benefits from the 
adaptations but after birth, in the long-term this re-programming results in an increased 
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risk for adult disease. 
 Fetal insulin hypothesis: The fetal insulin hypothesis was formulated in 1999 by 
Hattersley et al. This hypothesis states that the association between low birth weight 
and insulin resistance in adulthood is genetically mediated (40). Insulin is an important 
growth factor in utero. Therefore, parental genes involved in insulin resistance, which are 
passed to the fetus, can result in both low-insulin-mediated fetal growth and in insulin 
resistance in childhood and adulthood (Figure 4).
 Growth acceleration hypothesis: In 2004 Singhal and Lucas postulated the 
hypothesis that not low birth weight per se, but rapid postnatal growth is responsible for 
the increased risk for CVD in later life (Figure 5) (41). SGA fetuses naturally show faster 
Maternal undernutrition
Fetal undernutrition
Maternal or placental 
abnormalities 
Other organ 
malfunction, 
e.g. liver
Decreased 
β-cell mass
Insulin 
resistance
Abnormal 
vascular 
development
Hyperlipidemia Type 2 diabetes
Cardiovascular disease
Hypertension
Figure 3. Representation of the fetal origin hypothesis. Adapted from Barker et al. (35, 111)
Proefschrift Sandra W.K de Kort 20-08-09.indd   16 13-09-2009   16:58:36
16 17
chapter 
1
G
en
er
al
 In
tr
od
uc
tio
n
postnatal growth (while large newborns show growth deceleration (6) because they are 
small relative to their genetic growth potential. Therefore, associations between low birth 
weight and later CVD could be a proxy for the adverse effects of early postnatal growth 
acceleration (41). 
 Fat accumulation hypothesis: Based on measurement of body composition by dual 
energy x-ray absorptiometry (DXA), Leunissen et al. further specified growth acceleration 
into fat accumulation (42). This indicates that small size at birth followed by growth 
in height and weight as such is not a problem as long as a normal amount of fat is 
accumulated. Leunissen et al. also demonstrated that especially rapid weight gain during 
the first 3 months of life is a risk factor for a higher body fat percentage and associated 
Figure 4. Representation of the fetal insulin hypothesis. Adapted from Hattersley et al. (40)
Maternal glucose concentration
Glucose sensing by fetal pancreas
Insulin secretion by fetal pancreas
Insulin mediated growth of fetus
Birth weight
Fetal insulin resistance
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risk for cardiovascular disease in adulthood (43) (Figure 6). 
2.4.2 Assessment of risk for type 2 diabetes mellitus and cardiovascular 
disease
Reduced insulin sensitivity plays an important role in the pathogenesis of CVD and usually 
precedes the first symptoms of disease by many years (37, 38). Therefore measurement 
of insulin sensitivity provides important information on the risk to develop disease in 
later life. An accurate way to measure insulin sensitivity is by means of the frequent 
sampling intravenous glucose tolerance test (FSIGT), with Tolbutamide (44, 45). In a 
group of prepubertal short SGA children with a mean age of 8 years, 8% had an impaired 
oral glucose tolerance test (46). Further studies indicated that short SGA children were 
more insulin resistant than children with short stature who were born appropriate for 
gestational age (AGA) and they had a compensatory higher insulin secretion (47-49). 
The relationship between insulin sensitivity and insulin secretion is best described by 
a hyperbolic function. When insulin sensitivity decreases, more insulin is needed to 
maintain glucose homeostasis (50). If insulin secretion does not change appropriately 
in response to a change in insulin sensitivity, impaired glucose tolerance and ultimately 
type 2 DM will develop (51).
 SGA children and adolescents had a higher systolic blood pressure than references 
(48, 52, 53). Also, SGA children were reported to have more often hypercholesterolemia 
Fetal growth restriction
Postnatal growth acceleration
Development of adult disease
Figure 5. Representation of growth acceleration hypothesis. Adapted from Singhal and Lucas (41)
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(54) and more often serum free fatty acids levels above the normal range (48) than AGA 
children.
 It is well known that obesity is an important risk factor for the development of CVD 
and type 2 DM (55). In children born SGA with spontaneous catch-up in weight, early 
development of adiposity has been reported (56). Short children born SGA, however, 
usually have a lean appearance, as indicated by a low body mass index (BMI) SDS and a 
low sum of skinfolds SDS (52). Further analysis with DXA revealed that body fat percentage 
in short SGA children is significantly reduced compared with reference values (57). 
Any neonate
No growth acceleration in weight Growth acceleration in weight
(especially in the first three months of life)
Unfavourable body composition
Unfavourable lipid profile
Higher blood pressure
Development of adult disease
Lower insulin sensitivity
Figure 6. Representation of fat accumulation hypothesis. Adapted from Leunissen et al. (42)
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2.4.3 Family history
A family history of CVD could be an explanation for the higher prevalence of cardiovascular 
risk factors in subjects born with a lower birth weight (58). Clustering of cardiovascular 
risk factors within families has also been described irrespective of birth weight (59, 60), 
whereas there is also a relation between birth weight of parents and offspring (61, 62). 
Some studies described a relation between birth weight of offspring and subsequent 
cardiovascular mortality of the parents (63, 64). Women who were themselves born 
SGA are reported to be at increased risk of having an SGA infant and they are also at 
increased risk of preeclampsia and gestational diabetes (65). It is unknown whether the 
presence of risk factors for metabolic and CVD in short SGA children can be predicted by 
the presence of risk factors in their parents. 
2.4.4 Single nucleotide polymorphisms and the risk to develop type 2 DM and 
CVd
A polymorphism is a genetic variant, not necessarily related to disease, which exists 
in more than 1% of a normal population. A polymorphism that affects only one base 
is called a Single Nucleotide Polymorphism or SNP. Genome wide association studies 
identified SNPs in the human genome that associate with the risk to develop type 2 DM 
(66-71). These SNPs are also candidate genes for explaining the associations between 
low birth weight and Type 2 DM. Two important examples of such SNPs are found in the 
peroxisome proliferators-activated receptor γ (PPAR-γ) gene and the Transcription factor 
7-like 2 (TCF7L2) gene. 
 Polymorphisms of PPAR-γ are associated with adipocyte differentiation, lipid 
metabolism and insulin sensitivity (72). Genome-wide association (GWA) studies found 
that the Ala12 variant of the PPAR-γ gene is associated with a lower risk for type 2 DM 
compared with the Pro12Pro genotype (67, 69-71). However, in young adults born SGA 
(73), the Ala12 allele was associated with an increased risk for type 2 DM. A higher BMI 
in Ala12 carriers has also been described (74, 75), while other studies found a lower 
BMI in Ala12 carriers (76) or no association with BMI (75). The association between the 
PPAR-γ Ala12 allele and glucose homeostasis has been found to interact with size at 
birth (73). These results regarding associations of the Ala12 allele with insulin resistance 
and BMI suggest that the allele has a different effect in different environments, and 
that environmental factors may play a role to increase the genetic effect of PPAR-γ on 
metabolic risk factors.
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 Another, more recently found polymorphism that associates with the risk to develop 
type 2 DM is rs7903146 in the TCF7L2 gene. This is to date the polymorphism with the 
strongest association with type 2 diabetes mellitus (DM) (66-68), probably because the 
rs7903146 T-allele associates with decreased insulin secretion (77-81). So far, literature 
is inconclusive whether the rs7903146 T-allele also associates with insulin sensitivity 
and disposition index (77-79, 81). Because insulin is an important growth factor in 
utero, TCF7L2 might also influence size at birth. One study investigated the association 
between birth weight and TCF7L2 genotype and found a positive effect of the rs7903146 
T-allele when present in the mother (82). Presence of one or two copies of the T-allele in 
the fetus seemed not to influence birth weight (82). 
3. GrowtH HorMone (GH) treAtMent in SGA CHildren
3.1 Effect on linear growth
In 1991, the first Dutch multi-center, randomized, double-blind, dose-response GH trial 
was started to investigate the efficacy of GH treatment on growth in short SGA children 
(28, 83). Children were treated with either 1 or 2 mg GH/m2 /day. In this study, 85% of the 
children reached a normal adult height above – 2 SDS and 98% reached an adult height 
within the target height range (83). The catch-up growth in height was accompanied by 
catch-up growth in BMI (28). Interestingly, adult height SDS was not significantly different 
between the two GH dosage groups. In 1996, the second Dutch GH trial was started with 
a randomized control group for 3 years. After 3 years, GH treatment with a dose of 1 mg 
GH/m2 /day resulted in a normalization of height, whereas children in the control group, 
who did not receive GH treatment during those 3 years, remained short (84). Several 
other studies have demonstrated that GH treatment effectively induces catch-up growth 
in short SGA children (85-88). 
3.2 Effect on the GH-IGF-IGFBP-axis
Previous reports showed that GH treatment of short SGA children leads to increases in 
serum IGF-I and IGFBP-3 levels, which are positively related to the GH dose (8, 28, 89). 
After one year of GH treatment with a dose of 1 mg/m2/day, a rise of 90% in IGF-I levels 
was reported, and after two years a rise of 123% (8). Another study reported a rise in 
IGF-I levels up to 1.2 SDS and a rise in IGFBP-3 levels up to 0.2 SDS during one year of 
GH treatment with a dose of 1 mg / m2 /day (28). Treatment with 2 mg/m2/day resulted 
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in mean IGF-I and IGFBP-3 levels of 1.9 SDS and 0.5 SDS, respectively (28). After 3 years 
of GH treatment, IGF-I and IGFBP-3 levels were similar in both GH dosage groups (28). 
At discontinuation of GH treatment after attainment of adult height, mean IGF-I SDS 
was 1.0 in children treated with 1 mg/m2/day and 1.3 in children treated with 2 mg/
m2/day, both significantly higher than the population mean (83). Mean IGFBP-3 levels 
were –0.8 SDS in children treated with 1 mg/m2/day, which is significantly lower than 
the population mean, and –0.06 in children treated with 2 mg/m2/day (83). At 6.5 years 
after discontinuation of GH treatment, IGF-I (-0.4 SDS) and IGFBP-3 (-1.6 SDS) levels had 
decreased and were similar to levels in untreated short SGA subjects, indicating that the 
GH-induced rise in IGF-I and IGFBP-3 levels is completely reversible after discontinuation 
of GH (45). 
 During overnight GH profiles in short prepubertal SGA children, mean and maximum 
GH levels were respectively 34.8 and 104 mU/l when treated with 1 mg/m2/day, and 
64.4 and 161 mU/l when treated with 2 mg/m2/day (90). For comparison, overnight GH 
levels in normal prepubertal children are 10.5 mU/l in boys and 10.8 mU/l in girls, and 
during puberty these levels rise to values of 17.1 mU/l in boys and 20 mU/l in girls (91). 
Thus, especially short SGA children receiving 2 mg/m2/day have very high mean serum 
GH levels (90). Because treatment with a GH dose of 1 mg/m2/day is as effective as 
treatment with 2 mg/m2/day with regard to reach a normal adult height (83) and the long 
term risks of high GH levels in short SGA children are unknown, most short SGA children 
are nowadays treated with 1 mg/m2/day. 
3.3 Effect on thyroid hormone axis
It has been suggested that GH therapy has an inhibitory effect on the hypothalamo-
pituitary-thyroid axis (92) and might increase peripheral conversion of T4 to T3 (93). 
Because normal thyroid status is necessary for growth and development, it is important 
to know whether GH treatment alters thyroid function in short SGA children without GH 
deficiency. This was not yet investigated.
3.4 Effect on insulin sensitivity and cardiovascular risk factors
GH has well-documented insulin-antagonistic effects and its use has been associated 
with a reduction in insulin sensitivity and an increase in insulin levels (94-96). Therefore, 
concern was expressed regarding the long-term consequences of GH-treatment on risk 
factors for type 2 DM and associated comorbidities, especially in possibly predisposed 
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subjects, such as SGA children. Particularly because it was previously shown that short 
SGA children had reduced insulin sensitivity before receiving GH (47-49) and that 
GH treatment resulted in a further decline of insulin sensitivity and a compensatory 
increase in insulin secretion (47, 97). Most studies reported a recovery of insulin sensitivity 
and insulin levels to pre-treatment levels within 3 to 6 months after withdrawal of GH 
treatment (45, 97-99). Van Dijk et al. reported that at 6.5 years after discontinuation of 
GH, insulin sensitivity and insulin secretion were similar in GH-treated SGA subjects and 
untreated SGA controls (45). Thus, changes in insulin sensitivity and insulin secretion 
were reversible after discontinuation of GH treatment and, moreover, remained so until 
at least 6.5 years after discontinuation (45). This suggests that long-term GH treatment 
of short SGA children does not have permanent effects on glucose homeostasis and 
does not increase the risk of type 2 DM (45, 98, 99). 
 GH treatment has also been associated with a reduction in systolic blood pressure 
as well as a reduction in cholesterol levels in SGA children (45, 98). These are beneficial 
effects since SGA children were reported to have a higher systolic blood pressure and 
more often hypercholesterolaemia (52, 54). At a mean age of 22 years, 6.5 years after 
discontinuation of long-term GH treatment, systolic and diastolic blood pressure and 
serum cholesterol were significantly lower in previously GH treated SGA subjects than 
in untreated SGA subjects (45). Thus, GH treatment might have long-lasting beneficial 
effects on blood pressure and serum cholesterol levels in short SGA subjects (45). 
However, long-term surveillance of insulin sensitivity and other cardiovascular parameters 
in previously GH-treated SGA subjects remains important to exclude any negative effects 
of GH. This need for long-term follow-up was also emphasized during the last SGA 
consensus meeting in 2007 (1).
3.5 Effect on body composition
GH has well-documented anabolic effects on muscle mass and lipolytic effects on 
adipose tissue (100, 101). GH deficiency has been associated with increased fat mass 
and truncal obesity (102), while GH excess as in acromegaly, has been associated with 
reduced fat mass and increased lean body mass (103). 
 Few studies investigated the effect of GH treatment on body composition in SGA 
children. Leger et al. measured body composition of the thighs during GH treatment 
by magnetic resonance imaging (MRI) and reported an increase in muscle tissue and 
a decline in adipose tissue (104). Total body fat and muscle mass were not measured 
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in this study and only the first 3 years of GH treatment were analyzed. Willemsen et 
al. investigated the effect of GH treatment on body composition during 6 years of GH 
treatment and adjusted for catch-up in height (99). They found a significant decline of fat 
mass SDS adjusted for gender and height and no change in lean mass SDS adjusted for 
gender and height (99).
 Discontinuation of GH treatment was associated with significant changes in body 
composition 6 months after stop of treatment. Percentage body fat and fat mass SDS 
adjusted for gender and height increased, whereas lean mass SDS adjusted for gender and 
height decreased (99). Fat distribution had not changed 6 months after discontinuation 
of GH treatment. All values remained within the normal range and therefore the clinical 
relevance of the observed changes is unclear (99). It remains to be elucidated how body 
composition changes many years after discontinuation of GH treatment.
 
3.6 Interaction between GH treatment and genetic polymorphisms 
As explained in the previous paragraphs, GH treatment of short SGA children generally 
results in weight gain and a decrease in blood pressure, serum cholesterol and insulin 
sensitivity. However, not all children respond in the same way. This variation in response 
to GH treatment might be explained by the genotype of the patients.
 The PPAR-γ Ala12 allele was associated with BMI and glucose homeostasis (72), so 
this polymorphism might influence the change of these parameters during GH treatment. 
The TCF7L2 T-allele was associated with decreased insulin secretion (77-81) and during 
GH treatment extra insulin secretion is needed to compensate for the reduced insulin 
sensitivity. Therefore this SNP might indicate which children are less capable of producing 
extra insulin. Children with less insulin secretion during GH-treatment might be more at 
risk to develop DM in later life. 
 
3.7 Safety of GH treatment
The National Cooperative Growth Study (NGCS) monitored the safety of GH treatment from 
1984 until 1995 in children with various diagnoses. Reported adverse events included 
idiopathic intracranial hypertension, edema and lymphedema, carpal tunnel syndrome, 
slipped capital femoral epiphysis, diabetes mellitus and glucose intolerance (105). The 
authors concluded that major adverse events in relation to GH treatment were rare and 
that their frequency might have been affected by preexisting medical conditions.
 Concern has been expressed regarding the possible harmful effects of high serum 
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GH and IGF-I levels for many years (106, 107). Epidemiological studies in adults evaluating 
the risk for breast (108), prostate (109), and colon (110) cancer , indicated that serum 
levels of IGF-I in the upper tertile to quintile are associated with an increased risk of 
cancer, especially when IGFBP-3 levels are low (109, 110). These studies did, however, 
not establish causality (107) whereas during GH treatment serum levels of IGFBP-3 also 
increase. It is therefore important to evaluate the serum levels of IGF-I in GH-treated 
short SGA children and adjust the GH dose when IGF-I levels rise to levels far above the 
normal range.
 Several studies demonstrated that GH treatment was well tolerated by SGA children 
and that side effects were uncommon (46, 52, 98). Nevertheless, it was concluded that 
all SGA children receiving GH treatment should be monitored regularly for changes in 
glucose homeostasis, serum lipid levels, blood pressure and serum IGF-I levels to exclude 
any possible adverse effect of GH (1). 
4. AiMS of tHe Study
Familiar clustering of SGA and risk for type 2 DM and CVD in parents and offspring
To evaluate in parents of short SGA children, anthropometry, blood pressure, fasting 
serum lipids, glucose and insulin levels and compare these values with those of a 
population-based reference group. We hypothesized that parents of short SGA children 
have an increased risk for type 2 DM and CVD and that a relative high percentage of 
parents was born SGA themselves. Also, to evaluate whether anthropometric data and 
cardiovascular risk factors correlate between parents and children.
Thyroid function
To measure TSH and free T4 levels before and during 2 years of GH treatment in short SGA 
children who were divided in those born preterm and those born at term. To investigate 
the effect of preterm birth and the effect of GH treatment on thyroid hormone levels. 
Differences between preterm and term born short SGA children
Since both SGA and preterm birth have been associated with increased incidence of 
adult cardiovascular disease and type 2 DM, the aim was to investigate in short children 
born SGA whether preterm birth had an independent effect on the response to GH-
treatment with regard to the gain in height and weight and the change in risk factors for 
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CVD and type 2 DM.
Genetic polymorphisms and cardiovascular risk factors
To investigate whether polymorphisms in the PPAR-γ and TCF7L2 genes correlate with 
longitudinal changes in the metabolic and cardiovascular profile of short SGA children 
during GH treatment. Because insulin is an important growth factor in utero (40) and 
TCF7L2 is associated with insulin secretion (77-81) we aimed to evaluate whether 
TCF7L2 associates with fetal and postnatal growth.
IGFBP-2 levels
Since limited data exist on IGFBP-2 levels in children and young adults who were 
born SGA, to determine IGFBP-2 levels in a large cohort of SGA subjects. Levels were 
compared to those of age and gender-matched controls with normal stature. In addition, 
we aimed to investigate the associations between IGFBP-2 levels and various metabolic 
and cardiovascular risk factors.
5. outline of tHiS tHeSiS
Chapter 1 gives an introduction in the topics described in this thesis.
Chapter 2 describes the prevalence of cardiovascular risk factors in short SGA children 
and their parents and the association of these between parents and children.
Chapter 3 describes the effects of prematurity and GH treatment on thyroid function in 
short SGA children.
Chapter 4 reports on differences between preterm and term born short SGA children in 
anthropometry and in response to GH treatment. 
Chapter 5 describes differences between preterm and term short SGA children in GH-
induced changes in metabolic and cardiovascular risk factors.
Chapter 6 reports the contribution of the PPARγ Pro12Ala polymorphism to GH induced 
changes in determinants of metabolic and cardiovascular disease in short SGA children.
Chapter 7 describes whether TCF7L2 genotype is associated with growth patterns from 
fetal life until infancy. 
Chapter 8 describes the interaction between TCF7L2 genotype and growth hormone-
induced changes in glucose homeostasis in short SGA children.
Chapter 9 describes the association between IGFBP-2 levels and metabolic and 
Proefschrift Sandra W.K de Kort 20-08-09.indd   26 13-09-2009   16:58:38
26 27
chapter 
1
G
en
er
al
 In
tr
od
uc
tio
n
cardiovascular risk determinants in children and young adults who were born SGA.
Chapter 10 discusses our findings in relation to current literature and comments on the 
clinical implications and conclusions of our study results.
Chapter 11 summarizes our findings in English.
Chapter 12 summarizes our findings in Dutch.
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ABStrACt
SGA children have a higher prevalence of cardiovascular risk factors at a young age. 
It is not known whether this increased risk is caused by their size at birth, a familial 
predisposition for cardiovascular disease or smallness at birth or a combination of 
these factors. The cardiovascular risk profile of parents of SGA children is unknown. We 
compared anthropometry, blood pressure, fasting serum lipid, glucose and insulin levels 
of 482 parents (mean age 41 years) and 286 short SGA children with age- and sex-
matched references. We also investigated whether these parameters correlated between 
parents and their offspring. Mothers had higher systolic blood pressure, fathers had a 
higher body mass index (BMI) and parents had more frequently high fasting glucose levels 
than age- and sex-matched references. Children had significantly higher systolic and 
diastolic blood pressure than sex- and height-matched references. Twenty-four percent 
(mothers) and 10% (fathers) were born SGA but they did not have more cardiovascular 
risk factors than those born appropriate for gestational age. Cardiovascular risk factors 
did not correlate between parents and children. In conclusion, parents of short SGA 
children have a modest increase in some cardiovascular risk factors but risk factors did 
not correlate between parents and children.
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introduCtion
Epidemiological studies reported an inverse association between birth weight and risk 
for cardiovascular disease (CVD) in adult life (1-3). In addition, some studies described 
a relation between birth weight of offspring and subsequent cardiovascular mortality of 
the parents (4, 5). The exact mechanism behind these associations and the relative roles 
of environmental and genetic factors has not yet been elucidated. A familial component 
has been proposed (4, 5), but others could not find a family history of CVD as explanation 
for the higher prevalence of cardiovascular risk factors in subjects born with a lower 
birth weight (6). Clustering of cardiovascular risk factors within families has also been 
described irrespective of birth weight (7, 8), whereas there is a relation between birth 
weight of parents and offspring (9, 10). 
 Short small for gestational age (SGA) children constitute a special group within the 
group of low birth weight children because they did not reach a normal height. An increased 
prevalence of cardiovascular risk factors in short SGA children has been described 
(11, 12). Some parents of short SGA children were born SGA themselves (13, 14). It 
is unknown whether an increased risk for CVD in a short SGA child can be predicted by 
the presence of risk factors in his/her parents. We hypothesized that parents of short 
SGA children have an increased risk for CVD. In addition, we hypothesized that a relative 
high percentage of parents was born SGA themselves and that anthropometric data 
and cardiovascular risk factors correlate between parents and children. We therefore 
evaluated in parents of short SGA children anthropometry, blood pressure, fasting serum 
lipids, glucose and insulin levels, which are regarded as predictors of CVD (15). Outcome 
variables were compared with those of a population-based reference group. 
 
Proefschrift Sandra W.K de Kort 20-08-09.indd   43 13-09-2009   16:58:39
44
chapter 
2
CV
D
 ri
sk
 fa
ct
or
s 
in
 S
G
A 
pa
re
nt
s
45
SuBjeCtS And MetHodS
Subjects
Five-hundred-and-fifty-one parents (mean age 41 years, 276 (50%) fathers) of 286 
Caucasian short SGA children (151 (53%) boys), were eligible for inclusion in the 
period between December 1999 and September 2006. In 482 (87%) of these parents, 
anthropometric measurements were performed and 472 (86%) parents filled out a 
questionnaire. A complete dataset (anthropometry and questionnaire) was available in 
410 parents (74%). Two children had the same mother but different fathers. Inclusion 
criteria for the children have previously been described (16). In short, the children 
were included when prepubertal, with a birth length or birth weight standard deviation 
score (SDS) and actual height SDS below –2, without signs of catch-up growth in height 
and without growth failure caused by other disorders. The study was approved by the 
Medical Ethics Committees of the participating centres and written informed consent 
was obtained from all parents.
 The reference group consisted of 1699 women (aged 45 (8.5) years) and 1630 
men (aged 46 (8.5) years), participating in the year 2001 in a Dutch population-based 
health survey. The aim of this survey was to monitor risk factors or determinants of chronic 
disease in the general population (17). This reference group was used to calculate age- and 
sex-matched SD scores in the following manner: SD score = (value of parent – mean for 
references of the same age and sex) / SD for references of the same age and sex. 
Study design
Parents
Height, weight and waist circumference were measured with the subject standing. BMI 
was calculated. Systolic and diastolic blood pressure (BP) were measured in the non-
dominant arm while in a sitting position and the mean of three measurements was used 
for analysis. Height and weight for height were expressed as SDS using Dutch standards 
(18, 19). Waist circumference, BMI and BP were expressed as SDS adjusted for age and 
sex using the reference group (17). All parents were asked to fill out a questionnaire about 
birth characteristics, medical history, present health and family history on CVD and DM. 
CVD was defined as the occurrence of myocardial infarction, cerebrovascular accident, 
pulmonary embolism or deep vein thrombosis. Small for gestational age (SGA) was 
defined as a birth length and/ or birth weight standard deviation score (SDS) below –2 
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for gestational age (20). Fasting blood samples were available for parents of 93 children 
(92 mothers and 78 fathers). The availability of a fasting blood sample in the parents 
deviated from the year in which their child was included. Parents with an available fasting 
blood sample were comparable with parents without an available blood sample with 
respect to all outcome variables except for age (38.7 versus 42.1 years, p<0.001) and 
systolic blood pressure SDS (0.09 versus 0.33 SDS, p < 0.05). Of the 92 mothers with an 
available blood sample, 44 had birth data and 10 were born SGA. Of the 78 fathers with 
an available blood sample, 33 had birth data and 4 were born SGA. 
Children
Height, weight, head circumference, systolic and diastolic blood pressure (BP) were 
measured and BMI was calculated. Height, head circumference and BMI were expressed 
as SD scores adjusting for sex and age according to Dutch reference data (19), whereas 
BP was adjusted for sex and height (21). Fasting blood samples were available for 191 
children.
Biochemical measurements
After centrifugation, all samples were frozen (-80 °C) until assayed. Fasting serum insulin 
levels were determined by chemoluminescent assay on an Immulite 2000 analyser 
(Diagnostic Products Corporation, Los Angeles, CA). Fasting glucose was measured on 
a Hitachi 917 analyser. HOMA-IR was calculated (22). Serum total cholesterol (TC) and 
triglycerides (TG) were determined enzymatically and LDL-cholesterol and HDL-cholesterol 
were determined using a homogeneous assay on a Hitachi 917 (Roche Diagnostics, 
Mannheim, Germany). 
 Parental fasting TC and HDL-c levels were expressed as SDS adjusted for age and 
sex using the reference group (17). For children we used reference values of our hospital 
(Erasmus MC-Sophia) to define high TC, LDL-c and TG levels and low HDL-c levels. Cut-off 
values for high total cholesterol were ≥5.0 mmol/l for age 0-3 years, ≥5.4 mmol/l for age 
4-12 years and ≥6.5 mmol/l for adults (23). Cut-off values for high LDL- cholesterol levels 
were ≥3.5 mmol/l for age 0-3 years; ≥3.4 mmol/l for age 4-12 years and ≥4.2 mmol/l 
for adults (23). As TG and HDL-c levels are components of the ATP III criteria, applied cut-
off values for these lipids are described in the section about the definition of metabolic 
syndrome. 
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Metabolic Syndrome definition
Metabolic syndrome (MS) increases the risk for CVD and DM type 2 (15). According to 
the Third Report of the National Cholesterol Education Program’s Adult Treatment Panel 
(ATPIII) criteria, MS is present in adults when 3 or more of the following symptoms are 
present: central obesity (waist circumference ≥ 102 (males) or 88 cm (females), raised 
TG levels (TG ≥ 1.7 mmol/L), reduced HDL-c levels (HDL-c < 1.0 (males) or 1.3 (females) 
mmol/L), high BP (systolic ≥ 130 and/or diastolic bp ≥ 85 mm Hg or current treatment 
for hypertension), and increased fasting glucose levels (glucose ≥ 5.6 mmol/L) (24). 
 In children, we used the modified ATP III criteria by Weiss et al. to diagnose MS 
(25). High BP was defined as a height- and sex-adjusted systolic or diastolic BP >95th 
percentile (21). MS was diagnosed in children if 3 or more of the following symptoms 
were present: obesity (BMI ≥ 2 SDS (19)), TG levels >95th percentile (TG ≥ 1.2 mmol/L 
for age 0-3 years, TG ≥ 1.0 mmol/L for age 4 – 12 years), HDL-c levels <5th percentile 
(HDL-c < 0.5 mmol/L for age 0-3 years and HDL-c < 0.9 mmol/L for age 4-12 years), high 
BP and increased fasting glucose levels (glucose ≥ 5.6 mmol/L).
Statistics
Analyses were performed using the statistical package SPSS (version 12.0.1; SPSS Inc., 
Chicago, IL) for Windows. Results are expressed as means with standard deviations for 
continuous data and as percentages for dichotomous or categorical variables. Because of 
a skewed distribution, insulin levels and HOMA-IR are expressed as median (interquartile 
range). Differences between parents and references were evaluated using the two-
tailed one-sample t test and Chi-square test for proportions. Chi-square tests were also 
used to detect associations between risk factors in children and parents. Independent-
sample t tests were used to detect differences between subgroups of parents or children. 
Correlations within families (child-mother and child-father couples) were analyzed using 
Spearman’s correlation coefficient. All analyses were performed separately for men and 
women. Because independent samples t-tests demonstrated no significant differences 
between boys and girls, the children were analyzed as one group.
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reSultS
Clinical characteristics
Clinical characteristics of 482 parents and 286 children are shown in Table 1. Parental 
height SDS and head circumference SDS were significantly lower than zero SDS (p<0.001). 
Mothers and fathers had a relatively larger head circumference SDS compared with 
height SDS (p<0.01 and p<0.001, respectively). BMI SDS of the fathers was significantly 
higher than zero SDS (p<0.05).  Systolic BP SDS of the mothers was significantly higher 
(p<0.001) compared with age-matched female references but diastolic BP SDS was not. 
BP in fathers was comparable with age- and sex-matched references. In the children, 
systolic and diastolic BP SDS were significantly higher compared with sex- and height-
matched references (p<0.001). 
Table 1: Clinical characteristics of parents (n=482) and children (n=286)
Mothers Fathers Children
P value P value P value
Age (yr) 39.7 (5.0) - 42.3 (5.5) - 6.4 (2.4) -
Height (cm) 163.4 (6.8) - 177.0 (7.1) - 106.1 (13.2) -
Height SDS -0.8 (1.1) <0.001 -0.7 (1.1) <0.001 -3.0 (0.6) <0.001
HC (cm) 54.5 (1.6) - 57.2 (1.6) - 49.5 (1.9) -
HC SDS -0.5 (1.0) <0.001 -0.3 (0.9) <0.001 -1.2 (1.0) <0.001
HC SDS – Ht SDS 0.2 (1.1) <0.01 0.3 (1.1) <0.001 1.8 (1.1) <0.001
BMI 24.9 (4.8) - 26.4 (3.9) - 14.1 (1.2) -
BMI SDS 0.1 (1.2) 0.11 0.2 (1.1) <0.05 -1.4 (1.0) <0.001
Waist circ. (cm) 82.8 (11.6) - 93.1 (12.1) - - -
Waist circ. SDS 0.0 (1.1) 0.74 -0.1 (1.2) 0.14 - -
Systolic BP (mmHg) 121.5 (16.2) - 131.1 (16.2) - 103.5 (12.8) -
Systolic BP SDS 0.3 (1.1) <0.001 0.1 (1.2) 0.15 0.9 (1.1) <0.001
Diastolic BP (mmHg) 79.5 (10.7) - 83.0 (12.1) - 59.2 (9.2) -
Diastolic BP SDS 0.0 (1.1) 0.85 0.0 (1.2) 0.82 0.4 (1.1) <0.001
SDS = standard deviation score; HC = head circumference; Ht = height; BMI = body mass index; BP 
= blood pressure. Values are expressed as mean (SD); p values express the difference with age- and 
sex-matched references
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Birth characteristics
Birth characteristics are listed in Table 2. Compared with reference values, mothers had 
a significantly lower birth weight SDS (p<0.001). Birth length SDS was significantly lower 
than zero SDS in both mothers (p<0.001) and fathers (p<0.05). Twenty-four mothers 
(24%) and 9 fathers (10%) with known birth characteristics were born SGA themselves. 
These percentages are significantly higher than the 2.3%, which is by definition the 
prevalence of SGA birth in live-born neonates. Even when all parents without known birth 
characteristics were regarded as born AGA, the prevalence of being born SGA in parents 
(24/275 (9%) mothers and 9/276 (3%) fathers) was still higher than 2.3%.
Biochemical measurements
TC SD scores were significantly higher than zero SDS, i.e. compared with the median 
for references (Table 3). Nine percent of the mothers had high TC levels compared with 
5% of the female references, but this difference was not significant (p=0.16). Fifteen 
percent of the fathers had high TC levels compared with 7% of the male references 
(p<0.05). HDL-c SD scores were significantly higher than zero SDS in both mothers and 
fathers (p<0.001). Prevalence of high LDL-c was 11% in mothers and 25% in fathers. 
In the reference population, LDL-c, TG, and insulin were not measured. Compared with 
references, parents had more frequently fasting glucose levels above the ATP III cutoff 
level of 5.6 mM (Table 4). Nonetheless, mean parental fasting levels of glucose, insulin, 
TC, TG, HDL-c, and LDL-c were all within the normal range. Median HOMA-IR was 0.8 (0.5 
– 1.1) in mothers, 0.9 (0.5 – 1.7) in fathers and 0.3 (0.2 – 0.4) in children. In the SGA 
Table 2: Birth characteristics
Mothers Fathers Children
n n n
Gestational age 121 39.3 (2.1) 104 39.4 (1.7) 286 36.2 (3.7)
Birth weight (kg) 169 3.0 (0.6) 130 3.3 (0.7) 286 1.9 (0.7)
Birth weight SDS 100  -0.6 (1.2)* 87 -0.2 (1.5) 286 -2.3 (1.1)*
Birth length (cm) 112 48.4 (2.8) 68 49.9 (3.4) 209 42.3 (5.0)
Birth length SDS 67  -1.1 (1.4)* 47 -0.7 (1.8)** 209  -3.1 (1.5)*
Born SGA (%) 101 24% 87 10% 286 100%
Data expressed as mean (SD); n = number of persons with available data
Compared with gestational age- and sex- matched references: *p < 0.001; **p < 0.01
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children, mean fasting serum levels of TC, TG, HDL-c and LDL-c were within the normal 
range (Table 3). Only one child had a TC level above the normal range. 
Parents born SGA versus parents born AGA
Mothers born SGA had a significantly smaller head circumference (-1.0 SDS versus –0.3 
SDS, p<0.01) and shorter stature (-1.5 SDS versus –0.5 SDS, p<0.001) than mothers 
born appropriate for gestational age (AGA). Fathers born SGA also had a larger head 
circumference and shorter stature than AGA fathers but these differences were not 
significant. Glucose and insulin levels and SD scores for waist circumference, BMI, 
systolic and diastolic blood pressure, TC and HDL-c of SGA parents were not significantly 
different from those born AGA. 
Metabolic Syndrome (MS)
Table 4 shows the different components of the MS. According to the ATP III criteria, the 
prevalence of MS was 15% in mothers and 22% in fathers. The number of MS components 
in parents born SGA was not significantly different from those born AGA. There was one 
child (age 5 years) with three components of the MS (elevated blood pressure, high 
Table 3: Fasting serum lipid, glucose and insulin levels
Mothers Fathers Children
TC (mmol/L) 5.3 (0.9) 5.6 (1.0) 4.1 (0.8)
TC SDS 0.5 (1.1)* 0.4 (1.1)** -
TG (mmol/L) 1.2 (0.7) 1.7 (1.2) 0.8 (0.4)
HDL-c (mmol/L) 1.5 (0.4) 1.2 (0.3) 1.4 (0.4)
HDL-c SDS 0.5 (1.3)* 0.5 (1.2)* -
TC / HDL-c ratio 3.7 (1.3) 4.8 (1.4) 3.2 (1.1)
LDL-c (mmol/L) 3.1 (0.9) 3.5 (1.0) 2.3 (0.7)
Glucose (mmol/L) 4.7 (1.1) 4.9 (0.7) 4.4 (0.6)
Insulin (pmol/L) 40.8 (27.8-63.2) 45.7 (25.5-89.4) 14.0 (14.0-22.8)
HOMA-IR 0.8 (0.5-1.1) 0.9 (0.5-1.7) 0.3 (0.2-0.4)
Data expressed as mean (SD) and insulin and HOMA-IR as median (interquartile range)
Compared with age- and sex- matched references: *p<0.001; **p<0.01 
TC = total cholesterol N: 2.0-5.5 mmol/l (children) or <6.5 mmol/l (adults); TG = triglycerides N: 0.3-1.6 mmol/l (children) or 
<1.7 mmol/l (adults); HDL-c = high-density lipoprotein cholesterol N: 1.1-2.7 mmol/l (children) or >1.0 mmol/l (male adults) or 
>1.3 mmol/l (female adults); LDL-c = low-density lipoprotein cholesterol N: 0.0-4.2 mmol/l (children) or <4.2 mmol/l (adults); 
glucose N: 2.6-6.0 mmol/l; insulin N: < 180 pmol/L
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fasting glucose level and a low fasting HDL-c level). 
Cardiovascular disease, DM type 2 and family history 
One mother and four fathers had suffered from a non-lethal myocardial infarction (mother 
at age 44 years; fathers at ages 30, 36, 45 and 52 years, respectively). One father and 
two mothers had had deep vein thrombosis and one mother pulmonary embolism. Sixty-
three of 254 (25%) mothers and 69/249 (28%) fathers had ≥ 1 first-degree relative with 
CVD. Of these relatives, CVD occurred before the age of 60 in respectively 12 of 63 (19%) 
and 19 of 69 (28%). Two mothers and one father had DM type 2, whereas 53 (21%) 
mothers and 49 (20%) fathers had ≥ 1 first-degree relative with DM type 2.
Correlations between parents and children
There was no correlation between birth weight SDS, birth length SDS, systolic and 
diastolic BP SDS, BMI SDS, fasting levels of lipids and insulin and HOMA-IR within parent-
child couples. Glucose levels correlated positively between mothers and children (r = 
0.4, p <0.01) and fathers and children (r = 0.3, p< 0.05). Chi-square tests showed no 
association between parents and children in having a glucose level ≥ 5.6 mmol/l. Head 
circumference correlated weakly between mothers and children (r =0.2, p<0.01) and 
fathers and children (r = 0.3, p<0.001).  
Table 4: Components of metabolic syndrome according to ATP III criteria
Mothers Reference Fathers Reference Children
n P value n P value
High sys BP 229 23% 20% 0.32 204 43% 41% 0.70 271 13%
High dia BP 229 29% 27% 0.46 204 38% 37% 0.84 271 6%
Central obesity 225 27% 34% 0.43 199 19% 21% 0.81 286 none
High glucose 92 7% 3% 0.05 78 19% 8% <0.01 153 5%
Low HDL-c 92 30% 41% <0.05 78 24% 37% <0.05 73 6%
High TG 92 17% - - 78 35% - - 63 18%
≥3 criteria 92 15% - - 78 22% - - 64 2%
n = number of persons; p values express the difference with the reference group; BP = blood pressure; sys = systolic; dia = diastolic; 
HDL-c = high-density lipoprotein cholesterol; TG = triglycerides
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diSCuSSion
This study shows that parents of short SGA children have a modestly higher prevalence 
of cardiovascular risk factors than age- and sex-matched references. Mothers had higher 
mean systolic blood pressure SDS, fathers had higher mean BMI SDS and parents had 
more frequently high fasting glucose levels. On the other hand, parents had less frequently 
low HDL-c levels than references. Risk factors did not correlate between parents and 
offspring. To the best of our knowledge, we provide the first data on cardiovascular risk 
factors in a large cohort of parents of short SGA children.
 Our hypothesis was based on reported associations between low birth weight and 
cardiovascular risk, within subjects and across generations (26). The exact mechanism 
behind these associations is not completely understood. The fetal origins hypothesis poses 
that exposure to an adverse in utero environment leads to permanent programming of 
tissue function and an inceased risk of CVD (27). Alternatively, low birth weight and adult 
cardiovascular disease might be independent features of a genetic predisposition to CVD 
(28, 29). There is also evidence of a nongenetic predisposition to low birth weight and 
adverse cardiovascular risk across a number of generations (26). Because we found only 
a modest increase of risk factors in parents and no correlation of risk factors between 
parents and children, we could not demonstrate a familial cause for an increased risk for 
CVD in short SGA subjects. 
 Systolic blood pressure of the mothers was significantly higher than that of age-
matched female references. Systolic and diastolic blood pressure of the children was 
also higher than reference values. However, blood pressure in fathers was normal and 
there was no significant difference in the percentage of parents with elevated blood 
pressure according to the ATP III criteria (>130 / 85 mm Hg) compared with references. 
A limitation is that blood pressure was measured thrice within 10 min and not during 24 
h. Also, parents were significantly shorter than reference subjects. As blood pressure is 
known to increase with height (30, 31), parental blood pressure was relatively high for 
their shorter height. 
 The percentage of parents with fasting glucose levels above the ATP III cutoff level of 
5.6 mmol/L was higher than in age- and sex-matched references. Higher fasting glucose 
levels might indicate insulin resistance, which in turn might increase the risk to develop 
DM and subsequently CVD (32). HOMA-IR, on the other hand, was <1, indicating a low 
level of insulin resistance (22,33). The percentage of parents with a family history of DM 
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type 2 was comparable with that in a population-based Danish cohort (34).
 Parents had higher cholesterol levels than age- and sex-matched references and 
fathers had significantly more frequent hypercholesterolemia. LDL-c levels were not 
measured in references but levels were above the normal range of our laboratory in 
11% of the mothers and 25% of the fathers. On the other hand, HDL-c levels were also 
significantly higher in parents than in references. As HDL-c levels contribute to total 
cholesterol levels, the higher total cholesterol level in parents might thus be explained. 
This is supported by the total cholesterol/HDL-c ratio of the parents, which was slightly 
lower than the ratio of the white participants of the community-based Bogalusa Heart 
Study (35). Higher HDL-c levels are generally known to lower the risk for cardiovascular 
disease. Therefore , the higher total cholesterol level in the parents might not reflect an 
increased risk. 
 Prevalence of MS was 15% in mothers and 22% in fathers. Comparing the 
prevalence of MS between parents and the age-matched reference group was not 
possible because triglyceride (TG) levels were not measured in the reference group. No 
other study described the prevalence of MS in healthy subjects of the same age as our 
parents. Most reports on the prevalence of MS in Europe comprise older populations 
or populations with DM or CVD. For example the Dutch Hoorn study (age 50-75 years) 
reported a prevalence of MS of 19% in females and 26% in males (36). A German study 
(PROCAM study, age 36-39 years) reported a prevalence of 18% in females and 25% 
in males (37). In a Danish cohort of women (age 45 years), the prevalence of MS was 
15% (34). Compared with these cohorts, the prevalence of MS in parents of short SGA 
children was comparable or lower.
 Power calculations (alpha 0.05 and power 0.8) showed that correlations within 
parent-child couples with an r>0.3 were detectable for birth weight, birth length, systolic 
and diastolic blood pressure, BMI, head circumference, glucose and insulin levels. Thus, 
for these parameters there was sufficient power to detect clinically relevant correlations. 
We only found a correlation between parents and children with regard to glucose levels 
and head circumference. In contrast to previous population-based studies (9,10,38), 
there were no correlations for birth weight or blood pressure. Lipid levels were measured 
in a smaller number of children. As a result, our study did not have enough power to 
detect correlations in lipid levels between parents and children.
 A substantial proportion of parents (24% mothers and 10% fathers) with known birth 
characteristics, was born SGA themselves but they did not have more cardiovascular risk 
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factors than the parents who were born AGA. However, the absolute number of parents 
born SGA was small and even less of them provided a blood sample. This small number 
limited the power to detect differences between parents born SGA and parents born 
AGA. 
 Several other factors may have influenced our results. First, the parent group was 
relatively young. It is possible that increased risk for cardiovascular disease will be 
detectable when they are 10 years older. On the other hand, in the children, a higher 
diastolic and systolic blood pressure was already present at a mean age of 6.4 years. 
Second, parents with an available blood sample were younger and had a lower systolic 
blood pressure than parents without an available blood sample. Because analyses were 
performed after the collection of blood samples, we do not think there was a selection 
bias. Third, the references were 5 years older than the parents. By transforming all 
outcome variables to SD scores before analysis, we corrected for the difference in 
mean age of both populations. Therefore, the difference in mean age cannot explain the 
absence of markedly increased cardiovascular risks. 
 In conclusion, parents of short SGA children have a modest increase in some 
cardiovascular risk factors. Mothers had higher mean systolic blood pressure SDS and 
fathers had a higher mean BMI SDS, whereas parents had more often high fasting glucose 
levels than age- and sex-matched references. On the other hand, HOMA-IR was low and 
parents had less frequently low HDL-c levels than references. Also, the prevalence of MS 
according to ATP III criteria was 15% in mothers and 22% in fathers, which is not higher 
than the reported prevalence. Risk factors did not correlate between parents and children 
and a substantial proportion of parents (24% mothers and 10% fathers) with known birth 
characteristics, was born SGA themselves. 
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ABStrACt
Context: Disturbances in thyroid function have been described in SGA 
children but the influence of prematurity is unclear. In addition, the effect 
of growth hormone (GH) treatment on thyroid function has not been 
studied in short SGA children.
Objectives: To determine whether short SGA children have higher TSH levels 
compared to age-matched controls and evaluate the influence of gestational 
age. To investigate whether GH treatment alters thyroid function. 
Patients: 264 short SGA children (116 preterm), pre-pubertal and non-GH 
deficient.
Measurements: Serum FT4 and TSH at baseline and after 6, 12 and 24 
months of GH treatment.
Results: Baseline mean TSH was higher in preterm short SGA children 
than in age-matched controls (p<0.05). Mean FT4 was not significantly 
different between short SGA children and controls. Baseline FT4 or TSH did 
not correlate with gestational age, or SDS for birth weight, birth length, 
height, BMI, IGF-1 or IGFBP-3. Mean FT4 decreased significantly during 
the first 6 months of GH treatment, but remained within the normal range. 
TSH did not change during treatment. The change in FT4 did not correlate 
with the change in height SDS during 24 months of GH treatment. 
Conclusion: Preterm short SGA children have higher, although within the 
normal range, TSH levels than controls. The level of TSH does not correlate 
with gestational age, birth weight SDS or birth length SDS. FT4 decreases 
during GH treatment, but is not associated with an increase in TSH, nor 
does it affect the response to GH treatment. Since these mild alterations in 
thyroid function do not appear clinically relevant, frequent monitoring of 
thyroid function during GH therapy is not warranted in short SGA children.
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introduCtion
Since recombinant human growth hormone (GH) treatment was licensed (Food and 
Drug Administration, FDA, 2001; European agency for the Evaluation of Medicinal 
products, EMEA, 2003) for short children born SGA, it has become a frequently applied 
growth promoting therapy. Because normal thyroid status is necessary for growth and 
development, it is important to know whether GH treatment alters thyroid function. 
 Reports about thyroid function in untreated children born SGA are limited. Short 
SGA children were reported to have higher TSH levels compared to SGA children with 
catch-up growth (1) but these results could not be replicated in term SGA children (2). 
A recent paper suggested that not SGA, but preterm birth is associated with higher TSH 
levels (3). However, this was studied in SGA children with catch-up growth. There are no 
data on thyroid hormone levels in term and preterm short SGA children. In addition, GH 
treatment was associated with a decline in serum FT4 without a change in TSH level in 
other patient groups (4-6). The effect of GH administration on thyroid function in short 
SGA children has not been studied yet. 
 In this paper we report FT4 and TSH levels in a large group of short SGA children 
before and during 2 years of GH treatment. We hypothesized that short SGA children 
have higher TSH levels compared to reference values. To evaluate whether thyroid 
hormone levels are related to prematurity or SGA, we evaluated term and preterm short 
SGA children separately. Our second hypothesis was that FT4 levels would decrease 
during GH treatment. 
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MetHodS
Subjects
The study group consisted of 264 prepubertal short children born SGA (144 boys; 116 
born preterm). Children were included according to the following criteria: 1) birth length 
and/ or birth weight standard deviation score (SDS) below –2 for gestational age (7); 
2) height SDS for age below – 2 according to Dutch standards (8); 3) height velocity 
SDS below zero to exclude children with spontaneous catch-up growth; 4) prepubertal 
stage defined as Tanner breast stage 1 for girls and testicular volume less than 4 ml for 
boys; 5) an uncomplicated neonatal period, without signs of severe asphyxia (defined as 
Apgar score below 3 after 5 minutes), sepsis or long-term complications of respiratory 
ventilation such as chronic lung disease. Children with GH deficiency (peak response of 
serum GH < 20 mU/l to a provocative test (arginine or clonidine)), endocrine or metabolic 
disorders, chromosomal defects, syndromes and growth failure caused by other conditions 
(e.g. emotional deprivation, severe chronic illness, chondrodysplasia) were excluded, 
with the exception of Silver-Russell syndrome. The Medical Ethics Committees of the 
participating centers approved the study and written informed consent was obtained 
from the parents.
Study design
All children were treated with biosynthetic GH at a dose of 1 mg /m2·day. GH was 
administered subcutaneously once daily at bedtime. Three-monthly, the GH dose was 
adjusted to the calculated body surface area. At baseline and after 6, 12 and 24 months 
of GH treatment, standing height and weight were measured and body mass index (BMI) 
was calculated. Height, weight for height and BMI were expressed as SD scores adjusting 
for sex and age according to Dutch reference data (8). At the same time points, blood 
samples were taken for determination of FT4, TSH, IGF-I and IGFBP-3 levels. Prematurity 
was defined as a gestational age <37 weeks. Because this was a multicenter study and 
only measurements performed in one hospital were evaluated, there were missing data 
at the different time points. The number of patients after 6, 12 and 24 months of GH 
treatment was 174, 177 and 163, respectively.
Assays
Serum FT4 and TSH levels were measured by Vitros Eci technology (Ortho-Clinical 
Proefschrift Sandra W.K de Kort 20-08-09.indd   64 13-09-2009   16:58:41
64 65
chapter 
3
Th
yr
oi
d 
ho
rm
on
e 
le
ve
ls
 in
 S
G
A 
an
d 
ef
fe
ct
s 
of
 G
H
 tr
ea
tm
en
t
Diagnostics, Amersham, UK). The within-assay coefficients of variation of Vitros were 
3-7% for FT4 and 8-9% for TSH. The between-assay coefficients of variation were 5-10% 
for FT4 and 5-7% for TSH. Normal TSH reference values were 0.7 – 6.4 mU/l (-2 SD to 
2 SD). Normal FT4 reference values were 11.8 – 26.2 pmol/l (-2 SD to 2 SD). Thyroid 
hormone levels were expressed as age-adjusted SD scores, which were calculated with 
data of a control group comprising 500 healthy Dutch children (age 1.4-18 years) from the 
Rotterdam region, The Netherlands, participating in a study to assess reference values. 
The Medical Ethics Committee of the Erasmus Medical Centre Rotterdam approved 
this reference study, and written informed consent was obtained from the parents or 
guardians. All measurements were performed at the same laboratory. Serum levels of 
total IGF-I and IGFBP-3 were measured in another laboratory using specific RIAs, as 
previously described (9-11). Serum levels of total IGF-I and IGFBP-3 were also expressed 
as SDS adjusting for age and sex, using reference values for healthy children with normal 
stature determined in the same laboratory (12).
Statistics
All analyses were performed using the statistical package SPSS (version 11.1; SPSS 
Inc., Chicago, IL) for Windows. Differences between term and preterm born children at 
baseline were evaluated using an independent sample-t-test. We used a one-sample 
t-test to compare results, expressed as SDS, with 0 SDS (median value for age-matched 
healthy references). To correct for missing data and multiple testing, changes over 
time were analyzed with repeated measures of variance (mixed model ANOVA). Firstly, 
an F test was performed to test whether time had a significant effect. Then, only when 
p<0.005, repeated measures of variance (mixed model ANOVA) was used to test 
differences between baseline and different time points. Clinical data are presented 
as mean (SD), model estimates as mean (95% CI). Correlations were calculated using 
Spearman’s correlation coefficient. Multiple linear regression analysis was used to 
assess multivariable relationships between birth characteristics and FT4 and TSH levels 
at the start of GH treatment. Statistical significance was defined as p < 0.05. 
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reSultS
Clinical characteristics at baseline
Mean (SD) age was 7.39 (2.6) years (Table 1). Preterm children had significantly lower 
birth weight SDS, BMI SDS and head circumference SDS and significantly higher height 
SDS than term children (Table 2). Mean height SDS was significantly lower compared to 
age-matched references in all SGA patients. Of 3 adopted children no information was 
available about their gestational age. 
Thyroid hormone levels at baseline
Preterm children had significantly higher FT4 SDS than term children but in both groups 
FT4 SDS was comparable with age-matched references (Table 2). FT4 levels were above 
the normal range (>2 SDS) in 2% of the term children and in 4% of the preterm children, 
with values ranging from 26.2 to 41.9 pmol/l. None of the children had a FT4 level < 
-2 SDS.  TSH SDS was significantly higher in preterm short SGA children than in age-
matched references (p<0.05). TSH levels were above the normal range (>2 SDS) in 2% 
of the term children and in 4% of the preterm children, with values ranging from 6.4 to 
7.6 mU/l. There was no significant relation between prematurity and TSH levels above 
the upper limit of normality. TSH levels were below the normal range (< -2 SDS) in 2% of 
the children, in both the term and the preterm group. 
Table 1. Clinical characteristics at baseline
n 264
Male/female 145/119
Gestational age 36.3 (3.5)
Preterm/ term 116/145
Birth weight SDS -2.16 (1.2)a
Birth length SDS -2.89 (1.5)a
Age 7.39 (2.6)
Data expressed as mean (SDS)
Compared with zero SDS (median for age and sex): ap<0.001
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Thyroid hormone levels during GH treatment
As shown in Figure 1, FT4 SDS decreased significantly during the first 6 months of GH 
treatment and remained subsequently at the same level until 24 months. Although 
reduced compared to baseline, the levels remained within the normal range. Mean TSH 
SDS did not change during treatment (Table 3). Changes in FT4 SDS did not correlate 
with changes in TSH SDS. None of the children developed symptomatic hypothyroidism 
during the follow-up period. The effect of GH treatment on FT4 levels was the same for 
Table 2. Preterm vs. term born short SGA children at baseline
Preterm (n=116) Term (n=145)
Birth weight SDS -2.46 (1.4)a,d -1.92 (0.9)d
Birth length SDS -3.19 (2.1)d -2.71 (1.0)d
Age 6.86 (2.4)b 7.80 (2.7)
Height SDS -2.88 (0.5)b,d -3.05 (0.6)d
Weight SDS -1.58 (1.2)a,d -0.92 (1.1)d
BMI SDS -1.58 (1.1)a,d -1.11 (0.9)d
Head Circ. SDS -1.45 (0.9)c,d -1.16 (0.9)d
TSH 2.74 (1.5) 2.53 (1.2)
TSH SDS 0.23 (1.0)e 0.14 (0.9)
FT4 19.63 (4.1)c 18.65 (3.4)
FT4 SDS 0.18 (1.1)c -0.10 (0.9)
Data expressed as mean (SDS)
Preterm short SGA subjects vs term short SGA subjects: ap<0.001; bp<0.01; cp<0.05
Compared with zero SDS (median for age and sex): dp<0.001; ep<0.05
Table 3 Thyroid hormone levels before and during GH treatment
T=0 T=6 mo T=12 mo T=24 mo
FT4 19.1 (18.6 to 19.6) 17.6 (17.2 to 18.0)a 17.5 (17.1 to 18.0)a 17.8 (17.4 to 18.2)a
FT4 SDS 0.03 (0.1 to 0.2) -0.38 (-0.5 to -0.3)a,c -0.40 (-0.5 to -0.3)a,c -0.33 (-0.4 to -0.2)a,c
TSH 2.6 (2.5 to 2.8) 2.6 (2.5 to 2.8) 2.5 (2.3 to 2.6)b 2.5 (2.4 to 2.7)
TSH SDS 0.17 (0.1 to 0.3)d 0.23 (0.1 to 0.3)c 0.11 (o.1 to 0.2)b 0.17 (0.1 to 0.3)d
Data expressed as model estimate (95% CI)
Compared with baseline values: ap < 0.001
Compared with previous visit: bp<0.05
Compared with zero SDS (median for age): cp<0.001; dp< 0.01
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term and preterm born children (p = 0.99). Table 4 shows the change of anthropometric 
parameters and serum levels of IGF-I and IGFBP-3 during GH treatment. 
Correlations
There was no significant correlation between baseline FT4 SDS or TSH SDS and birth 
weight SDS, birth length SDS or gestational age. Baseline FT4 SDS and baseline TSH 
SDS did not significantly correlate. There were also no significant correlations between 
baseline FT4 SDS or TSH SDS and height SDS, BMI SDS, IGF-1 SDS or IGFBP-3 SDS. 
 The change in height SDS during 24 months GH treatment (Δ height) did not correlate 
with the 24-months change in FT4 SDS (Δ FT4) or the change in TSH SDS. However, 
Δ FT4 correlated weakly with the 24-months change in IGF-I SDS (Δ IGF-I) (r = -0.22; 
p = 0.009). Multiple regression analysis with Δ height as the dependent variable and 
age at start of treatment, sex, Δ FT4 and Δ IGF-I as independent variables yielded a 
significant model that explained 60% of the variation of Δ height. However, Δ FT4 did 
not significantly contribute to the model (β = 0.03, p = 0.246) in contrast to Δ IGF-I (β = 
0.09, p < 0.001). This means that corrected for age, sex and the 24-months increase in 
IGF-1, the decrease of FT4 SDS had no influence on the 24-months change in height SDS 
during GH treatment.
 Using multiple regression, we evaluated whether, corrected for age and sex and 
Figure 1: FT4 during GH treatment
Compared with zero SDS (median for age): *p < 0.001
Compared with baseline values: ¶p < 0.001
0.1
-0.0
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-0.2
-0.3
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gestational age, birth weight SDS or birth length SDS influenced TSH levels at the 
age when GH treatment was started. These predictors could, however, not explain the 
variation in TSH levels, indicating that neither the degree of SGA (birth weight SDS or 
birth length SDS) nor being born preterm (gestational age) is associated with higher TSH 
levels.
diSCuSSion
We studied thyroid hormone levels in a large population of prepubertal non-GH deficient 
short SGA children. Baseline mean TSH levels were within the normal range but 
significantly higher than mean levels of age-matched references. This was more evident 
in preterm born short SGA children, although gestational age did not correlate with TSH 
levels. During growth hormone treatment, FT4 levels decreased significantly within 6 
months after start, but levels remained within the normal range. The change in FT4 
levels was not associated with a change in TSH levels and there was no effect on the 
2-year-growth response. None of the children developed symptomatic hypothyroidism.
 Our results are not completely comparable to the few reports that have been 
published about thyroid hormone levels in SGA children because they studied SGA 
children with catch-up growth to a normal height (1-3, 13). These studies intended to 
determine the roles played by size at birth and gestational age on thyroid function in 
childhood. SGA children without catch-up growth had higher TSH levels compared to SGA 
Table 4. Anthropometric parameters, IGF-1 and IGFBP-3 during GH treatment
T=0 T=6 months T=12 months T=24 months
Height SDS -1.8 (-1.9 to -1.7)a,b,d -2.2 (-2.3 to -2.2)a,b,d -2.5 (-2.6 to -2.5)a,d -3.0 (-3.1 to -2.9)d
Weight SDS -0.7 (-0.8 to -0.5)a,b,d -0.9 (-1.1 to -0.8)a,b,d -1.1 (-1.2 to -1.0)a,d -1.2 (-1.4 to -1.1)d
BMI SDS -1.3 (-1.5 to -1.2)d -1.3 (-1.4 to -1.2)d -1.2 (-1.3 to -1.1)a,b,d -1.0 (-1.1 to -0.9)a,b,d
Head Circ. SDS -1.3 (-1.4 to -1.2)d -1.1 (-1.2 to -1.0)a,d -1.0 (-1.1 to -0.9)a,c,d -0.9 (-1.0 to -0.8)a,b,d
IGF-1 SDS -1.2 (-1.4 to -1.1)d 0.7 (0.6 to 0.9)a,d 0.6 (0.4 to 0.8)a,d 0.9 (0.7 to 1.1)a,c,d
IGFBP-3 SDS -1.2 (-1.3 to -1.1)d 0.1 (0.0 to 0.3)a 0.2 (0.0 to 0.3)a 0.2 (0.1 to 0.4)a,e
Data expressed as model estimate (95% CI)
Compared with baseline values: ap<0.001 
Compared with previous visit:  bp<0.001; cp<0.01 
Compared with zero SDS (median for age and sex): dp<0.001; ep<0.05
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children with catch-up growth (1) but these results could not be replicated in term SGA 
children (2). One study reported no significant difference in FT4 and TSH levels between 
82 SGA children and 53 AGA children (1), while another study described significantly 
higher TSH levels in 40 SGA children compared to 35 term AGA children (13). When 88 
SGA children (56 preterm) were compared to 29 preterm AGA children, there was no 
significant difference in TSH levels (3). TSH correlated negatively with gestational age, 
independently from birth weight or birth length. (3) In our much larger population of 264 
short SGA children, we found no correlation between TSH and gestational age. TSH levels 
were significantly greater than zero SDS in preterm SGA children and not significantly 
different from zero SDS in those born at term but there was no significant difference in 
TSH SDS between term and preterm short SGA children. Also, we found no significant 
influence of birth length SDS or birth weight SDS on TSH levels. We therefore consider 
the association between size at birth or gestational age and TSH levels to be weak and 
not clinically relevant.
 To our knowledge, this is the first report about the effect of GH treatment on thyroid 
function in short SGA children. In GH deficient children and adults and girls with Turner’s 
syndrome, the effect of GH treatment has been studied (5, 6, 14, 15). Similar to our 
population, a decrease of FT4 levels without a change in TSH levels was described. In 
most studies, these changes were transitory and disappeared during the second year of 
GH treatment (5, 6, 14, 15).   Others reported a decline in FT4 levels that was maintained 
during the follow-up period (4), corresponding with our results. The only study performed 
in short non-GH-deficient children reported no effect of GH treatment on thyroid function 
(16). However, it is not stated whether the participating subjects had idiopathic short 
stature (ISS) or were short SGA and the study included only 20 patients receiving GH 3 
days a week and in a much lower dose than the children in our study. Therefore, these 
results are not comparable to ours.
 Two mechanisms have been suggested to explain the decline in FT4 levels without a 
parallel change in TSH levels during GH treatment. The first one points to an inhibition of 
TSH release mediated by a hypersecretion of somatostatin directly induced by GH (17, 18). 
The second explains the discrepancy by an increase of peripheral conversion of FT4 to T3 
(6, 17, 19). This effect might be mediated by either GH itself or via IGF-I, or both (6, 20). 
 Because none of the children developed hypothyroidism and there was no effect on 
the growth response, there seems to be no clinical relevance of the GH-related decline in 
FT4 levels. This indicates that it is not required to monitor thyroid function more than once 
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a year in short SGA children during GH therapy, in contrast to children with multiple pituitary 
hormone deficiencies who may develop true hypothyroidism during GH therapy (4). 
 We did not measure autoantibodies to thyroglobulin or thyroid peroxidase as FT4 
levels remained in the normal range, in combination with completely normal TSH levels. 
In the study by Radetti et al, none of the SGA children with TSH levels above the upper 
limit of normal had thyroid antibodies (3).
 In conclusion, our study demonstrates that preterm born short SGA children have 
TSH levels within the normal range, although significantly higher than the average level 
in healthy controls. The higher TSH levels could not be explained by gestational age, 
birth weight SDS or birth length SDS. GH treatment coincided with a significant decrease 
of FT4 during the first 6 months of treatment but mean levels remained in the normal 
range and there was no compensatory increase in TSH. The decrease in FT4 levels did 
not affect the 2-year growth response during GH treatment.
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ABStrACt
Objective: To investigate if prematurity has an independent influence 
on the response to growth hormone (GH) treatment, in short, small for 
gestational age (SGA) children.
Design: longitudinal 3-year GH study
Patients: 392 prepubertal non-GH deficient, short SGA children, divided in 
138 preterm (<36 weeks) and 254 term (≥ 36 weeks) children.
Measurements: Height, weight, head circumference, skinfolds and serum 
insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) 
levels were measured before start of GH treatment and after 6 months, 1, 
2 and 3 years of treatment.
Results: Preterm short SGA children were significantly lighter and shorter 
at birth after correction for gestational age than term short SGA children 
(p<0.001). At start of GH treatment, preterm children were significantly 
shorter than term children when height was corrected for target height 
(TH). Preterm children were also significantly leaner as shown by a lower 
BMI SDS and lower sum of 4 skinfolds SDS. Prematurity had no influence 
on childhood IGF-I and IGFBP-3 levels. The response to GH treatment was 
similar for preterm and term SGA children. 
Conclusions: Within a population of short SGA children prematurity is 
associated with a smaller size for gestational age, and a shorter height 
corrected for TH and leaner phenotype in childhood. The response to GH 
treatment is similar for preterm and term short SGA children. 
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introduCtion
Since growth hormone (GH) treatment was licensed for short children born small for 
gestational age (SGA), it has become a frequently applied growth promoting therapy. 
Short SGA children comprise a heterogeneous group because some are born at term 
and others are born preterm. Despite this important difference, all SGA children are 
treated in the same way. SGA is probably caused by a combination of environmental and 
genetic factors and the contribution of these components is variable (1). The prenatal 
environment and genetic background might be different when there is a shorter duration 
of pregnancy. Therefore, preterm birth might be associated with a smaller size for 
gestational age. 
  Children who are born SGA have a suboptimal growth pattern in utero. Prematurity 
often has an additional detrimental effect on spontaneous postnatal growth (2). SGA 
children with persistent short stature failed to catch-up to a normal height during infancy. 
When preterm short SGA children suffer from an extra growth impairment during their 
neonatal period, this may result in a height significantly below the genetic height potential 
of the child (3). We hypothesized that premature SGA children have a greater height 
deficit at birth and due to less optimal circumstances in the neonatal period also later 
on, which would lead to a smaller GH-induced catch-up growth in preterm born short SGA 
children than in those born at term. To test our hypothesis, we compared preterm short 
SGA children with short SGA children born at term, with respect to birth characteristics, 
anthropometry when GH treatment was started and growth during GH treatment.
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 pAtientS And MetHodS
Subjects
The study cohort consisted of 392 prepubertal short children born SGA (217 boys). 
Children were included according to the following criteria: 1) birth length and/ or birth 
weight standard deviation score (SDS) below –2 for gestational age (4); 2) height SDS 
for age below – 2 according to Dutch standards (5); 3) height velocity SDS below zero 
to exclude children with spontaneous catch-up growth; 4) prepubertal stage defined 
as Tanner breast stage 1 for girls and testicular volume less than 4 ml for boys; 5) an 
uncomplicated neonatal period, without signs of severe asphyxia (defined as Apgar score 
below 3 after 5 minutes), sepsis or long-term complications of respiratory ventilation 
such as chronic lung disease. Children with GH deficiency (defined as an IGF-I level below 
–2 SDS and a GH peak < 10 μg/l during two GH stimulation tests), other endocrine 
or metabolic disorders, chromosomal defects, syndromes and growth failure caused by 
other conditions (e.g. emotional deprivation, severe chronic illness, chondrodysplasia) 
were excluded. Children without information on gestational age were excluded as well. 
In total, 138 children (79 boys) were born preterm, defined as a gestational age < 36 
weeks, and 254 children (138 boys) were born at term (≥ 36 weeks). The gestational 
age of the subjects was determined by ultrasound scans during the first trimester, if 
available, and otherwise calculated from the date of the last menstruation. The Medical 
Ethics Committees of the participating centers approved the study and written informed 
consent was obtained from the parents.
Study design
All children were treated with biosynthetic GH at a dose of 1 mg/m2 body surface area (~ 
0.033 mg/kg), administered subcutaneously once daily at bedtime. Three-monthly, the 
GH dose was adjusted to the calculated body surface area. 
 At baseline and subsequently every three months after the start of GH treatment, 
height, weight, head circumference and Tanner stage were recorded, as previously 
described (6). To exclude the influence of puberty on linear growth and body composition, 
only measurements in prepubertal children were included in the analyses. Body mass 
index (BMI) was calculated as weight divided by height squared (kg/m2). Target height was 
calculated as TH = (maternal height + paternal height +13) / 2 + 4.5 for boys and TH = 
(maternal height + paternal height –13) / 2 + 4.5 for girls (7). Height, head circumference, 
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target height and BMI were expressed in SDS adjusting for age and sex according to 
Dutch reference data (5). Height corrected for target height was calculated as height 
SDS – target height SDS. Biceps, triceps, subscapular and suprailiacal skinfold thickness 
was measured at baseline and subsequently every six months after the start of GH 
treatment, using a Holtain skinfold caliper (8). For skinfold thickness analysis, the mean 
of three measurements, expressed as SDS using references for healthy Dutch children, 
was used (9). Limb skinfold SDS was calculated as biceps SDS + triceps SDS. Trunk 
skinfold SDS was calculated as subscapular SDS + suprailiacal SDS. Bone age (BA) was 
determined at start and after 1, 2 and 3 years of GH treatment according to Greulich 
& Pyle (10). At baseline and after 6 months, 1, 2 and 3 years of GH treatment a blood 
sample was taken. After centrifugation all samples were frozen (-80 °C) until assayed. 
Assays
Serum insulin-like growth factor (IGF-I) and insulin-like growth factor binding protein-3 
(IGFBP-3) were measured in one laboratory using specific RIA’s, as previously described 
(11-13). Serum levels of total IGF-I and IGFBP-3 were expressed as SDS adjusting for age 
and sex, using reference values for healthy children with normal stature determined in 
the same laboratory (14).
Statistics
A one-sample t-test was used to compare data, expressed as SDS, with those of healthy 
references (0 SDS). An independent samples t-test was used to compare preterm 
and term children at baseline. Clinical data are presented as mean (SD). Statistical 
significance was defined as p < 0.05. 
 The number of prepubertal patients after 6 months, 1, 2, and 3 years of GH 
treatment was 363, 354, 293, and 191, respectively. To correct for missing data and 
multiple testing, the changes over time and differences between preterm and term 
children were analyzed with repeated measures of variance (15). Firstly, we tested 
whether prematurity had a significant effect on the change of the various parameters 
during GH treatment. This was done by testing whether the interaction time*prematurity 
was significant in a model with time and prematurity as covariables. Because all p values 
were > 0.05, further analyses were not performed. Model estimates are presented in 
figures as mean (95% CI). 
 Correlations were calculated using Spearman’s rank correlation coefficient. Multiple 
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linear regression analysis was used to assess multivariable relationships between 
prematurity and response to GH treatment.
 Analyses were performed using the statistical package SPSS (version 15.0; SPSS 
Inc., Chicago, IL) for Windows. For repeated measures of variance analyses SAS 8.2 (SAS 
Institute Inc., Cary, /nC, USA) was used.
reSultS
Size at birth
Birth characteristics of the preterm and term short SGA children are shown in Table 1. 
Unfortunately, birth length and birth head circumference are not routinely measured by 
all obstetricians. As auxological data at birth were collected retrospectively we were not 
able to obtain information on birth length and head circumference from all subjects. 
Birth weight SDS and birth length SDS were significantly lower in preterm than in term 
short SGA children. Preterm children also had a smaller head circumference SDS at birth 
than term children but this difference did not reach statistical significance. A positive 
value for the difference between birth head circumference SDS and birth length SDS 
indicates brain sparing and a negative value indicates that head circumference SDS is 
Table 1. Clinical characteristics
Preterm Term
N N P value
Male/female 138 79 / 59 254 138 / 116 0.58
Gestational age 138 32.21(2.6) 254 38.6 (1.5) < 0.001
range 25.7 to 35.9 36.0 to 42.0
Birth weight SDS 138 -2.8 (1.3)* 254 -2.0 (1.0)* < 0.001
range -5.4 to 1.3 -4.7 to 0.4
Birth length SDS 85 -3.7 (1.9)* 185 -2.9 (1.2)* < 0.001
range -8.6 to 1.5 -7.2 to 0.1
Birth Head Circ. SDS 38 -2.3 (1.3)* 45 -1.7 (1.3)* 0.054
range -5.6 to 0.5 -4.9 to 1.3
Birth Head Circ. SDS - length SDS 26 2.1 (1.2)* 36 1.6 (1.8)* 0.28
Data expressed as mean (SD)
Compared with zero (median for gestational age and sex): *p < 0.001
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lower than birth length SDS. As shown in Table 1, the degree of brain sparing at birth was 
not significantly different between preterm and term children. 
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Anthropometry at start of GH treatment 
Before start of GH treatment, height SDS was comparable for preterm and term short 
SGA children (-2.96 versus –3.04 SDS, p = 0.21) (Table 2). However, adjusted for target 
height SDS, preterm children were shorter than term children (-2.66 versus –2.39 SDS, 
p = 0.004). Preterm children had a lower BMI SDS (-1.68 versus –1.19, p < 0.001) and 
lower sum of 4 skinfolds SDS (-1.22 versus –0.89, p = 0.004). Preterm children had lower 
skinfolds SDS in the limbs (-1.65 versus –1.03, p = 0.004) and trunk (-2.38 versus –1.90, 
p = 0.02). The distribution of subcutaneous fat, measured as the difference between 
limb and trunk skinfolds SDS (limb SF SDS – trunk SF SDS), was comparable in preterm 
and term children (0.73 versus 0.87, p = 0.36). At a mean age of 7 years, at start of 
GH treatment, head circumference was smaller in preterm children compared with term 
children (-1.45 versus –1.11, p = 0.003). The difference between head circumference 
SDS and height SDS was significantly smaller in preterm children compared with term 
children (1.54 versus 1.90, p = 0.001), indicating that preterm children also had smaller 
heads than term children in relation to their height. There were no significant differences 
between preterm and term children in SD scores of serum levels of IGF-I and IGFBP-3. 
Time after start GH therapy
    6 months                1 year              2 years                   3 years
preterm
term
2
1
0
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Time after start GH therapy
    6 months                1 year              2 years                   3 years
preterm
term
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
-0.1
Time after start GH therapy
    6 months                1 year              2 years                   3 years
preterm
term
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Figure 1. Change in anthropometry during 3 years of GH treatment 
Data expressed as model estimate (95% CI)
BMI = body mass index; HC = head circumference
p values for difference in overall growth response between preterm and term children: 
Δ height SDS: 0.52, Δ BMI SDS: 0.20 and Δ HC SDS: 0.11 
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Response to GH treatment
As shown in Figures 1 and 2, there was a parallel change of all anthropometric parameters 
in preterm and term children. Only measurements in prepubertal children were included 
in the analyses and a correction for missing data was made. The interaction between 
time and being born preterm was not significant for any of the parameters indicating 
that prematurity did not have a significant effect on the change of the parameters during 
GH treatment, including IGF-I and IGFBP-3 levels. This indicates that preterm birth 
does not influence the response to GH treatment. The increase in head circumference 
SDS was greater in preterm children than in term children but the difference did not 
reach significance (p = 0.11). Table 2 shows mean values of the various parameters after 
3 years of GH treatment. The increase in height SDS during 3 years of GH treatment was 
similar for boys and girls. All children responded with an increase in height SDS during the 
3-year treatment period (range 0.5 to 2.9 SDS). No side effects were observed during GH 
treatment. There was no significant correlation between the 1-year or 3-year increase in 
height SDS during GH treatment and gestational age, birth length SDS or birth weight SDS. 
Time after start GH therapy
    6 months                1 year              2 years                   3 years
preterm
term
0.0
-0.5
-1.0
-1.5
-2.0
-2.5
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Time after start GH therapy
    6 months                1 year              2 years                   3 years
preterm
term
0.0
-0.5
-1.0
-1.5
-2.0
-2.5
Time after start GH therapy
    6 months                1 year              2 years                   3 years
preterm
term
0.5
0.0
-0.5
-1.0
-1.5
-2.0
Figure 2. Change in skinfold thickness SDS during 3 years of GH treatment 
Data expressed as model estimate (95% CI) SF = skinfold thickness
limb SF = biceps SF SDS + triceps SF SDS; trunk SF = subscapular SF SDS + suprailiacal SF SDS
p values for difference in overall growth response between preterm and term children: Δ sum of 4 SF SDS: 0.36, Δ limb SF 
SDS: 0.12 and Δ trunk SF SDS: 0.76 
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Because preterm and term children differed at baseline, we also investigated the 
influence of preterm birth on the 1-year and 3-year increase in height SDS during GH 
treatment corrected for possible confounders in a multiple regression analysis (Table 
3). In both models, prematurity (yes/no) did not significantly contribute (β = -0.02, p = 
0.58 and β = 0.09, p = 0.18, respectively). This suggests that corrected for age, sex, 
height SDS, target height SDS, IGF-I SDS and IGFBP-3 SDS at start, preterm birth has 
no influence on the change in height SDS during GH treatment. When we performed the 
same multiple regression analyses with gestational age instead of prematurity (yes/no), 
we found similar results.
diSCuSSion
In a large population of 392 short SGA children, we demonstrate that preterm SGA children 
were significantly smaller for gestational age than those born at term. During childhood, 
preterm SGA children remained significantly shorter than term SGA children compared 
to their target height (TH). Preterm SGA children were leaner and had a smaller head 
circumference. In spite of these differences at birth and at start of GH treatment, the 
growth response to GH treatment was similar for preterm and term short SGA children.
 Birth length, weight and head circumference SD scores were more reduced in 
preterm SGA children than in term SGA children. Previously, our group demonstrated that 
the smallest SGA newborns were more often born prematurely and by caesarean section 
(16). The hypertensive complications of the mother or the severe intra uterine growth 
retardation might have led to an elective preterm birth to prevent further intrauterine growth 
deterioration. This might explain why the smallest SGA children were born preterm.
 To the best of our knowledge, this is the first study evaluating whether preterm 
and term SGA children respond differently to GH treatment. We only included children 
without serious complications during their neonatal period but nonetheless preterm 
children often experience nutritional problems during the postnatal period (17, 18) which 
might inhibit postnatal growth (2). Because preterm SGA children have experienced 
this additional growth inhibition, we hypothesized that they would respond worse to GH 
treatment than term children. Growth during GH treatment was, however, similar for both 
groups. Head circumference increased more in preterm children but this difference did 
not reach significance.
 Target height (TH) SDS was significantly greater in preterm children than in term 
Table 3. Multiple linear regression analyses
Δ Height SDS 0-1 year Δ Height SDS 0-3 years
Variables β P-value β P-value
Prematurity# -0.02 0.58  0.09 0.18
Age (yr) -0.08 <0.001 -0.10 <0.001
Sex* -0.08 <0.01 -0.13 0.04
Baseline Height SDS -0.04 0.12 -0.12 0.02
Baseline IGF-I SDS -0.02 0.04 -0.03 0.28
Baseline IGFBP-3 SDS -0.03 <0.01 No effect
Target height SDS  0.04 0.03  0.04 0.32
N 304 167
Overall < 0.001 <0.001
R2 0.47 0.24
Adjusted R2 0.46 0.21
* Coded as male=0 and female=1
# Coded as preterm=1 and term=0 
SDS = standard deviation score
Multiple linear regression analysis with gestational age instead of prematurity as independent 
variable in these models yielded similar results.
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children. This indicates that according to their genetic potential, preterm children should 
have been taller than term children. Thus, preterm children were growing more below their 
genetic height potential than term children. This is in line with the findings of Cutfield et al. 
(19). Despite their greater height potential, preterm children did not respond better to GH 
treatment. In the multiple regression analysis, after correction for several confounders 
including TH, no significant effect of prematurity on the growth response was found. 
 Serum IGF-I and IGFBP-3 levels were significantly below age-matched reference 
values in both groups. This is in agreement with previous reports on short children 
born SGA (19, 20). We found no significant correlation between IGF-I SDS and IGFBP-3 
SDS and gestational age, whereas baseline IGF-1 and IGFBP-3 levels were comparable 
between term and preterm SGA children. Conversely, Cutfield et al. reported lower plasma 
IGF-I and IGFBP-3 levels in preterm versus term SGA children and a positive association 
between gestational age and plasma IGF-I and IGFBP-3 (3). Unfortunately, Cutfield et al. 
did not mention height as an inclusion criterium which renders it unclear whether all SGA 
children in their study were short (3). The difference with our results might be explained 
Table 3. Multiple linear regression analyses
Δ Height SDS 0-1 year Δ Height SDS 0-3 years
Variables β P-value β P-value
Prematurity# -0.02 0.58  0.09 0.18
Age (yr) -0.08 <0.001 -0.10 <0.001
Sex* -0.08 <0.01 -0.13 0.04
Baseline Height SDS -0.04 0.12 -0.12 0.02
Baseline IGF-I SDS -0.02 0.04 -0.03 0.28
Baseline IGFBP-3 SDS -0.03 <0.01 No effect
Target height SDS  0.04 0.03  0.04 0.32
N 304 167
Overall < 0.001 <0.001
R2 0.47 0.24
Adjusted R2 0.46 0.21
* Coded as male=0 and female=1
# Coded as preterm=1 and term=0 
SDS = standard deviation score
Multiple linear regression analysis with gestational age instead of prematurity as independent 
variable in these models yielded similar results.
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by a much larger number of subjects in our study. In addition, we also included children 
with a gestational age of 32-36 weeks while Cutfield et al. did not. When we performed 
the analyses without the group born after a gestational age of 32-36 weeks (data not 
shown), we could not confirm their results either. We therefore conclude that prematurity 
has no influence on childhood serum IGF-I and IGFBP-3 levels in short SGA children. 
 In conclusion, within a population of short SGA children prematurity was associated 
with a smaller size for gestational age (length, weight and head circumference), a shorter 
height SDS corrected for TH and a leaner phenotype during childhood. Despite the 
differences in body size, there were no significant differences in age and sex adjusted 
IGF-I and IGFBP-3 levels between preterm and term short SGA children. Notably, the GH 
induced catch-up growth and change in serum IGF-I and IGFBP-3 levels were similar for 
preterm and term short SGA children. Therefore preterm short SGA children should not 
be excluded from GH treatment.
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ABStrACt
Context: We reported that short, small for gestational age (SGA) children 
who were born preterm have a lower body fat percentage and a higher 
blood pressure, insulin secretion and disposition index than short SGA 
children born at term. Whether preterm birth also influences these 
parameters during growth hormone (GH) treatment is unknown.
 
Objective: To compare blood pressure, insulin sensitivity, beta cell function 
and body composition during 4 years of GH treatment, between preterm 
and term short SGA children. 
Patients: 404 prepubertal non-GH-deficient short SGA children, divided 
into 143 preterm (<36 weeks) and 261 term children.
Outcome measures: Height, blood pressure (n=404), body composition 
measured by Dual energy X-ray Absorptiometry (n=138), and insulin 
sensitivity and beta cell function calculated from a frequent sampling IV 
glucose tolerance test (FSIGT) with tolbutamide (n=74) or from HOMA-IR 
(n=204). 
Results: In preterm and term children, GH treatment resulted in a similar 
decrease of systolic and diastolic blood pressure, body fat percentage, 
limb fat/total fat ratio and insulin sensitivity, and a similar increase in 
insulin secretion and disposition index. lean body mass (lBM) corrected 
for gender and height increased in term children and did not change in 
preterm children. Multiple regression analysis revealed that this difference 
in GH effect on lBM was not associated with gestational age.
Conclusion: The effect of growth hormone treatment on metabolic and 
cardiovascular risk factors is similar in preterm and term short, small for 
gestational age children.
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introduCtion
A small size at birth for gestational age (SGA) and prematurity have both been associated 
with adult diseases such as cardiovascular disease and diabetes mellitus type 2 (1-5). 
Children born SGA with persistent short stature, have a higher prevalence of risk factors 
for adult diseases during childhood compared to normal references (6-8). Recently, we 
reported that preterm birth has independent and divergent effects on the cardiovascular 
risk profile of short SGA children (9). Preterm short SGA children had a higher systolic and 
diastolic blood pressure than term short SGA children and a lower body fat percentage, 
a higher insulin secretion and a higher disposition index (9). 
 Apart from preterm birth, growth hormone (GH) treatment also influences 
cardiovascular risk factors of short SGA children. During GH treatment, blood pressure (6), 
insulin sensitivity (10) and fat percentage corrected for age (11) decrease while there is a 
compensatory increase in insulin secretion (10). However, these studies were performed 
in mixed populations with subjects born preterm and at term. The independent effect 
of prematurity was not evaluated and it is therefore unknown whether GH treatment 
influences cardiovascular risk factors in a different way in preterm than in term SGA 
children.
 The aim of our study was to investigate whether GH-induced changes in cardiovascular 
risk factors are influenced by preterm birth. Our second aim was to evaluate whether the 
differences in cardiovascular risk factors between preterm and term short SGA children 
disappear or increase during GH treatment. To answer our questions, we compared short 
SGA children born preterm with short SGA children born at term, with respect to the 
change in blood pressure, insulin sensitivity, beta cell function and body composition 
during 4 years of GH treatment
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SuBjeCtS And MetHodS
Subjects
The study cohort consisted of 404 prepubertal short children born SGA (227 boys) who 
were participating in GH trials with the same inclusion criteria. Children were included if 
they fulfilled the following criteria: 1) a birth length and/ or birth weight standard deviation 
score (SDS) of below –2 for gestational age (12); 2) a height SDS for age of below – 2 
according to Dutch standards (13); 3) a height velocity SDS of below zero; 4) a Tanner 
breast stage 1 for girls and a testicular volume of less than 4 ml for boys (14); 5) an 
uncomplicated neonatal period, with no signs of severe asphyxia (defined as Apgar score 
below 3 after 5 minutes), sepsis or long-term complications of respiratory ventilation 
such as chronic lung disease; 6) no GH deficiency defined as a GH peak > 10 μg/l during 
two GH stimulation tests. Children with endocrine or metabolic disorders, chromosomal 
defects, syndromes and growth failure caused by other conditions (e.g. emotional 
deprivation, severe chronic illness, chondrodysplasia) were excluded. Children without 
information on gestational age were also excluded. The Medical Ethics Committees of 
the participating centers approved the study and written informed consent was obtained 
from the parents. 
Study design
Children were divided into two groups based on their gestational age: 1) preterm 
(gestational age < 36 weeks), and 2) term (gestational age ≥ 36 weeks). The gestational 
age of the subjects was determined by ultrasound scans during the first trimester, if 
available, and otherwise calculated from the date of the last menstruation.
 Children were treated with biosynthetic GH at a dose of 1 mg/m2 body surface 
area, administered subcutaneously, once daily at bedtime. The GH dosage was adjusted 
to the calculated body surface area every three months. A subgroup of 35 children was 
randomized to receive 1 or 2 mg/m2 GH during the first 6 months and 1 mg/m2 thereafter 
(15). The proportion of children receiving 2 mg/m2 was similar in the preterm group as 
in the term group (6/13 versus 12/22; p = 0.63). Another subgroup of 57 children was 
randomized to receive 1 or 2 mg/m2 GH for the entire follow-up period (16). Also in this 
subgroup the proportion of children receiving 2 mg/m2 was similar in the preterm group 
as in the term group (12/20 versus 17/37; p = 0.31). Because independent samples 
t-tests demonstrated that the effect of GH treatment on the change in blood pressure, 
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body composition or insulin sensitivity after 4 years of treatment was not different 
between the GH dosage groups, the groups were combined to form one GH-group. 
Anthropometry
At start and after 6 months, 1, 2, 3 and 4 years of GH treatment, standing height and 
weight were measured as previously described (16) and expressed as SDS using Dutch 
reference data (13). Systolic and diastolic blood pressure (BP) was measured twice on the 
left arm with an automated device and using an appropriate cuff size (Dinamap Critikon, 
southern Medical Corp., Baton Rouge, LA, USA). The mean of two measurements was 
used for analysis. As blood pressure is known to increase with height, BP was expressed 
as SDS adjusted for height and gender (17). 
Glucose homeostasis
In a subgroup of 74 children, a modified, frequently sampled intravenous glucose tolerance 
test (FSIGT) using tolbutamide, was performed before the start of GH treatment and after 
6 months, 2 and 4 years, as previously described (18, 19). Serum glucose and insulin 
levels were measured in one laboratory as previously described (9) and insulin sensitivity 
(Si), glucose effectiveness (Sg), acute insulin response (AIR) and disposition index (DI) 
were calculated using Bergman’s MINMOD MILENNIUM software (20). All blood samples 
were taken after an overnight fast. Insulin sensitivity quantifies the capacity of insulin to 
promote glucose disposal and glucose effectiveness reflects the capacity of glucose to 
mediate its own disposal. The acute insulin response, an estimate of insulin secretory 
capacity, was measured as the area under the curve from zero to ten minutes corrected 
for baseline insulin levels. Disposition index equals AIR*Si and is an estimate of beta 
cell function. 
 In 204 children fasting glucose was measured on a Hitachi 917 analyzer. Also, 
fasting insulin was measured by chemoluminescent assay on an Immulite 2000 analyzer 
(Diagnostic Products Corporation, Los Angeles, CA) and HOMA insulin resistance index 
(HOMA-IR) was calculated (21).
Body Composition
Dual-Energy X-ray Absorptiometry scans (DEXA, type Lunar DPX-L, GE Healthcare, 
Madison, Wisconsin, USA) were performed in a subgroup of 138 children at start and 
after 6 months, 2 and 4 years of GH treatment. Lean body mass (LBM), fat mass (FM) 
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and body fat percentage (FM%, % fat mass of total body weight) were determined. FM% 
and LBM were transformed into SD-scores for gender and chronological age using Dutch 
reference values for children, which were obtained using the same machine and software 
(22, 23). Since body composition is strongly related to height, LBM and FM expressed 
as SDS for age and gender may result in an underestimation in case of short stature. In 
addition we were interested to know whether GH has an additional effect on LBM and 
FM beyond the effects due to catch-up in height. For these reasons, LBM and FM were 
expressed as SDS for height and gender (11). 
Statistics
FSIGT parameters, fasting insulin levels, HOMA-IR, the amount of limb fat and trunk 
fat were logarithmically transformed because of a skewed distribution. A one-sample 
t-test was used to compare data, expressed as SDS, with those of healthy references (0 
SDS). Differences between preterm and term children were tested using an independent 
samples t-test for continuous variables and the χ2 test for categorical variables. Clinical 
data are presented as mean (SD) unless stated otherwise. To correct for missing data 
and multiple testing, the changes over time and differences between preterm and term 
children were analyzed using repeated measures of variance (24). Model estimates are 
presented as mean (95% CI).
 Correlations were analyzed using Spearman’s correlation coefficient. Multiple linear 
regression analysis was used to adjust the differences in response to GH treatment 
between the groups for possible baseline differences. Statistical significance was defined 
as p < 0.05. Analyses at baseline were performed using the statistical package SPSS 
(version 12.0; SPSS Inc., Chicago, IL) for Windows. For repeated measures of variance 
analyses SAS 8.2 (SAS Institute Inc., Cary, /nC, USA) was used.
reSultS
Clinical characteristics
Table 1 lists the clinical data of the preterm and term short SGA children. The preterm 
group was significantly younger, had a lower birth weight SDS and a lower birth length 
SDS. Current height SDS was slightly higher in the preterm group while weight for height 
SDS was lower in the preterm group. 
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Blood pressure
Systolic and diastolic blood pressure SDS at start of GH were significantly higher in 
preterm short SGA children than in short SGA children born at term (p = 0.008 and 
p < 0.001, respectively, Table 2). In both groups, blood pressure at start was significantly 
higher than that of gender- and height-matched references (p < 0.001). The decrease in 
systolic and diastolic blood pressure over 4 years of GH treatment was similar in preterm 
and term children (p = 0.50 and p = 0.15, respectively, Figure 1). Because age and blood 
pressure of preterm and term children differed at start, we also compared the decrease in 
blood pressure between preterm and term children corrected for age and blood pressure 
at start. Again, systolic and diastolic blood pressure decreased similarly (p = 0.10 and 
p = 0.30, respectively, Table 2) in the preterm and the term group. After 4 years, systolic 
blood pressure remained higher than zero SDS, e.g. higher than that of gender-and-
height matched references but diastolic blood pressure had completely normalized. 
Table 1. Clinical characteristics at birth and at start of GH treatment
SGA born preterm (< 36 weeks) SGA born at term (≥ 36 weeks) p-value
N 143 261
Age (yr) 6.7 (2.1) 7.4 (2.6) 0.01
Sex (m/f) 84/59 143/118 0.44
Gestational age (wks) 32.2 (2.5) 38.7 (1.5) <0.001
Birth weight SDS -2.8 (1.3)* -2.0 (1.0)* <0.001
Birth length SDS -3.8 (2.0)* -2.9 (1.2)* <0.001
Birth head circumference SDS -2.2 (1.3)* -1.8 (1.3)* 0.19
Height SDS -2.9 (0.6)* -3.1 (0.6)* 0.008
Weight SDS -1.7 (1.1)* -1.1 (1.2)* <0.001
Data expressed as mean (SD)
SDS = standard deviation score; f = female; m = male.
Birth weight and birth length were adjusted for gestational age and sex, height was adjusted for age and sex and weight 
was adjusted for height and sex. 
*p < 0.001 compared with zero SDS, e.g. mean value for references
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Figure 1: Changes in (A) systolic and (B) diastolic blood pressure during GH treatment. Data are expressed as model esti-
mates (95% CI). P-values express the difference between the groups in overall change in blood pressure during 4 years of 
GH treatment.
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Glucose homeostasis
 Table 2 shows the results of the FSIGT tests at start and after 4 years of GH 
treatment, while Figure 2 shows how the various parameters changed during the 4 years 
period. The overall decrease in Si during GH treatment was comparable for preterm and 
term children (p=0.40, Figure 2A), but after 4 years of GH treatment, preterm children 
had a higher Si than term children. In both groups, there was an increase of insulin 
secretion (AIR) after 6 months of treatment, which persisted until the end of the 4-year 
period. DI did not significantly change during GH treatment but the difference between 
the groups slowly increased over time, resulting in a significantly higher DI in preterm 
than in term children after 4 years of treatment (Figure 2D). The change in the FSIGT 
parameters during the 4-year period was, however, comparable between preterm and 
term children (Figure 2), also after correction for values at start and age at start (Table 2). 
Fasting glucose and insulin levels and HOMA-IR were comparable for preterm and term 
children before start and after 4 years of GH treatment (Table 2).
Body composition
Results are shown in Table 3. Body fat percentage (FM%) and FM adjusted for height 
at start were lower in preterm than in term children but the fat distribution was similar. 
During 4 years of GH treatment weight adjusted for height increased similarly in both 
preterm and term children while FM adjusted for height remained at the same level. In 
both groups the increase in limb fat over time was less pronounced than the increase in 
trunk fat and therefore the ratio of limb fat/total fat decreased (Figure 3B) while the ratio 
of trunk fat/total fat increased. 
 Of children with a DEXA scan, those born preterm were significantly taller than 
those born at term (Table3 and Figure 4B). LBM adjusted for age and gender was higher 
in preterm children than in term children, both at start and during GH treatment (Figure 
4A). However, when we adjusted LBM for height and gender instead of age and gender, 
there was no increase in LBM in the preterm children (Figure 4C). In term children, LBM 
adjusted for height and gender increased, indicating that term children had an additional 
increase in LBM beyond their increase in LBM due to catch-up in height.
 To further investigate the influence of several factors on the change in LBM 
adjusted for height and gender during GH treatment, we performed multiple regression 
analysis. In this analysis we only included children who remained prepubertal for 4 years 
and in which a DEXA scan was performed after 4 years of GH treatment (n=32). The 
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increase in LBM SDS during 4 years of GH treatment was associated with gender (β = 
-1.31, p=0.002), birth weight SDS (β = 0.21, p=0.03) and LBM SDS at start (β = -0.65, 
p<0.001), and not with gestational age and age at start of GH treatment. This model 
explained 93% of the variance of the change in LBM SDS during 4 years of GH treatment. 
Thus, children with a higher birth weight SDS had a greater increase of LBM SDS during 
GH treatment. As preterm children had a lower birth weight SDS than term children, this 
might explain why the change in LBM SDS was smaller in preterm children.
diSCuSSion
Our study shows that GH-induced changes in blood pressure, fat mass, beta cell function 
and insulin sensitivity are similar in preterm and term born short SGA children. In children 
born preterm, lean body mass (LBM) adjusted for height and gender remained low during 
GH treatment whereas in children born at term there was an additional increase in LBM 
beyond the increase in LBM due to catch-up in height. 
 Concerns have been expressed that GH treatment may increase any pre-existent risk 
for cardiovascular disease and type 2 DM of SGA children. Previously, we demonstrated 
that preterm short SGA children have a higher blood pressure than term SGA children, 
which suggests a higher risk for cardiovascular disease in later life (9.) On the other 
hand, they also had a lower fat percentage and a higher disposition index, suggesting a 
lower risk for later disease (9). The present study is the first one investigating whether 
GH treatment induces a different cardiovascular risk profile in preterm versus term short 
SGA children.
 Systolic and diastolic blood pressure at start of GH treatment were both significantly 
higher in preterm children than in term children and also higher than in sex and height 
matched references. SGA and preterm birth have both been associated with a reduced 
number of nephrons and a subsequently higher blood pressure (4, 5, 25, 26). We 
demonstrated that the combination of SGA and preterm birth resulted in a higher blood 
pressure than SGA alone (9). During GH treatment, blood pressure decreased in both 
preterm and term children and after 4 years of GH treatment the initial difference in 
diastolic blood pressure between preterm and term children had disappeared. Thus, 
although preterm children had a higher blood pressure at start, the GH-induced decrease 
in blood pressure was similar for preterm and term children.
 Insulin sensitivity was not significantly different between the groups at start but 
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Figure 2. Insulin sensitivity (A), Glucose effectiveness (B), Acute insulin response (C) and Disposition index (D) during GH 
treatment.
Data expressed as model estimates (95% CI). Data were log transformed for analysis and the exponents of the model esti-
mates were used in the figure.
P-values express the difference between the groups in overall change of the parameter during 4 years of GH treatment.
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after 4 years of GH treatment, preterm children had significantly higher insulin sensitivity 
than term children. A reduction in insulin sensitivity is a known phenomenon during GH 
treatment and it appears to be reversible after withdrawal of GH treatment (27, 28). 
When insulin sensitivity decreases, glucose homeostasis is maintained by increasing 
insulin secretion (AIR). Because term children had a lower insulin sensitivity than preterm 
children, we expected to find a compensatory stronger increase in insulin secretion (AIR) 
in the term group. However, after 4 years of GH treatment, the AIR did not significantly 
differ between the groups. As a result the disposition index (DI) – the product of insulin 
sensitivity and AIR – was higher in preterm children than in term children. DI reflects the 
capacity of pancreatic islets to compensate for insulin resistance. It has been shown 
that particularly a reduction in DI relates to an increased risk for type 2 DM (29, 30). 
There was no significant change in DI during GH treatment, neither in preterm nor in 
term children. This might indicate that in both groups glucose homeostasis remained 
unaffected during GH treatment. 
 Preterm SGA children had a considerably lower body fat percentage (FM%) than 
age-and- sex-matched references but also than term SGA children. As the third trimester 
of pregnancy is a period of rapid adipose tissue deposition, preterm infants have often 
less adipose tissue (31). Also, the postnatal course of preterm infants is often marked by 
nutritional problems and poor growth. These are plausible reasons for reduced adipose 
tissue deposition in preterm children. FM% is known to strongly correlate with insulin 
sensitivity (32). At start, insulin sensitivity was comparable between the groups despite 
the significant difference in FM%. GH treatment induced a further reduction in FM% in 
preterm children but not in term children. The lipolytic effects of GH treatment have been 
well documented (33, 34) but it is unknown why these effects are greater in the adipose 
tissue of preterm children. The reduction in FM% in preterm children resulted in a greater 
difference in FM% between preterm and term children after 4 years of GH which might 
explain why at that time insulin sensitivity was indeed higher in preterm children than in 
term children. 
 During GH treatment, we observed a decrease of limb fat/total fat ratio in both 
groups. The increase in trunk fat/total fat ratio demonstrated that this was due to a 
relatively lower amount of limb fat and not due to a relatively higher amount of trunk 
fat. Recently De Schepper et al. suggested that GH treatment of short SGA children is 
accompanied by a centripetal shift in fat distribution (35). However, they showed that 
the increase in trunk fat was not significantly different between 11 GH treated and 14 
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untreated short SGA children while the increase in limb fat was (35). Therefore, the data 
of De Schepper et al. in fact demonstrate that there is not a centripetal shift of fat mass 
but that GH treated SGA children loose fat mass in their limbs while the amount of trunk 
fat remains stable. This is in line with our results. 
 Children born at term had an increase in LBM beyond the increase associated with 
catch-up in height while preterm children had not. The absence of an additional increase 
in LBM in preterm children might be explained by several factors. Firstly, preterm children 
had a significantly lower birth weight and birth length SDS, indicating a more severe 
degree of growth retardation, which might adversely affect the development of LBM. 
A lower LBM at birth might limit the increase in LBM during stimulation by GH. This 
explanation is supported by the multiple regression analysis, which showed that birth 
weight SDS was positively associated with the increase in LBM. Secondly, the neonatal 
period of preterm infants is often characterized by nutritional and other problems (36, 
37) which might result in a different development of LBM. 
 The clinical relevance of a change in LBM during GH treatment is unknown. Skeletal 
muscle plays a major role in insulin-mediated glucose uptake (38) and decreased muscle 
mass may therefore lead to more insulin resistance (39). Others, however, did not find 
an association between LBM and insulin sensitivity (32). In our cohort, preterm children 
had a lower LBM after 4 years of GH treatment but their insulin sensitivity was higher 
than that of term children. The latter does not support an increased risk for type 2 DM 
for preterm SGA children during GH treatment. 
 In conclusion, within a population of short SGA children, preterm birth does not 
have an independent influence on the effect of GH on blood pressure, insulin sensitivity, 
beta cell function and body composition. Children born at term had a higher birth weight 
for gestational age, which was associated with an increase in LBM even after adjustment 
for height and gender during GH treatment. We conclude that GH treatment has the 
same effect on cardiovascular risk factors in preterm as in term short SGA children.
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Figure 3. Percentage body fat (FM%) and limb fat / total fat ratio during GH treatment
Data are expressed as model estimates (95% CI)
P-values express the difference between the groups in overall change of the parameter during 4 years of GH treatment.
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Figure 4. Lean body mass (LBM) and height SDS of the children with a DEXA scan, during GH treatment. A) LBM adjusted 
for age and gender; B) Height adjusted for age and gender; C) LBM adjusted for height and gender. Data are expressed as 
model estimates (95% CI)
P-values express the difference between the groups in overall change of the parameter during 4 years of GH treatment.
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ABStrACt
Context: Short children born small for gestational age (SGA) have a lean 
phenotype with a lower insulin sensitivity and higher blood pressure. 
Growth hormone (GH) treatment results in weight gain, and a decrease in 
blood pressure and insulin sensitivity. However, not all children respond in 
the same way. The Pro12Ala polymorphism of the peroxisome proliferator-
activated receptor (PPARG) gene is inversely associated with BMI, changes 
in BMI and the risk to develop type 2 diabetes mellitus (DM).
Objective: To analyze the contribution of the PPARγ Pro12Ala polymorphism 
to GH induced changes in determinants of metabolic and cardiovascular 
disease in short SGA children.
Methods: PPARγ was genotyped in 238 Caucasian short SGA children 
(mean age 7.5 years). Height, weight, blood pressure and serum lipids 
were measured before start and during 4 years of GH treatment. In 
addition glucose homeostasis by HOMA-IR (n = 148) and by frequently 
sampled intravenous glucose tolerance test (FSIGT) (n = 51), and body 
composition by DXA (n = 79) were measured.
Results: At baseline, the Ala12 allele was not associated with any 
determinant of metabolic and cardiovascular disease. After 4 years of 
GH treatment, the increase in weight for height SDS and BMI SDS was 
significantly greater in carriers of an Ala12 allele than in non-carriers. 
The change in all other parameters was not associated with Pro12Ala 
genotype. 
Conclusion: The Ala12 variant of the PPARγ gene is associated with higher 
weight gain during GH treatment but not with changes in determinants of 
metabolic and cardiovascular diseases in Caucasian subjects born SGA.
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introduCtion
Growth hormone (GH) treatment may be a modifier of the association between 
polymorphisms in the peroxisome proliferators-activated receptor γ (PPAR-γ) gene and 
glucose homeostasis and the risk of type 2 diabetes mellitus (DM) in later life. PPAR-γ is 
a nuclear hormone receptor that controls genes involved in adipogenesis and lipid and 
glucose metabolism (1). The Ala12 variant of the PPAR-γ gene has been associated with 
improved insulin sensitivity and a lower risk for type 2 DM compared with the Pro12Pro 
genotype (2-5). In contrast, in a study in overweight individuals with impaired glucose 
tolerance (6) and in young adults born small for gestational age (SGA) (7), the Ala12 
allele was associated with an increased risk for type 2 DM. 
 Results about the association of the Ala12 variant with BMI are conflicting. The 
Ala12 variant has been associated with a higher BMI (8, 9) and a tendency to gain weight 
over time (10). However, in subjects with a normal body weight the Ala12Ala genotype was 
associated with a lower BMI and a lower increase in BMI at follow-up (11) and in a meta-
analysis of subjects with a mean BMI < 27 kg/m2, there was no significant difference in 
BMI between genotype groups (9). Size at birth also interacts with the effect of the Ala12 
allele. In young adults who were born SGA, increased BMI amplified the effect of PPAR-γ 
polymorphism on glucose homeostasis while in those born appropriate for gestational 
age (AGA) there was not such an association (7). These conflicting results regarding 
associations of the Ala12 allele with insulin resistance and BMI demonstrate that the 
allele has a different effect in different environments, and that environmental factors 
may play a role to increase the genetic effect of PPAR-γ on metabolic risk factors. 
 Subjects born SGA might have an increased risk to develop type 2 DM in later life 
(12, 13), particularly those with catch-up in weight (14). It is, however, unknown whether 
this increased risk is genetically or environmentally determined or by a combination of 
both. Most children with short stature who were born SGA are nowadays treated with GH. 
GH treatment generally results in weight gain, a decrease in blood pressure, serum lipid 
levels and insulin sensitivity (15-17). Also, there is a compensatory increase in insulin 
secretion (17). However, not all children respond in the same way. Since the PPAR-γ 
gene was associated with BMI, glucose homeostasis, and atherosclerosis (1), genotyping 
might indicate which children are less capable to compensate for the effects of GH-
treatment on metabolic and cardiovascular risk factors and are thus more at risk to 
develop adult diseases. 
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 The present study aimed to investigate whether PPAR-γ polymorphisms correlate 
with changes in the metabolic and cardiovascular profile during GH treatment. To 
investigate this question, we performed genotyping of the PPAR-γ gene, measurements 
of anthropometry, blood pressure, serum lipids, FSIGTs and calculations of HOMA-IR in 
238 short children who were born SGA and treated with GH.
SuBjeCtS And MetHodS
Subjects
The study group comprised 238 children born SGA. Children were included when they 
were SGA at birth, had short stature (height standard deviation score (SDS) for age and 
gender of below – 2 (18)), did not show catch-up growth to a height > -2 SDS, and had no 
growth failure caused by other disorders. These inclusion criteria have previously been 
described (19). SGA was defined as a birth length and/or birth weight SDS of below –2.0 
for gestational age (20). The Medical Ethics Committees of Erasmus Medical Center, 
Rotterdam, and the other participating centers approved all studies and written informed 
consent was obtained from all participants and their parents. Birth characteristics were 
collected from hospital registries. The gestational age of the subjects was determined by 
ultrasound in the first trimester, if available, and otherwise calculated from the date of 
the last menstruation. 
Study design
Children were treated with biosynthetic GH at a dose of 1 mg/m2 body surface area, 
administered subcutaneously, once daily at bedtime. The GH dosage was adjusted to 
the calculated body surface area every three months. At start and after 6 months, 1, 2, 
3 and 4 years of GH treatment, standing height and weight were measured as previously 
described (19) and expressed as SDS using Dutch reference data (18). Body mass index 
(BMI) was calculated as weight divided by height squared (kg/m2) and was expressed as 
SDS adjusting for age and gender (18). Systolic and diastolic blood pressure (BP) was 
measured twice on the left arm with an automated device and using an appropriate cuff 
size (Dinamap Critikon, southern Medical Corp., Baton Rouge, LA, USA). The mean of 
two measurements was used for analysis. As blood pressure is known to increase with 
height, BP was expressed as SDS adjusted for height and gender (21). The pubertal 
stage was determined according to Tanner (22) and coded as prepubertal or pubertal.
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Glucose homeostasis
In 148 children, fasting glucose was measured on a Hitachi 917 analyzer and fasting 
insulin was measured by chemoluminescent assay on an Immulite 2000 analyzer 
(Diagnostic Products Corporation, Los Angeles, CA). HOMA insulin resistance index 
(HOMA-IR) was calculated (23).
 In a subgroup of 51 children (determined by the date of inclusion), a modified, 
frequently sampled intravenous glucose tolerance test (FSIGT) using tolbutamide, was 
performed before the start of GH treatment and after 6 months, 2 and 4 years, as 
previously described (16, 24). Serum glucose and insulin levels were measured in one 
laboratory as previously described (25) and insulin sensitivity (Si), glucose effectiveness 
(Sg), acute insulin response (AIR) and disposition index (DI) were calculated using 
Bergman’s MINMOD MILENNIUM software (26). All blood samples were taken after an 
overnight fast. Insulin sensitivity quantifies the capacity of insulin to promote glucose 
disposal and glucose effectiveness reflects the capacity of glucose to mediate its own 
disposal. The acute insulin response, an estimate of insulin secretory capacity, was 
measured as the area under the curve from zero to ten minutes corrected for baseline 
insulin levels. The Disposition index (DI) is an overall measure of the ability of the beta 
cells to secrete insulin in response to the degree of insulin resistance. DI is the product 
of AIR and Si (DI = AIRg * SI) (26).
Serum lipids
All blood samples were taken after an overnight fast. Serum cholesterol levels were 
determined as previously described (27). Triglycerides were measured on the Chem-I 
analyzer according to the manufacturer’s instructions (Technicon Instruments, Tarrytown, 
New York) and after 1998 on the Hitachi 917 analyser according to the manufacturer’s 
instructions (Roche Diagnostics, Mannheim, Germany). Both methods were comparable 
(y = x – 0.030).
Body Composition
Dual-Energy X-ray Absorptiometry scans (DXA, type Lunar DPX-L, GE Healthcare, Madison, 
Wisconsin, USA) were performed in a random subgroup of 79 children at start and after 
6 months, 2 and 4 years of GH treatment. The date of inclusion determined in which 
subjects a DXA scan was performed. Lean body mass (LBM), fat mass (FM) and body 
fat percentage (FM%, % fat mass of total body weight) were determined. FM% and LBM 
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were transformed into SD-scores for gender and chronological age using Dutch reference 
values for children, which were obtained using the same machine and software (28, 29). 
Since body composition is strongly related to height, LBM and FM expressed as SDS for 
age and gender may result in an underestimation in case of short stature. Therefore, 
LBM and body fat percentage were expressed as SDS for height and gender (15). 
Genotyping
Genomic DNA was extracted from samples of peripheral venous blood according to salting 
out procedure (30). Genotyping of the PPARγ gene Pro12ala polymorphism (rs1801282) 
was performed using the Taqman allelic discrimination assay. PCR was performed in 
384 wells PCR plates in an ABI 9700 PCR system (Applied Biosystems Inc., Foster City, 
CA, USA) and consisted of initial denaturation for 10 minutes at 95o and 40 cycles with 
denaturation of 15 seconds at 92o and annealing and extension for 60 seconds at 60o. 
Results were analysed by ABI Taqman 7900HT using the sequence detection system 
2.22 software (Applied Biosystems Inc., Foster City, CA, USA).
Statistics
Fasting insulin levels, FSIGT results and HOMA-IR were logarithmically transformed 
because of a skewed distribution. Because the number of subjects carrying the rare 
homozygous genotype was low, we used the dominant genetic model in our analyses. 
Homozygosity for the Pro12 allele was coded as 0, and the heterozygous state and 
homozygosity for the Ala12 allele were coded as 1. Genotype distributions for significant 
departure from the Hardy-Weinberg equilibrium were calculated using the χ2 test. 
Differences between genotype groups were evaluated using independent sample t-tests. 
A retrospective power analysis with a level of significance (α) of 0.05 and a chosen power 
of 80% showed that with our number of subjects per Pro12Ala genotype-subgroup we 
could detect differences in weight for height SDS of 0.48 SDS, in systolic and diastolic 
blood pressure of 0.41 SDS (25), in HOMA IR of 0.22 (25), in insulin sensitivity (Si) of 
6.1*10-4 μU/ml, in AIR of 107 mU/l (31) and in cholesterol levels of 0.38 mmol/l (25). 
 To assess longitudinally measured growth and metabolic characteristics from 
the start of GH treatment to 4 years after start of treatment, we performed repeated 
measures regression analysis with weight for height SDS, body fat percentage, body fat 
percentage SDS, LBM SDS, blood pressure SDS, fasting insulin and fasting glucose levels, 
HOMA-IR, insulin sensitivity, insulin secretion and disposition index as outcomes. This 
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regression technique takes the correlation of multiple measurements within one subject 
into account, assesses both the time-independent and time-dependent effect of PPAR-γ 
genotype on the outcome variable, and allows for incomplete outcome data (32). In 
these models, genotype was included as both independent variable and as interaction 
with the study duration. All models were corrected for age, gender and puberty. The 
models can be written as:
Outcome variable = ß0 + ß1*age + ß2*gender + ß3*puberty + ß4* study duration + 
ß5* genotype + ß6*genotype*study duration.
In this model, the term including ‘ß0’ reflects the intercept, the terms including ‘ß1, 
ß2 and ß3’ reflect the corrections for age, gender and puberty, respectively and the 
term including ‘ß4’ reflects the slope of change (in weight SDS, body fat %, body fat 
% SDS, LBM SDS, systolic blood pressure SDS, diastolic blood pressure SDS, glucose, 
insulin, HOMA-IR, Si, AIR or DI) per month GH therapy for the reference group (Pro12Pro 
genotype). The term including ‘ß5‘ reflects the difference in outcome variable between 
the genotype groups independent of age, gender, puberty and study duration. The term 
including ‘ß6’ reflects the difference in change of the outcome variable between the 
genotype groups independent of age, gender, puberty and study duration (33). 
 Clinical data are presented as mean (SD) unless stated otherwise. Statistical 
significance was defined as p < 0.05. Analyses were performed using the statistical 
package SPSS (version 15.0; SPSS inc., Chicago, IL) for Windows. SAS 8.2 (SAS Institute 
Inc., Cary, /nC, USA) was used for repeated measures of variance analyses.
reSultS
The genotype distribution was Pro12Pro 70.6%, Pro12Ala 26.9%, and Ala12Ala 2.5% 
and was not different from the Hardy-Weinberg expectations (χ2 = 0.001, p = 0.97). The 
frequency of the Ala12 allele was 16%, as reported in literature (6, 34). No significant 
differences in age, gender distribution, size at birth, anthropometry, or body composition 
were observed between the Ala12 carriers and non-carriers (Table 1). Blood pressure, 
glucose homeostasis and serum lipid levels were also not significantly different between 
Ala12 carriers and non-carriers (Table 2). There were 23 (9.7%) children in puberty at 
start of the study. The proportion of pubertal subjects was similar in both genotype 
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groups (p = 0.91) and all results were similar when pubertal subjects were excluded.
 During 4 years of GH treatment the increase in weight for height SDS and in BMI 
SDS was greater in carriers of Ala12 than in non-carriers (Table 3). The change in all other 
evaluated parameters was not significantly different between carriers and non-carriers 
of the Ala12 allele. The genotype distribution of the Pro12Ala polymorphism was not 
significantly different for children with a change in weight for height SDS (n = 186) or BMI 
SDS (n = 172) greater than zero and children with a change in weight for height SDS (χ2 
= 2.23, p = 0.14) or BMI SDS (χ2 = 1.79, p = 0.18) of zero or less. In the subgroup of 79 
children with a DXA scan, the Pro12Ala polymorphism was not associated with the change 
in body fat % SDS or the change in lean body mass SDS. However, in this much smaller 
group, weight for height SDS and BMI SDS were also not associated with the Pro12Ala 
polymorphism, which might indicate a power problem in the relatively small DXA group. 
Table 1. Clinical characteristics before the start of GH treatment
All Pro/Pro Pro/Ala or Ala/Ala p-value
N 238 168 70
Age 7.51 (2.9) 7.56 (3.0) 7.40 (2.5) 0.68
Gender (m/f) 124/114 90/78 34/36 0.48
Birth weight SDS -2.27 (1.1) -2.28 (1.0) -2.25 (1.2) 0.86
Birth length SDS -3.15 (1.4) -3.15 (1.4) -3.15 (1.4) 0.97
Birth head circumference SDS -1.42 (1.3) -1.46  (1.4) -1.34 (1.1) 0.60
Height SDS -2.98 (0.7) -2.97 (0.7) -3.01 (0.7) 0.72
Weight SDSheight -1.14 (1.2) -1.16 (1.3) -1.09 (1.0) 0.68
BMI SDSage -1.25 (1.0) -1.29 (1.0) -1.16 (0.9) 0.36
Body fat %* 12.68 (7.0) 12.83 (7.7) 12.32 (5.0) 0.77
Body fat % SDSage* -0.76 (1.0) -0.76 (1.1) -0.76 (1.0) 1.00
Body fat % SDSheight* -0.77 (1.3) -0.79 (1.4) -0.73 (1.2) 0.87
LBM SDSage* -2.49 (0.7) -2.54 (0.8) -2.39 (0.4) 0.38
LBM SDSheight* -0.87 (1.9) -1.03 (1.9) -0.50 (1.8) 0.25
Values are expressed as mean (SD)
* n = 79
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diSCuSSion
In this study we investigated the impact of the PPAR-γ Pro12Ala polymorphism on 
determinants of metabolic and cardiovascular disease in short children who were born 
SGA and treated with GH. We demonstrated that the Pro12Ala polymorphism was not 
associated with baseline weight SDS, BMI SDS or other determinants of metabolic and 
cardiovascular disease. During GH treatment the Ala12 allele was associated with a 
greater increase in weight for height SDS and in BMI for age SDS. The Ala12 allele was 
not associated with the change in determinants of metabolic and cardiovascular disease 
during GH treatment.
 No other study evaluated whether PPAR-γ polymorphisms associate with GH-
induced changes in body composition and determinants of DM and cardiovascular 
disease (CVD). GH treatment changes the environment by inducing insulin resistance 
and a compensatory increase in insulin secretion (17). Also, GH treatment reduces blood 
pressure in short SGA children (16) but the mechanism behind this effect is not yet 
known. Because of the effect of GH-treatment on determinants of DM and CVD and the 
variation between patients in this GH-effect, our unique cohort of short SGA children 
provided an ideal opportunity to investigate whether there is an interaction between 
polymorphisms of the PPAR-γ gene and GH treatment on the metabolic risk profile of 
short SGA subjects. We found no indication that the PPAR-γ Pro12Ala variant explains the 
variation in GH-induced changes in determinants of DM and CVD. 
 During GH treatment some SGA children remain lean while others demonstrate 
catch-up in BMI SDS. As the PPAR-γ gene is involved in lipid metabolism and adipocyte 
differentiation (1) it might be a response modifier to a triggering factor such as GH 
treatment. Other studies indicated that the effect of PPAR-γ on BMI is different in 
various phenotypes, which suggests gene-environment interactions (1, 11). We found a 
significantly higher increase in BMI SDS in carriers of the Ala12 allele but the frequency 
of the Ala12 allele was not different in subjects with catch-up in BMI SDS and subjects 
without catch-up in BMI SDS. Also, in the subgroup with DXA scans there was no 
significant effect of genotype on the increase in body fat percentage. Thus, the Pro12Ala 
polymorphism possibly predicts weight gain during GH treatment but further research is 
needed to confirm and extend our findings.
 The association between PPAR-γ polymorphisms and measures of glucose 
homeostasis was not yet studied in a population of short children born SGA. Most SGA 
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born individuals have catch-up growth to a normal height and catch-up growth in weight 
is associated with insulin resistance (35). Among the risk factors that potentiate the 
insulin resistance associated with low birth weight, obesity is known to play a key role 
(14). Short SGA subjects are usually lean. As the association of PPAR-γ Pro12Ala with 
insulin 
sensitivity might be mediated through body weight (3), it is important to study SGA born 
subjects with short stature separately.
 In SGA subjects, the Ala12 variant of PPAR-γ was associated with insulin resistance 
(7) while in various other clinical situations, such as in subjects with type 2 DM and obesity, 
the Ala12 variant was associated with an increased insulin sensitivity (36-38). Other 
studies in SGA subjects found the opposite and reported that the Ala12 allele protects 
against the insulin resistance and higher systolic blood pressure that is associated with 
a small size at birth (34, 39). Notably, these studies comprised SGA subjects with catch-
up growth to a normal height and weight and therefore these results are not comparable 
Table 3. Association of PPARγ with changes in body size and determinants of metabolic and cardiovascular dis-
ease during 4-years of GH-treatment 
All Pro/Pro Pro/Ala or Ala/Ala p-value *
Change of Weight SDSheight 0.7 (0.6 to 0.9) 0.6 (0.4 to 0.8) 0.9 (0.6 to 1.3) 0.02
Change of BMI SDSage 0.5 (0.3 to 0.6) 0.4 (0.2 to 0.6) 0.6 (0.3 to 0.9) 0.03
Change of systolic bp SDS -0.2 (-0.3 to 0.0) -0.2 (-0.4 to 0.0) -0.1 (-0.4 to 0.2) 0.32
Change of diastolic bp SDS -0.2 (-0.3 to 0.0) -0.1 (-0.3 to 0.1) -0.3 (-0.5 to 0.0) 0.79
Change of F Glucose (mmol/L) 1.1 (-0.4 to 2.7) 1.4 (-0.4 to 3.2) -0.3 (-0.5 to 0.0) 0.22
Change of F Insulin (pmol/L) 21.5 (11.6 to 31.3) 23.2 (12.0 to 34.4) 15.5 (-5.2 to 36.2) 0.38
Change of HOMA-IR 0.4 (0.2 to 0.6) 0.4 (0.2 to 0.6) 0.3 (-0.1 to 0.6) 0.18
Change of Si*10-4/min-1 (μU/ml) -7.0 (-9.8 to -4.3) -6.1 (-9.4 to -2.9) -9.8 (-15.4 to -4.2) 0.83
Change of AIR (mU/L) 423 (271 to 575) 411 (229 to 592) 470 (154 to 786) 0.40
Change of DI (AIR*Si) 453 (6 to 899) 577 (62 to 1093) 84 (-825 to 993) 0.31
Values are expressed as model estimates (95% CI). SDS = standard deviation score; F  = fasting; HOMA %B = beta cell 
function; HOMA IR = insulin resistance index; Si = insulin sensitivity; AIR = acute insulin response; DI = disposition index
*  p-values are derived from repeated measures regression analyses under dominant model adjusted for gender, age and  
puberty. Parameters with a skewed distribution were log-transformed for analysis. 
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with our results. In our study in short SGA subjects, there was no association between 
PPAR-γ Pro12Ala genotype and glucose homeostasis or blood pressure. 
 We found no association between the Pro12Ala polymorphism and serum lipid levels 
before the start of GH treatment. In obese children, the Ala12 variant of PPAR-γ was also 
not associated with serum lipid levels (38). One study in adults found no differences 
between Ala12 carriers and non-carriers in serum lipid concentrations (34) while another 
study found higher HDL cholesterol and lower triglycerids levels in subjects homozygous 
for the Ala12 allele (3). In a study that took birth weight into account, the Ala12 allele was 
associated with higher concentrations of total and LDL cholesterol but only in people with 
a birth weight below 3000 grams (40). It was not specified whether these birth weights 
were low due to prematurity or due to SGA. Based on our study, it appears that the 
Pro12Ala polymorphism of the PPAR-γ gene does not associate with serum lipid levels 
but a larger sample size would allow more definitive conclusions.
 We previously demonstrated that blood pressure in short SGA children is higher 
than blood pressure of height and gender matched references at a mean age of 7 years 
(41). A study in elderly hypertensive subjects found that in carriers of an Ala12 allele, 
low birth weight was not associated with adult blood pressure while in subjects with 
the Pro12Pro genotype this association was present (39). The authors suggested that 
the insulin resistance associated with the Pro12Pro genotype enhanced the regulatory 
responses of the renin-angiotensin system and thus induced raised blood pressure levels 
(39). Our subjects were much younger and we found no association between PPAR-γ 
genotype and blood pressure adjusted for height and gender. 
 In conclusion, our data demonstrate the possible involvement of the PPAR-γ 
Pro12Ala polymorphism in weight gain during GH treatment in short SGA children. The 
polymorphism was not associated with determinants of metabolic and cardiovascular 
disease at baseline and during GH treatment. 
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ABStrACt
Background:
An inverse association between birth weight and the risk of developing 
type 2 diabetes (T2D) in adulthood has been reported. This association 
may be explained by common genetic variants related to insulin secretion 
and resistance, since insulin is the most important growth factor in 
fetal life. The objective of this study was to examine whether T2D gene 
polymorphism tCf7l2 rs7903146 is associated with growth patterns from 
fetal life until infancy. 
Design and Methods:
This study was performed in two independent birth cohort studies, one 
prospective population-based (Generation R), and one of subjects born 
small-for-gestational-age (SGA cohort). Fetal growth was assessed by 
ultrasounds in second and third trimesters of pregnancy in Generation 
R. Growth in infancy was assessed in both cohorts at birth and at 6, 12 
and 24 months postnatally. tCf7l2 genotype was determined in 3,419 
subjects in Generation R and in 566 subjects in the SGA cohort. 
Results:
Minor allele frequency did not differ significantly (p=0.47) between 
Generation R (T-allele: 28.7%) and the SGA cohort (T-allele: 29.8%). 
no differences at birth were found in gestational age or size (head 
circumference, length, weight) between the genotypes in either cohort. 
tCf7l2 genotype was also not associated with any pre- or postnatal 
growth characteristic in either Generation R or the SGA cohort. 
Discussion:
We found no evidence for an association between tCf7l2 genotype and 
fetal and early postnatal growth. Furthermore, this tCf7l2 polymorphism 
was not associated with an increased risk of SGA. 
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introduCtion
Several epidemiological studies have shown inverse associations between birth weight 
and metabolic diseases, including type 2 diabetes (T2D) in adulthood (1, 2). These 
associations may be influenced by common genetic variants (2). Insulin is the most 
important fetal growth factor and insulin-mediated fetal growth might be affected by 
genetic polymorphisms that regulate fetal insulin secretion or insulin sensitivity (2). 
Therefore, gene variants associated with T2D have been suggested as candidate genes 
for influencing early growth (2). 
 Genome-wide association (GWA) studies have consistently shown that the C>T 
substitution in TCF7L2 gene (rs7903146) increases the risk of T2D approximately 
2-fold when two risk allele copies (TT) are present (3-5). The T-allele of this TCF7L2 
polymorphisms has been suggest to reduce proinsulin to insulin conversion (6), though 
the exact mechanism has not been elucidated yet. Other single nucleotide polymorphisms 
(SNPs) of the TCF7L2 gene have been shown to be associated with type 2 diabetes, 
although less strongly (7). The T-allele of rs7903146, which according to HapMap has an 
allele frequency amongst Caucasians (CEU) of 28% (8), has been shown to be associated 
with reduced insulin response and secretion in both diabetic and non-diabetic individuals 
(9-11), though results in non-diabetics are not consistent (12). This polymorphism may 
also lead to an increased risk of gestational diabetes (13). Such findings make TCF7L2 
one of the most important candidate genes for explaining the associations between low 
birth weight and T2D.
 Freathy et al. were the first to investigate the association between TCF7L2 genotype 
and birth weight, and they found an association with maternal TCF7L2 genotype (14). 
Each maternal copy of the risk allele was associated with a 30 grams increase in offspring 
birth weight, probably as a result of higher maternal glucose levels stimulating fetal 
insulin production (14). After adjustment for maternal genotype, fetal TCF7L2 genotype 
did not influence fetal birth weight (14). This finding was replicated in the Helsinki birth 
cohort (15). In another study, no association was found between fetal TCF7L2 genotype 
and the risk of small size for gestational age (16). Birth weight might be an inappropriate 
measure of the individual growth potential since different fetal growth rates may lead 
to the same birth weight (17). Furthermore, rapid postnatal weight gain, especially in 
fat mass, has also been shown to be associated an increase risk of obesity and type 2 
diabetes in later life, independent of birth weight (18, 19). 
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 Therefore we hypothesized that longitudinally measured fetal and postnatal growth 
are better parameters in the investigation of the possible effect of TCF7L2 on growth than 
specific growth characteristic such as birth weight. We first assessed the associations of 
TCF7L2 rs7903146 with fetal and postnatal growth characteristics in a population-based 
prospective cohort study among 3,419 subjects followed from early fetal life onwards. 
Second, we assessed associations of this genotype with birth weight and postnatal 
growth in 566 small-for-gestational-age (SGA) children participating in an independent 
cohort study. 
MAteriAlS And MetHodS
Cohort Descriptions
The Generation R Study 
The Generation R Study is a population based prospective cohort study from early fetal life 
onwards. The study is designed to identify early environmental and genetic determinants 
of growth, development and health from fetal life until young adulthood. It has been 
described previously in detail (20, 21). Fetal and postnatal growth and their main 
determinants were repeatedly measured by physical examinations, fetal ultrasounds, 
biological samples and questionnaires. We have previously shown that of all eligible 
children born in the study area 61% participated in the study (21). The study has been 
approved by the Medical Ethics Committee of the Erasmus Medical Center, Rotterdam. 
Written informed consent was obtained from all participants or their parents.
Fetal growth and birth characteristics
Fetal ultrasound examinations were carried out during visits to one of the research centers. 
These fetal ultrasounds were used for establishing gestational age in the first trimester 
of pregnancy (conception to 12 weeks of gestational age), as well as for assessing fetal 
growth characteristics in second (17-25 weeks of gestational age) and third trimesters 
(>25 weeks of gestational age) of pregnancy (22). Fetal growth measurements used 
in the present study included head circumference (HC), abdominal circumference (AC) 
and femur length (FL) measured in second and third trimesters to the nearest mm using 
standardized ultrasound procedures (23). Estimated fetal weight (EFW) was calculated by 
means of the formula from Hadlock using head circumference, abdominal circumference 
and femur length (log10 EFW = 1.5662 – 0.0108 (HC) + 0.0468 (AC) + 0.171 (FL) + 
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0.00034 (HC)2 – 0.003685 (AC * FL)) (24). First trimester ultrasound measures were not 
included for assessing growth characteristics because these ultrasound examinations 
were primarily performed to establish gestational age. 
Birth and postnatal growth 
Birth weight, date of birth and gender were obtained from community midwife and hospital 
registries. Information on head circumference or length at birth was not available, but 
many children were measured during the first two months of life. Well-trained staff in 
community health centers obtained postnatal growth characteristics using standardized 
procedures. Based on the routine health care program, the visits at which these growth 
characteristics were measured were grouped into three age periods: 6 months (range 5 
to 8.99); 12 months (range 9 to 12.99); and 24 months (range 23 to 34.99 months). 
Postnatally, head circumference was not measured at the age of 24 months. 
Population for analysis
Analyses were restricted to singletons from whom DNA was available for TCF7L2 
genotyping and who also had Dutch or other Caucasian ethnicity as defined by having 
both parents born in the Netherlands or another European country (n = 3,419)(Figure 
1). Fetal growth measurements were available for 3,320 and 3,384 children in second 
and third trimesters, respectively. Of these children, those living outside the study area 
postnatally (10%) were not followed up in infancy and a further 12% were lost during 
postnatal follow-up, leaving 2,675 subjects eligible for the postnatal analyses (Figure 
1). 
the SGA Cohort 
The SGA cohort was designed for the purpose of assessing growth and development of 
subjects born SGA. Subjects were included at childhood age (n = 367) or at young adult 
age (n = 252). Children were included in the SGA cohort when they were SGA at birth, 
had short stature (height standard deviation score (SDS) for age and gender of below – 2 
(25)), did not show catch-up growth in height, and had no growth failure caused by any 
other identified disorder. These inclusion criteria have previously been described (26). 
Young adults included in the SGA cohort were randomly selected from hospitals in the 
Netherlands, where they had been registered because of being SGA. Only those young 
adults born at 36 weeks or more of gestation, being singleton and Caucasian and not 
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suffering from conditions or receiving treatment known to interfere with growth, were 
invited to participate.  SGA was defined as a birth length and/ or birth weight SDS of 
below –2.0 for gestational age (27). The Medical Ethics Committees of Erasmus Medical 
Center, Rotterdam, and of the participating centers approved all studies and written 
informed consent was obtained from all participants or their parents. 
Birth and postnatal growth
Birth characteristics of the SGA cohort were collected from hospital registries. The 
gestational age of the subjects was determined by ultrasound in the first trimester, if 
available, and otherwise calculated from the date of the last menstruation. Growth data 
(head circumference, height and weight) measured during the first two years of life were 
collected from records of hospitals, community health services and general practitioners. 
Longitudinal growth data were available in 272 participants in the SGA cohort (Figure 1). 
Genotyping
DNA was collected from cord blood samples in the Generation R cohort and from 
peripheral venous blood samples in the SGA cohort. Cord blood for DNA isolation was 
available for 59% of all participating children of the Generation R cohort. When cord 
blood samples were missing, this result was mainly due to logistical constraints at the 
delivery. Venous blood samples were available in the complete SGA cohort. Genotyping 
of the C>T substitution in TCF7L2 (rs7903146) gene was performed using Taqman 
allelic discrimination assay (Applied Biosystems, Foster City, CA) and Abgene QPCR 
ROX mix (Abgene, Hamburg Germany). The genotyping reaction was amplified using the 
GeneAmp® PCR system 9600 (95° C (15 minutes), with 40 cycles of 94° C (15 seconds) 
and 60° C (1 minute)). The fluorescence was detected on the 7900HT Fast Real-Time 
PCR System (Applied Biosystems) and individual genotypes were determined using SDS 
software (version 2.3, Applied Biosystems). Genotyping was successful in 98% and 91% 
of the samples in the Generation R and SGA cohort, respectively. To confirm the accuracy 
of the genotyping results, 276 randomly selected samples from the Generation R Study 
were genotyped for a second time with the same method. The error rate was less than 
1%. The frequency distribution in Generation R did not deviate from the Hardy-Weinberg 
equilibrium in subjects with Dutch ethnicity nor did it deviate in the SGA cohort.
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Data analysis
With sample sizes in the Generation R Study of 3,419 and 2,675 subjects for fetal 
and postnatal analyses respectively, and assuming a statistical power level (1 – β) of 
0.80, a level of significance (α) of 0.05 and a variance of 1.0, we were able to detect 
differences in growth characteristics of 0.048 SDS and 0.054 SDS respectively. First, 
differences in allele distribution between children born SGA (from the SGA cohort) and 
non-SGA subjects (from Generation R) were assessed. Differences were calculated 
using the Chi-square test. Second, we examined the differences in birth characteristics 
between genotype groups with linear regression analyses assuming an additive model. 
Weight, length and head circumference at birth and at different ages were analyzed 
using gender and age adjusted standard deviation scores (SDS) (27, 28). Standard 
deviation scores were obtained using Dutch reference growth curves (Growth Analyser 
3.0, Dutch Growth Research Foundation). For Generation R, we used the first length 
SDS and head circumference SDS measured after birth and before the second month 
of life, since these measurements were not available at birth. Third, we compared fetal 
(only Generation R) and postnatal characteristics between the genotypes with linear 
regression analyses. Finally, to assess longitudinally measured weight and length 
patterns from fetal life to infancy, we performed repeated measures regression analysis 
in both cohorts with weight and length from birth to 24 months as outcome variables. 
This regression technique takes the correlation of multiple measurements within one 
subject into account, assesses both the time-independent and time-dependent effect 
of TCF7L2 genotype on growth, and allows for incomplete outcome data (29). In these 
models, genotype was included as both intercept and interaction with age. To account 
for (gestational) age at each specific measurement, these analyses were conducted with 
age-adjusted standard deviation scores. The models can be written as:
Height (SDS) or weight (SDS) = ß0 + ß1*age + ß2* TCF7L2 genotype + ß3* TCF7L2 
genotype*age.
In this model, the term including ‘ß0’ reflects the intercept and the term including 
‘ß1’ reflects the slope of growth (weight or length) per week for the reference group 
(CC genotype). The terms including ‘ß2‘ and ‘ß3’ reflect the age independent growth 
differences in weight (and length) between the different categories of the TCF7L2 
genotype respectively (30). All models were unadjusted (all growth characteristics are 
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age and gender adjusted SD scores) since population genotype distribution is assumed 
to be unrelated to covariates and the effect estimates were not materially affected 
by adjusting for maternal age, pre-pregnancy body mass index or parity (31). The 
occurrence of gestational diabetes in the entire cohort was 0.6% and did not affect the 
effect estimates. Therefore, occurrence of gestational diabetes was not included in the 
analyses.
 All effect estimates are presented with their 95% confidence interval (95% CI). 
Statistical analyses were performed using the Statistical Analysis System version 9.1.3 
(SAS, Stata corporation, College Station, TX, USA), including the PROC MIXED module 
for unbalanced repeated measurements as well as the Statistical Package of Social 
Sciences version 15.0 for Windows (SPSS Inc, Chicago, IL, USA).
reSultS
Subject characteristics of Generation R and SGA cohort are presented in Table 1. The 
minor allele frequency distributions did not differ significantly (p=0.47) between non-SGA 
subjects (from Generation R) (T-allele: 28.7%) and the SGA cohort (T-allele: 29.8%) (Table 2). 
 No significant differences between genotype groups were observed in fetal growth 
characteristics in Generation R (Table 3). No differences in birth characteristics (head 
circumference, length and weight), between genotype groups were observed in either 
cohort (Table 4). Postnatal growth characteristics for both cohorts are shown in Table 5. 
No significant differences were found in either cohort for head circumference, weight or 
height at any age. 
 Finally, no differences were found in weight growth rate (SDS/year) from birth 
until the age of 2 years in either Generation R or the SGA cohort. Compared to the CC 
genotype, differences were -0.014 (95% confidence interval (CI): -0.064, 0.036) SDS/year 
and -0.028 (95% CI: -0.057, 0.002) SDS/year, for the CT and TT genotype, respectively, 
in Generation R. In the SGA cohort, differences were -0.134 (95% CI: -0.376, 0.108) 
SDS/year and 0.002 (95% CI: -0.125, 0.129) SDS/year, for the CT and TT genotype, 
respectively, using the CC genotype as a reference. Similarly, no differences were found 
in height growth rate from birth to 2 years in either cohort (data not shown).
Proefschrift Sandra W.K de Kort 20-08-09.indd   149 13-09-2009   16:58:55
150
chapter 
7
TC
F7
L2
 a
nd
 e
ar
ly
 g
ro
w
th
151
 
Table 1. Subject characteristics by cohort.
Characteristics Generation R The SGA cohort
Gender (% boys)  50.8% 47.2%
Gestational age (weeks) 40.1 (36.7 – 42.4) 38.0 (29.9 – 41.0)
Birth weight (grams) 3513 (511) 1819 (716)
Premature (gestational age < 37 weeks) (%) 2.9% 44.9%
Birth weight < 2500 grams (%) 2.5% 82.7%
Small for gestational age (weight < -2 SDS) (%) 0.9% 100%
Gestational diabetes (%) 0.6% N/A
Values are means (SD), medians (95% range) or percentages. N/A = not available
Table 2. Distribution of TCF7L2 rs7903146 minor allele frequency according to cohort.
Allele frequency
C-Allele T-Allele p-value
Non-SGA (Generation R) (%) 4828 (71.3) 1948 (28.7)
SGA (SGA cohort) (%) 795 (70.2) 337 (29.8) 0.49
Non-SGA = All subjects from Generation R, excluding SGA subjects
SGA = birth weight SDS and/or birth length SDS < -2
p-value express differences in distribution between SGA and General population tested with Chi-square test.
Table 3. Fetal characteristics according to fetal TCF7L2 rs7903146 genotype in the Generation R study.
CC (n = 1736) CT (n = 1329) TT (n = 301) p- value#
Fetal characteristics second trimester
Head circumference (SDS) 0.04 (1.0) 0.02 (1.0) 0.05 (0.9) 0.88
Femur length (SDS) -0.01 (1.0) -0.01 (1.0) 0.05 (0.9) 0.64
Estimated fetal weight (SDS) -0.06 (1.0) -0.07 (1.0) 0.00 (1.0) 0.57
Fetal characteristics third trimester
Head circumference (SDS) 0.11 (1.0) 0.13 (1.0) 0.15 (0.9) 0.45
Femur length (SDS) 0.01 (1.0) -0.02 (1.0) -0.04 (1.0) 0.34
Estimated fetal weight (SDS) 0.12 (1.0) 0.14 (1.0) 0.11 (0.9) 0.99
Values are means (SD). SDS = standard deviation score for age and gender.
#p-values for additive models. Differences were tested using linear regression analyses. 
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diSCuSSion
In the current study, we found that T2D gene polymorphism TCF7L2 rs7903146 is not 
associated with growth in fetal life in the general population or with growth in early 
postnatal life in either the general population or in a cohort of subjects born SGA. We 
also confirmed previous suggestions that this variant of TCF7L2 is not associated with 
birth weight and, more importantly, demonstrated that it does not influence the fetal 
development using direct fetal measurements. Finally, we showed that this polymorphism 
does not appear to be associated with the risk of being born SGA.
 To our knowledge, this study is the first to examine the association of TCF7L2 with 
longitudinally measured growth patterns in fetal and early postnatal life in two independent 
birth cohorts. In the Generation R Study, DNA for genotyping was available in 59% of all 
subjects and was isolated from cord-blood. Missing cord-blood was mainly caused by 
logistical restraints at delivery. Children who were not genotyped had a shorter gestational 
age (p < 0.001) and were lighter at birth (p < 0.001) than subjects who were genotyped. 
Of all genotyped eligible subjects at baseline, 22% did not participate in follow-up 
measurements. In the SGA cohort, genotyping was successful in 91% of the subjects and 
longitudinally growth data were available in 48% of the cohort. Our effect estimates could 
Table 4. Birth characteristics in both cohorts according to TCF7L2 rs7903146 genotype of child.
Generation R N CC (n = 1762) CT (n = 1351) TT (n = 306) p-value#
Gestational age (weeks) 3419 40.3 (36.7 – 42.3) 40.3 (36.6 – 42.4) 40.1 (37.1 – 42.6) 0.83
Birth head circumference (SDS)* 2314 0.22 (0.9) 0.24 (0.9) 0.26 (0.9) 0.55
Birth length (SDS)* 1959 -0.07 (1.0) -0.08 (1.0) 0.00 (1.1) 0.66
Birth weight (SDS) 3419 0.21 (1.0) 0.22 (1.0) 0.20 (1.0) 0.97
SGA Cohort CC (n = 270) CT (n = 255) TT (n = 41) p-value#
Gestational age (weeks) 566 38.0 (28.6 – 42) 38.0 (28.6 – 41.0) 38.0 (29.0 – 42.0) 0.57
Birth head circumference (SDS) 203 -1.51 (1.4) -1.20 (1.6) -1.31 (1.4) 0.32
Birth length (SDS) 491 -3.11 (1.4) -3.27 (1.5) -3.02 (1.5) 0.41
Birth weight (SDS) 566 -2.40 (1.0) -2.46 (0.9) -2.32 (0.9) 0.58
* Length and head circumference were measured in the fi rst two months of after birth.
Values are means (SD) or medians (95% range). SDS = standard deviation score for age and gender.
# p-values for additive models. Differences were tested using linear regression analyses. 
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be biased if the associations between genotypes and growth characteristics differed 
between those with and without postnatal growth data available. In the Generation R 
cohort, no differences were observed between children with and without postnatal growth 
measurements. In the SGA cohort the T-allele was slightly more frequent in subjects 
with postnatal growth measurements than in subjects without these measurements (p < 
0.05). Finally, it could be possible that there is differential effect of genotype on growth 
according to availability of follow-up data. This bias would affect our estimates, though 
such a bias seems unlikely.
 Several studies have investigated the effect of common genetic variants related to 
insulin action and secretion on early growth (14, 15, 32, 33). Of the initially identified 
T2D gene polymorphisms identified by the GWA, fetal CDKAL1 (rs7754840) and HHEX 
Table 5. Postnatal characteristics at 6, 12, and 24 months according to TCF7L2 rs7903146 genotype. 
Generation R CC (n = 1375) CT (n = 1063) TT (n = 237) p-value#
6 months Head circumference (SDS) -0.02 (0.93) -0.03 (0.89) -0.06 (0.91) 0.83
n = 2675 Height (SDS) 0.03 (0.91) 0.03 (0.90) 0.07 (0.93) 0.81
Weight (SDS) 0.41 (0.96) 0.44 (0.95) 0.54 (0.99) 0.14
12 months Head circumference (SDS) 0.00 (0.89) -0.04 (0.94) -0.03 (1.12) 0.54
n = 2559 Height (SDS) -0.01 (0.90) -0.05 (0.90) -0.01 (0.90) 0.70
Weight (SDS) 0.18 (0.98) 0.18 (0.99) 0.24 (1.00) 0.63
24 months Height (SDS) -0.19 (0.93) -0.21 (0.89) -0.18 (0.87) 0.82
n = 2445 Weight (SDS) -0.11 (0.99) -0.13 (1.00) -0.09 (0.96) 0.87
SGA cohort CC (n = 143) CT (n = 107) TT (n = 22)
6 months Head circumference (SDS) -1.38 (0.92) -1.36 (0.90) -1.74 (1.04) 0.41
n = 272 Height (SDS) -2.39 (1.37) -2.43 (1.26) -2.51 (1.55) 0.93
Weight (SDS) -2.18 (1.40) -2.22 (1.26) -2.37 (2.05) 0.86
12 months Head circumference (SDS) -1.21 (0.83) -1.24 (0.88) -1.72 (1.06) 0.16
n = 268 Height (SDS) -2.25 (1.25) -2.30 (1.06) -2.30 (1.47) 0.94
Weight (SDS) -2.14 (1.41) -2.25 (1.15) -2.17 (1.89) 0.82
24 months Head circumference (SDS) -1.10 (0.82) -1.13 (0.87) -1.60 (1.06) 0.20
n = 244 Height (SDS) -2.39 (1.24) -2.47 (1.05) -2.94 (1.04) 0.20
Weight (SDS) -2.19 (1.33) -2.31 (1.21) -3.06 (1.65) 0.04
Values expressed as mean (SD). SDS = standard deviation score for age and gender.
# p-values for additive models. Differences were tested using linear regression.
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(rs1111875) genotype, and maternal TCF7L2 (rs7903146) genotype have been shown 
to affect birth weight. Pulizzi et al. demonstrated in the Helsinki Birth Cohort that 
fetal TCF7L2 genotype did not interact with birth weight to increase the risk of T2D in 
adulthood (15). TCF7L2 rs7903146 has been shown to have the strongest genetic effect 
on T2D and this result has been replicated in several studies (3-5). Therefore, TCF7L2 is 
a very important candidate gene for explaining the association between low birth weight 
and T2D risk. Our study is the first to investigate the effect of TCF7L2 rs7903146 on 
longitudinal growth in early life. Longitudinal assessment of growth provides more 
information than just measurements at birth as we have demonstrated earlier that 
different fetal growth patterns may result in a similar birth weight (17). Furthermore, 
most SGA born children have catch-up growth during the first months of life but 15% 
remain small (34). Thus, to investigate whether TCF7L2 rs7903146 influences fetal and 
postnatal growth, longitudinal growth data provide more information than birth weight 
alone.
 Freathy et al. found an increase of birth weight for each fetal and maternal risk 
allele (14). They concluded that the most likely mechanism for this association was that 
maternal genotype was associated with a reduction of maternal insulin secretion, leading 
to increased fetal glucose and insulin levels and subsequently increased birth weight, 
rather than a direct effect of the fetal genotype on birth weight. Pulizzi et al. found no 
effect of the fetal genotype of this polymorphism on birth weight. Since fetal and maternal 
genotypes are 50% correlated, it cannot be excluded that, when the risk allele is present 
in both mother and child, small effects of fetal genotype that reduce fetal growth could 
be masked by opposing effects of maternal genotype. Since maternal genotype was not 
available in our study, we were not able to test this hypothesis. However, we did not find 
any effect of fetal genotype on birth weight in the general population nor in a specific 
population of children with insufficient fetal growth resulting in small size for gestational 
age at birth. Our findings are therefore in line with the conclusions of these previous 
studies. Furthermore, we found no effect of fetal genotype on estimated fetal weight or 
weight during infancy, indicating that there is no evidence for any association between 
this fetal genotype and weight or change in weight during early life either. The effect of 
this polymorphism on the metabolic phenotype found in adults would therefore appear 
to develop after early childhood. Nonetheless, our results also could be explained by a 
lack of power and we cannot rule out that we were unable to detect smaller effects of this 
variant on early growth. 
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 Regarding intra-uterine growth retardation, an earlier study examined the effect of 
TCF7L2 rs7903146 genotype on SGA. Cauchi et al. found no association between this 
genotype and SGA, using family-based association analyses in over 3,000 subjects of 
which 627 subjects were SGA (16). In this analyses, the SGA group was slightly larger 
than in our current study and included parents, but postnatal growth data were not 
analyzed longitudinally. In our study, we did not find a difference in minor allele frequency 
between the general population (Generation R) and the SGA cohort. On the basis of 
two independent and negative studies, one may conclude that there is no association 
between this genetic polymorphism and risk of SGA.
 In summary, our results suggest that TCF7L2 rs7903146 does not influence growth 
from early fetal life to infancy. Furthermore, minor allele frequency was not different in 
SGA subjects than in non-SGA subjects, indicating that it is unlikely that this polymorphism 
is associated with the risk of being born SGA. Systematic searches for common genetic 
variants by means of genome-wide association studies will enable us to obtain a more 
complete understanding of which genes are involved in growth in fetal life and infancy. 
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ABStrACt
Context: The tCf7l2 rs7903146 gene polymorphism has been associated 
with the risk of developing type 2 DM, possibly by decreasing insulin 
secretion. Small for gestational age (SGA) birth has been associated with 
type 2 DM in later life. Growth hormone (GH) treatment reduces insulin 
sensitivity and increases insulin secretion. Therefore, GH-treated SGA 
children are an ideal group to investigate whether tCf7l2 rs7903146 
genotype associates with changes in glucose homeostasis.
Objective: To determine the impact of the tCf7l2 rs7903146 polymorphism 
on changes in insulin secretion and insulin sensitivity during 4 years of GH 
treatment in children born SGA.
Subjects: 246 Caucasian short children born SGA, with a median age of 
7.8 years. 
Outcome measures: Insulin sensitivity and insulin secretion measured by 
FSIGTs (n = 68) and HOMA calculations (all).
Results: There was no association between rs7903146 genotype and 
insulin sensitivity or insulin secretion at baseline but after adjustment for 
possible confounders, insulin secretion was higher in the CT/TT group than 
in the CC group. During GH treatment, carriers of the rs7903146 T-allele 
had a similar increase in insulin secretion as carriers of the CC genotype. 
The decrease in insulin sensitivity was only significant in the CT/TT group 
but the difference in decrease between genotype groups did not reach 
significance (p = 0.06). The disposition index (insulin secretion * insulin 
sensitivity), which is an estimate of beta cell function was not associated 
with genotype and did not change during GH treatment.
Conclusion: The tCf7l2 rs7903146 polymorphism is not associated with 
the change in insulin secretion during GH treatment in short SGA children. 
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introduCtion
Transcription factor 7-like 2 (TCF7L2 [MIM 602228]) rs7903146 is to date the 
polymorphism with the strongest association with type 2 diabetes mellitus (DM) (1-3), 
probably because the rs7903146 T-allele associates with decreased insulin secretion 
(4-8). So far, literature is inconclusive whether the rs7903146 T-allele also associates 
with insulin sensitivity and disposition index (4-6, 8).
 Subjects born SGA are considered to have an increased risk to develop type 2 
DM in later life (9, 10), but it is unknown whether this increased risk is genetically or 
environmentally determined or by a combination of both. In a population of young adults 
born SGA, there was no association between TCF7L2 genotype and insulin sensitivity 
assessed by HOMA-IR (11). A more accurate method than HOMA calculations to assess 
beta cell function and insulin sensitivity is the frequently sampled intravenous glucose 
tolerance test (FSIGT). FSIGT results were previously assessed in relation to TCF7L2 
genotype (8, 12) but it was inconclusive whether they were associated with rs7903146 
genotype. FSIGT results in association with TCF7L2 rs7903146 genotype were not yet 
evaluated in a population born SGA. 
 Nowadays, most children with short stature who were born SGA are treated with 
growth hormone (GH). GH treatment is known to decrease insulin sensitivity and to 
induce a compensatory increase in insulin secretion (13). Concerns were expressed that 
GH may increase the risk to develop DM in adulthood. Since the TCF7L2 T-allele was 
associated with decreased insulin secretion, this SNP might indicate which children are 
less capable of producing extra insulin to compensate for the reduced insulin sensitivity 
induced by GH-treatment. Children with less insulin secretion during GH-treatment might 
be more at risk to develop DM in later life. 
 We have detailed measurements of insulin sensitivity and insulin secretion during 
long-term GH treatment in a cohort of short children born SGA. Because of the effect 
of GH-treatment on insulin sensitivity and insulin secretion, this unique cohort provides 
an ideal opportunity to investigate whether there is an interaction between the TCF7L2 
genotype and GH treatment on the metabolic risk profile of short SGA subjects. 
 The present study aimed to investigate whether TCF7L2 rs7903146 genotype 
correlates with changes in insulin sensitivity and insulin secretion during GH treatment. 
To investigate this question, we performed TCF7L2 genotyping, FSIGTs and HOMA 
calculations in 246 short children who were born SGA and treated with GH.
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SuBjeCtS And MetHodS
Subjects
The study cohort consisted of 246 Caucasian short SGA children who were participating 
in GH trials with the same inclusion criteria (14). SGA was defined as birth weight and/or 
birth length adjusted for gender and gestational age (15) < -2 SD.  The inclusion criteria 
were previously described (14). In short, the children were included when prepubertal, 
with a birth length or birth weight standard deviation score (SDS) and actual height SDS 
below –2 (16), without growth failure caused by other disorders. The gestational age of 
the subjects was determined by ultrasound scans during the first trimester, if available, 
and otherwise calculated from the date of the last menstrual period. The date of inclusion 
determined whether an FSIGT was performed. The Medical Ethics Committees of the 
participating centers approved the study and written informed consent was obtained 
from the parents. 
Genotyping and quality control
DNA was isolated from peripheral blood leucocytes by standard method from all 
patients. Genotyping of the TCF7L2 (rs7903146) gene was performed using TaqMan 
allelic discrimination assay (Applied Biosystems, Foster City, CA) and Abgene QPCR 
ROX mix (Abgene, Hamburg Germany). The genotyping reaction was amplified using the 
GeneAmp® PCR system 9600 (95° C (15 minutes), with 40 cycles of 94° C (15 seconds) 
and 60° C (1 minute)). The fluorescence was detected on the 7900HT Fast Real-Time 
PCR System (Applied Biosystems) and individual genotypes were determined using SDS 
software (version 2.3, Applied Biosystems). 
GH treatment
Short SGA children were treated with biosynthetic GH with a dose of 1 mg/m2 body 
surface area, subcutaneously, once daily at bedtime. The GH dosage was adjusted to 
the calculated body surface area every three months. A subgroup of 19 children was 
randomized to receive 1 or 2 mg/m2 GH during the first 6 months and 1 mg/m2 thereafter 
(17). Because independent samples t-tests demonstrated that the effect of GH treatment 
on the change in insulin sensitivity or HOMA values after 4 years of treatment was not 
different between the children who received 1 or 2 mg/m2 during the first 6 months, 
these children were added to the large GH-group. 
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Glucose homeostasis
Fasting glucose was measured on a Hitachi 917 analyzer. Fasting insulin was measured 
by chemoluminescent assay on an Immulite 2000 analyzer (Diagnostic Products 
Corporation, Los Angeles, CA) and HOMA insulin resistance index (HOMA-IR) and beta cell 
function (HOMA %B) were calculated (18). Fasting glucose and insulin levels were 
measured again after 6 months, 1, 2 and 4 years of GH treatment.
 In a subgroup of 68 subjects (determined by the date of inclusion), a modified, 
frequently sampled intravenous glucose tolerance test (FSIGT) using tolbutamide, was 
performed, as previously described (19, 20). The FSIGT was repeated after 6 months, 2 
years and 4 years of treatment. Serum glucose and insulin levels were measured in one 
laboratory as previously described (14) and insulin sensitivity (Si), acute insulin response 
(AIR) and disposition index (DI) were calculated using Bergman’s MINMOD MILENNIUM 
software (21). All blood samples were taken after an overnight fast. Insulin sensitivity 
quantifies the capacity of insulin to promote glucose disposal. The acute insulin 
response, an estimate of insulin secretory capacity, was measured as the area under the 
curve from zero to ten minutes corrected for baseline insulin levels. The Disposition index 
(DI) is an overall measure of the ability of the beta cells to secrete insulin in response to 
the degree of insulin resistance. DI is the product of AIR and Si (DI = AIRg * SI) (21).
Body Composition
Dual-Energy X-ray Absorptiometry scans (DEXA, type Lunar DPX-L, GE Healthcare, Madison, 
Wisconsin, USA) were performed in 83 subjects. The date of inclusion determined in 
which subjects a DEXA scan was performed. Fat mass (FM) and body fat percentage (% 
fat mass of total body weight) were determined. 
Statistical Analysis
FSIGT parameters and calculated HOMA values were logarithmically transformed 
because of a skewed distribution. Associations were tested under a dominant genetic 
model: homozygosity for the C allele was coded as 0, and the heterozygous state and 
homozygosity for the T allele were coded as 1. Genotype distributions for significant 
departure from the Hardy-Weinberg equilibrium were calculated using the χ2 test. A 
post-hoc power analysis with a level of significance (α) of 0.05 and a chosen power of 
80% showed that with a number of 110 subjects per genotype-subgroup we could detect 
differences in fasting glucose levels of 0.27 mmol/l, differences in fasting insulin of 1.1 
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pmol/l, and differences in HOMA IR of 0.15 (14). A similar power analysis showed that 
with 30 subjects per genotype-subgroup we could detect differences in insulin sensitivity 
(Si) of 4.9*10-4 μU/ml and differences in AIR of 85 mU/l (22). Clinical data are presented 
as mean (SD) unless stated otherwise. Statistical significance was defined as p < 0.05. 
 Differences between genotype groups were evaluated using independent sample 
t-tests. Multiple linear regression analysis was used to compare FSIGT parameters 
and calculated HOMA values between the CC and the CT/TT genotype adjusted for 
possible confounders. Known covariables for each parameter of glucose homeostasis 
were taken into account and genotype was added to the model as a covariable. To test 
whether a certain amount of body fat percentage was needed for the T-allele to influence 
parameters of glucose homeostasis we added an interaction term to the model: body fat 
percentage*T-allele.
 FSIGT parameters and calculated HOMA values during GH treatment were analyzed 
using repeated measures of variance (23). Model estimates are presented as mean 
(95% CI). To compare longitudinally measured FSIGT and HOMA parameters during 4 
years of GH treatment for genotype groups, we performed repeated measures regression 
analysis with Si, AIR, DI, HOMA %B and HOMA IR from start of treatment to 4 years later 
as outcome. In these models, genotype was included as both independent variable and 
as interaction with the study duration. All models were corrected for puberty. The models 
can be written as:
Outcome variable = ß0 + ß1*puberty + ß2* study duration + ß3* TCF7L2 genotype + ß4* 
TCF7L2 genotype*study duration.
In this model, the term including ‘ß0’ reflects the intercept, the term including ‘ß1’ reflects 
the correction for puberty and the term including ‘ß2’ reflects the slope of change (in 
Si, AIR, DI, HOMA %B or HOMA IR) per month GH therapy for the reference group (CC 
genotype). The term including ‘ß3‘ reflects the difference in Si, AIR, DI, HOMA %B or HOMA 
IR between the CC and CT/TT variant of TCF7L2 rs7903146 independent of puberty 
and study duration. The term including ‘ß4’ reflects the difference in change of Si, AIR, 
DI, HOMA %B or HOMA IR between the CC and CT/TT variant of TCF7L2 rs7903146 
independent of puberty and study duration (24). 
 Analyses were performed using the statistical package SPSS (version 15.0; SPSS 
inc., Chicago, IL) for Windows. SAS 8.2 (SAS Institute Inc., Cary, /nC, USA) was used for 
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repeated measures of variance analyses. 
reSultS
Clinical characteristics of the participants are presented in Table 1. Genotype distribution 
was in Hardy-Weinberg equilibrium (χ2 = 2.17; p = 0.14). The minor allele frequency 
(MAF) was 30 % and genotype frequencies for CC, CT, and TT were 46%, 46% and 7%, 
respectively. There was no significant association between the TCF7L2 rs7903146 SNP 
and insulin sensitivity (Si), insulin secretion (AIR and HOMA %B), disposition index or 
insulin resistance (HOMA IR) (Table 2). After adjustment for age, puberty, gender and 
body fat percentage insulin secretion (AIR) was higher in carriers of a T-allele (Table 
2). There were no significant differences between genotype groups in other measures 
of glucose homeostasis (adjusted P-values Table 2). The linear regression model for Si 
explained 38% of the variance in Si and the model for AIR explained 30% of the variance 
in AIR. There was no significant interaction between body fat percentage and genotype for 
TCF7L2 rs7903146 in any of the regression models, indicating that the influence of the 
T-allele on measures of glucose homeostasis did not depend on body fat percentage.
  During 4 years of GH treatment, there was a significant decrease in Si in the CT/
TT genotype group (from 13.2 to 7.2 μU/ml; p < 0.001) and a significant increase in DI 
Table 1. Clinical characteristics (n = 246)
Age 7.8 (5.3 to 10.8)
Gender (% males) 56%
Gestational Age (weeks) 38.0 (33.9 to 40)
Birth weight SDS -2.2 (1.1)
Birth length SDS -3.1 (1.5)
Height SDS -2.9 (0.7)
Weight SDS* -1.1 (1.2)
BMI SDS -1.3 (1.0)
Genotype (% carriers T-allele) 54%
Body fat %** 12.4 (9.5 to 17.6)
Values are expressed as mean (SD), percentage, or as median (interquartile range) in case of a skewed distribution.
*Weight for height SDS
**n = 83
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in the CC genotype group (from 2841 to 4189; p < 0.01) compared to values at start 
but the difference between genotype groups in overall change in Si and DI did not reach 
significance (Table 3). All other estimates of glucose homeostasis showed a similar 
change during GH therapy in the CC genotype and the CT/TT genotype group.  
diSCuSSion
We investigated whether there is an interaction between TCF7L2 rs7903146 genotype 
and the change in insulin sensitivity and insulin secretion during GH treatment in 
Caucasian subjects with short stature, born small for gestational age. We demonstrated 
that presence of the rs7903146 T allele was not associated with the increase in insulin 
secretion during GH treatment. The difference between genotype groups in change in 
insulin sensitivity did not reach significance but tended to be larger in carriers of a T-allele. 
Table 2. Insulin sensitivity and insulin secretion according to TCF7L2 rs7903146 genotype at baseline
All CC CT/TT P-
value
Adjusted 
P-value*
n 246 113 133
Fasting glucose (mmol/l) 4.7 (4.1 to 5.0) 4.7 (4.2 to 5.0) 4.7 (4.1 to 5.1) 0.99 0.96
Fasting insulin (pmol/l) 25.0 (14.0 to 41.0) 24.0 (14.0 to 36.0) 26.0 (14.0 to 43.5) 0.38 0.85
HOMA %B 68.1 (52.7 to 90.4) 64.7 (52.7 to 87.6) 71.1 (52.5 to 91.8) 0.38 0.85
HOMA IR 0.5 (0.3 to 0.8) 0.4 (0.3 to 0.7) 0.5 (0.3 to 0.8) 0.43 0.88
n 68 31 37
Si*10-4/min-1 (μU/ml) 12.1 (7.8 to 17.0) 11.3 (7.5 to 15.1) 12.6 (8.6 to 17.7) 0.44 0.11
AIR (mU/L) 283 (189 to 395) 255 (187 to 335) 296 (195 to 496) 0.20 0.02
DI (AIR*Si) 3028 (2377 to 4647) 2873 (1846 to 3851) 3329 (2637 to 4771) 0.15 0.06
Values are expressed as median (interquartile range) because of a skewed distribution
Data were log transformed before analysis with t-tests and linear regression.
HOMA %B = beta cell function; HOMA IR = insulin resistance index; Si = insulin sensitivity; AIR = acute insulin response; 
DI = disposition index. Signifi cant p-values are in bold.
*Adjusted p-values are derived from linear regression analyses under dominant model (CC versus CT/TT) adjusted for 
gender, age, puberty (coded as yes/no) and body fat percentage. Si was adjusted for gender, age, and puberty (coded 
as yes/no) because a linear regression models including body fat percentage was not signifi cant. DI was only adjusted 
for age for the same reason. 
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No other study evaluated the effect of the rs7903146 T allele on GH-induced changes 
in glucose homeostasis. GH treatment changes the environment by inducing insulin 
resistance and a compensatory increase in insulin secretion (13). Several studies 
demonstrated that the TCF7L2 rs7903146 T-allele is associated with decreased insulin 
secretion (4-8). Therefore, our cohort with detailed longitudinal information on glucose 
homeostasis of GH-treated short SGA children is very valuable to investigate whether 
there is a gene-environment interaction, e.g. whether TCF7L2 rs7903146 genotype 
predicts how well the beta-cells are capable to produce extra insulin in response to the 
GH-induced insulin resistance. We found no association between TCF7L2 genotype and 
the increase in insulin secretion. The decrease in insulin sensitivity compared to values 
at start was significant in the CT/TT group and not in the CC group, but the difference 
between the groups in decrease of insulin sensitivity was not significant. Despite the 
larger decrease in insulin sensitivity in carriers of a T-allele, both groups had a similar 
increase in insulin secretion during GH treatment. We conclude that TCF7L2 rs7903146 
genotype does not predict how well a short SGA child can produce extra insulin during GH 
treatment. With regard to the effect of rs7903146 on the decrease in insulin sensitivity 
a larger sample size would allow more definitive conclusions. 
 One other study analyzed whether the rs7903146 polymorphism in TCF7L2 has an 
effect on changes in glucose homeostasis (25). In overweight children and adolescents, 
aged 6-16 years, who participated in a lifestyle intervention program to reduce BMI, a 
positive association between the T allele of rs7903146 and the increase in insulin levels 
was found (25). The T allele at rs7903146 was associated with a negative effect on the 
improvement of HOMA-IR and a positive effect on the decrease in HOMA-%B after the 
lifestyle intervention (25). That study and ours have in common that there is a change 
in the environment (GH-treatment or weight reduction) that changes beta cell function. 
During GH-treatment the beta cells are stimulated to produce more insulin while during 
weight reduction insulin sensitivity increases and less insulin is needed. This different 
effect on the beta cells might explain why we did not find significant associations between 
rs7903146 genotype and the change in glucose homeostasis while the other study did 
find such an association.
 Another important difference between that study and ours is that we studied 
lean SGA children. Studies in adults did not find an association of TCF7L2 variants and 
obesity or BMI (5, 26). We did not find a significant interaction between rs7903146 
genotype and body fat percentage either. Therefore, we do not think that the absence 
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of a significant association between the rs7903146 T-allele and changes in measures 
of insulin sensitivity and insulin secretion in our population was caused by studying lean 
SGA children instead of obese children.
 We also investigated whether the TCF7L2 rs7903146 genotype correlated with 
estimates of glucose homeostasis at baseline. We found no associations between 
rs7903146 genotype and fasting levels of glucose and insulin, HOMA %B and HOMA-IR, 
which is in line with others (11). However, as we examined SGA subjects without catch-up 
growth to a normal height and Cauchi et al. did not specify the type of SGA participants 
(with or without catch-up growth to a normal height), our study is not completely 
comparable with that study. In addition, our study provides more detailed results 
because we also studied the association between TCF7L2 genotype and insulin secretion 
by means of FSIGT whereas others only used fasting glucose and insulin levels and 
HOMA calculations (11). After adjustment for possible confounders we did find a higher 
insulin secretion (AIR) measured by FSIGT in carriers of a T-allele. Most studies that 
found associations between genotype and glucose homeostasis were performed in large 
cohorts of adults (4-8). Our study and the study by Cauchi et al. have the limitation that 
they can only detect large genotypic influences on glucose homeostasis because of their 
sample size. Population studies demonstrated that TCF7L2 does not have a large effect 
size (1). 
 Insulin is an important growth factor in utero, so TCF7L2 might influence size at 
birth. The minor allele frequency (MAF) in our population was 30% which is similar as the 
29% in SGA subjects and 31% in appropriate for gestational age (AGA) subjects reported 
in literature (11). Thus, there seems to be no association between being born SGA and 
the TCF7L2 genotype. As far as we know only one study investigated the association 
between birth weight and TCF7L2 genotype and found a positive effect of the rs7903146 
T-allele when present in the mother (27). Presence of one or two copies of the T-allele in 
the fetus seemed not to influence birth weight (27). 
 In conclusion, our study indicates that in short children who were born SGA, TCF7L2 
rs7903146 genotype is not associated with the change in insulin secretion during GH 
treatment. The rs7903146 polymorphism does not predict which children are less 
capable of producing extra insulin to compensate for the reduced insulin sensitivity 
induced by GH-treatment and as a result have an increased risk to develop type 2 DM 
in later life. With regard to the effect of rs7903146 on the decrease in insulin sensitivity 
during GH treatment, a larger sample size would allow more definitive conclusions. 
Proefschrift Sandra W.K de Kort 20-08-09.indd   171 13-09-2009   16:58:59
172
chapter 
8
TC
F7
L2
, g
lu
co
se
 h
om
eo
st
as
is
 a
nd
 G
H
 in
 s
ho
rt
 S
G
A 
ch
ild
re
n
173
ACKnOWlEDGEMEnTS
We greatly acknowledge Mrs. C. Bruinings-Vroombout, Mrs. M. Huibregtse-Schouten, 
Mrs. J. van Houten, Mrs. J. van Nieuwkasteele, Mrs. J. Dunk and Mrs. E. Lems, research 
nurses, for their assistance and help with data collection; Mrs. J.P. Sluimer for performing 
and analyzing the DEXA measurements, Dr. W.H. Hackeng for his glucose and insulin 
assays and M.A.J. de Ridder for her help with the statistical analysis. We also greatly 
acknowledge the participating physicians: E.G.A.H. van Mil, Free University Hospital 
Amsterdam, The Netherlands; J. C. Mulder, Rijnstate Hospital, Arnhem, The Netherlands; 
R. J. H. Odink and J. J. J. Waelkens, Catharina Hospital, Eindhoven, The Netherlands; W. M. 
Bakker-van Waarde, University Medical Center Groningen, Groningen, The Netherlands; 
W. H. Stokvis, B. Bakker, Leiden University Medical Center, Leiden, The Netherlands; C. 
Noordam, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands; C. 
Westerlaken, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands; N. J. T. Arends, 
E.M. Bannink, V. H. Boonstra, M. Van Dijk , Y.K. van Pareren, T.C.J. Sas, Erasmus Medical 
Center Sophia, Rotterdam, The Netherlands; H. M. Reeser and E. C. A. M. Houdijk, Juliana 
Children’s Hospital, The Hague, The Netherlands; E.J. Schroor, Isala clinics, Zwolle, The 
Netherlands, J.P.C.M. van der Hulst, Zaans medical centre, Zaandam, The Netherlands; 
E.J. Sulkers, Walcheren Hospital, Vlissingen, The Netherlands and M. Jansen, Wilhelmina 
Children’s Hospital, Utrecht, The Netherlands. This study was supported by Novo Nordisk 
Farma B.V. and Pfizer B.V., the Netherlands.
 
Proefschrift Sandra W.K de Kort 20-08-09.indd   172 13-09-2009   16:58:59
172 173
chapter 
8
TC
F7
L2
, g
lu
co
se
 h
om
eo
st
as
is
 a
nd
 G
H
 in
 s
ho
rt
 S
G
A 
ch
ild
re
n
referenCeS
1 Weedon MN 2007 The importance of TCF7L2. Diabet Med 24:1062-1066
2 Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham 
 HM, Chines PS, Jackson AU, Prokunina-Olsson L, Ding CJ, Swift AJ, Narisu N, Hu 
 T, Pruim R, Xiao R, Li XY, Conneely KN, Riebow NL, Sprau AG, Tong M, White PP, 
 Hetrick KN, Barnhart MW, Bark CW, Goldstein JL, Watkins L, Xiang F, Saramies J, 
 Buchanan TA, Watanabe RM, Valle TT, Kinnunen L, Abecasis GR, Pugh EW, Doheny 
 KF, Bergman RN, Tuomilehto J, Collins FS, Boehnke M 2007 A genome-wide 
 association study of type 2 diabetes in Finns detects multiple susceptibility 
 variants. Science 316:1341-1345
3 Frayling TM, Timpson NJ, Weedon MN, Zeggini E, Freathy RM, Lindgren CM, Perry 
 R, Elliott KS, Lango H, Rayner NW, Shields B, Harries LW, Barrett JC, Ellard S, Groves 
 CJ, Knight B, Patch AM, Ness AR, Ebrahim S, Lawlor DA, Ring SM, Ben-Shlomo Y, 
 Jarvelin MR, Sovio U, Bennett AJ, Melzer D, Ferrucci L, Loos RJ, Barroso I, Wareham 
 NJ, Karpe F, Owen KR, Cardon LR, Walker M, Hitman GA, Palmer CN, Doney AS, 
 Morris AD, Smith GD, Hattersley AT, McCarthy MI 2007 A common variant in the FTO 
 gene is associated with body mass index and predisposes to childhood and adult 
 obesity. Science 316:889-894
4 Damcott CM, Pollin TI, Reinhart LJ, Ott SH, Shen H, Silver KD, Mitchell BD, Shuldiner 
 AR 2006 Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are 
 associated with type 2 diabetes in the Amish: replication and evidence for a role in 
 both insulin secretion and insulin resistance. Diabetes 55:2654-2659
5 Saxena R, Gianniny L, Burtt NP, Lyssenko V, Giuducci C, Sjogren M, Florez JC, 
 Almgren P, Isomaa B, Orho-Melander M, Lindblad U, Daly MJ, Tuomi T, Hirschhorn 
 JN, Ardlie KG, Groop LC, Altshuler D 2006 Common single nucleotide polymorphisms 
 in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin 
 response to glucose in nondiabetic individuals. Diabetes 55:2890-2895
6 Raitakari OT, Ronnemaa T, Huupponen R, Viikari L, Fan M, Marniemi J, Hutri-Kahonen 
 N, Viikari JS, Lehtimaki T 2007 Variation of the transcription factor 7-like 2 (TCF7L2) 
 gene predicts impaired fasting glucose in healthy young adults: the Cardiovascular 
 Risk in Young Finns Study. Diabetes Care 30:2299-2301
7 Lyssenko V, Lupi R, Marchetti P, Del Guerra S, Orho-Melander M, Almgren P, Sjogren 
 M, Ling C, Eriksson KF, Lethagen AL, Mancarella R, Berglund G, Tuomi T, Nilsson P, 
Proefschrift Sandra W.K de Kort 20-08-09.indd   173 13-09-2009   16:58:59
174
chapter 
8
TC
F7
L2
, g
lu
co
se
 h
om
eo
st
as
is
 a
nd
 G
H
 in
 s
ho
rt
 S
G
A 
ch
ild
re
n
175
 Del Prato S, Groop L 2007 Mechanisms by which common variants in the TCF7L2 
 gene increase risk of type 2 diabetes. J Clin Invest 117:2155-2163
8 Wegner L, Hussain MS, Pilgaard K, Hansen T, Pedersen O, Vaag A, Poulsen P 2008 
 Impact of TCF7L2 rs7903146 on insulin secretion and action in young and elderly 
 Danish twins. J Clin Endocrinol Metab 93:4013-4019
9 Hofman PL, Cutfield WS, Robinson EM, Bergman RN, Menon RK, Sperling MA, 
 Gluckman PD 1997 Insulin resistance in short children with intrauterine growth 
 retardation. J Clin Endocrinol Metab 82:402-406
10 Sas T, Mulder P, Aanstoot HJ, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A 
 2001 Carbohydrate metabolism during long-term growth hormone treatment in 
 children with short stature born small for gestational age. Clin Endocrinol (Oxf) 
 54:243-251
11 Cauchi S, Meyre D, Choquet H, Deghmoun S, Durand E, Gaget S, Lecoeur C, Froguel 
 P, Levy-Marchal C 2007 TCF7L2 rs7903146 variant does not associate with 
 smallness for gestational age in the French population. BMC Med Genet 8:37
12 Munoz J, Lok KH, Gower BA, Fernandez JR, Hunter GR, Lara-Castro C, De Luca M, 
 Garvey WT 2006 Polymorphism in the transcription factor 7-like 2 (TCF7L2) gene 
 is associated with reduced insulin secretion in nondiabetic women. Diabetes 
 55:3630-3634
13 Cutfield WS, Jackson WE, Jefferies C, Robinson EM, Breier BH, Richards GE, 
 Hofman PL 2003 Reduced insulin sensitivity during growth hormone therapy for 
 short children born small for gestational age. J Pediatr 142:113-116
14 Willemsen RH, de Kort SW, van der Kaay DC, Hokken-Koelega AC 2008 
 Independent effects of prematurity on metabolic and cardiovascular risk factors in 
 short small-for-gestational-age children. J Clin Endocrinol Metab 93:452-458
15 Usher R, McLean F 1969 Intrauterine growth of live-born Caucasian infants at sea 
 level: standards obtained from measurements in 7 dimensions of infants born 
 between 25 and 44 weeks of gestation. J Pediatr 74:901-910
16 Fredriks AM, Van Buuren S, Burgmeijer RJ, Verloove-Vanhorick SP, Wit JM 2002 
 Groeidiagrammen (2e, herziene en vermeerderde druk) [Growth diagrams, second 
 edition]. Bohn Stafleu van Loghum, Houten
17 van Dijk M, Mulder P, Houdijk M, Mulder J, Noordam K, Odink RJ, Rongen- 
 Westerlaken C, Voorhoeve P, Waelkens J, Stokvis-Brantsma J, Hokken-Koelega A 
 2006 High serum levels of growth hormone (GH) and insulin-like growth factor-I 
Proefschrift Sandra W.K de Kort 20-08-09.indd   174 13-09-2009   16:58:59
174 175
chapter 
8
TC
F7
L2
, g
lu
co
se
 h
om
eo
st
as
is
 a
nd
 G
H
 in
 s
ho
rt
 S
G
A 
ch
ild
re
n
 (IGF-I) during high-dose GH treatment in short children born small for gestational 
 age. J Clin Endocrinol Metab 91:1390-1396
18 Levy JC, Matthews DR, Hermans MP 1998 Correct homeostasis model assessment 
 (HOMA) evaluation uses the computer program. Diabetes Care 21:2191-2192
19 Cutfield WS, Bergman RN, Menon RK, Sperling MA 1990 The modified minimal 
 model: application to measurement of insulin sensitivity in children. J Clin Endocrinol 
 Metab 70:1644-1650
20 van Dijk M, Bannink EM, van Pareren YK, Mulder PG, Hokken-Koelega AC 2007 
 Risk factors for diabetes mellitus type 2 and metabolic syndrome are comparable 
 for previously growth hormone-treated young adults born small for gestational age 
 (sga) and untreated short SGA controls. J Clin Endocrinol Metab 92:160-165
21 Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM, Bergman RN 2003 
 MINMOD Millennium: a computer program to calculate glucose effectiveness and 
 insulin sensitivity from the frequently sampled intravenous glucose tolerance test. 
 Diabetes Technol Ther 5:1003-1015
22 Arends NJ, Boonstra VH, Duivenvoorden HJ, Hofman PL, Cutfield WS, Hokken- 
 Koelega AC 2005 Reduced insulin sensitivity and the presence of cardiovascular 
 risk factors in short prepubertal children born small for gestational age (SGA). Clin 
 Endocrinol (Oxf) 62:44-50
23 Verveke G, Molenberghs G 2001 Linear mixed models for longitudinal data. 
 Springer-Verlag, Berlin
24 Littell RC, Henry PR, Ammerman CB 1998 Statistical analysis of repeated measures 
 ata using SAS procedures. J Anim Sci 76:1216-1231
25 Reinehr T, Friedel S, Mueller TD, Toschke AM, Hebebrand J, Hinney A 2008 
 Evidence for an influence of TCF7L2 polymorphism rs7903146 on insulin 
 resistance and sensitivity indices in overweight children and adolescents during a 
 lifestyle intervention. Int J Obes (Lond) 32:1521-1524
26 Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PI, Shuldiner AR, Knowler 
 WC, Nathan DM, Altshuler D, Diabetes Prevention Program Research G 2006 
 TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention 
 Program. N Engl J Med 355:241-250
27 Freathy RM, Weedon MN, Bennett A, Hypponen E, Relton CL, Knight B, Shields B, 
 Parnell KS, Groves CJ, Ring SM, Pembrey ME, Ben-Shlomo Y, Strachan DP, Power 
 C, Jarvelin MR, McCarthy MI, Davey Smith G, Hattersley AT, Frayling TM 2007 Type 
Proefschrift Sandra W.K de Kort 20-08-09.indd   175 13-09-2009   16:58:59
176
chapter 
8
TC
F7
L2
, g
lu
co
se
 h
om
eo
st
as
is
 a
nd
 G
H
 in
 s
ho
rt
 S
G
A 
ch
ild
re
n
177
 2 diabetes TCF7L2 risk genotypes alter birth weight: a study of 24,053 individuals. 
 Am J Hum Genet 80:1150-1161
Proefschrift Sandra W.K de Kort 20-08-09.indd   176 13-09-2009   16:59:00
176 177
chapter 
8
TC
F7
L2
, g
lu
co
se
 h
om
eo
st
as
is
 a
nd
 G
H
 in
 s
ho
rt
 S
G
A 
ch
ild
re
n
Proefschrift Sandra W.K de Kort 20-08-09.indd   177 13-09-2009   16:59:00
Proefschrift Sandra W.K de Kort 20-08-09.indd   178 13-09-2009   16:59:00
1Dept. of paediatrics, Division of endocrinology, erasmus Mc-Sophia, rotterdam, the Netherlands 
2Dept. of Metabolic and endocrine Diseases, and Laboratory of clinical chemistry and hematology 
 – University Medical center Utrecht – Utrecht, the Netherlands 
Sandra W.K. de Kort1
Jaap van Doorn2
ad G.M. van de Sande2
ralph W.J. Leunissen1
anita c.S. hokken-Koelega1
Serum Insulin-like Growth 
Factor-Binding Protein-2 
levels and metabolic and 
cardiovascular risk factors 
in young adults and children 
born small for gestational age
chapter 9
Submitted
Proefschrift Sandra W.K de Kort 20-08-09.indd   179 13-09-2009   16:59:00
180 181
ABStrACt
Background: IGF binding protein (IGFBP)-2 might protect against 
cardiovascular disease (CVD). Small for gestational age (SGA) birth could 
be associated with a higher risk for type 2 diabetes mellitus and CVD in 
later life. no data are available on the relationship between serum IGFBP-2 
levels and cardiovascular risk factors in young adults and children born 
SGA.
Objective: To determine circulating IGFBP-2 levels in subjects born SGA, 
and to investigate the association with cardiovascular risk factors.
Methods: IGFBP-2 levels were measured in sera from 151 young adults 
born SGA and 147 short SGA children. Age and gender adjusted standard 
deviation scores (SDS) were calculated. Blood pressure, serum lipids, body 
composition by DXA and glucose homeostasis by HOMA-IR or frequently 
sampled intravenous glucose tolerance test (FSIGT) were determined.
Results: Serum IGFBP-2 SDS was significantly reduced in SGA young 
adults (with normal or short stature). Fat mass SDS was relatively high 
in SGA young adults and reduced in short SGA children. Serum IGFBP-2 
SDS in SGA young adults correlated positively with insulin sensitivity (Si) 
and negatively with fat mass SDS, insulin secretion (AIR), fasting insulin, 
HOMA-IR, total cholesterol, triglycerides and blood pressure SDS. The 
association between serum IGFBP-2 SDS and Si, blood pressure, total 
cholesterol and triglycerides levels persisted after adjustment for known 
covariates including fat mass SDS. In short SGA children, IGFBP-2 SDS did 
not correlate with any of the cardiovascular risk factors.
Conclusion: Serum IGFBP-2 SDS is an independent cardiovascular risk 
marker in young adults who were born SGA. 
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introduCtion
Plasma insulin like growth factor binding protein 2 (IGFBP-2) belongs to the family of 
IGFBPs that is present in extracellular fluids and binds both IGF-I and IGF-II (1). Serum 
levels of IGFBP-2 show little diurnal variation and do not vary in response to meals or 
glucose infusions (1, 2). IGFBP-2 levels do increase after a prolonged period of fasting 
(1), indicating that IGFBP-2 concentrations are metabolically regulated and might reflect 
long-term alterations in hepatic exposure to insulin (3). It has been reported that IGFBP-2 
possibly alters the activity of intracellular kinases which modulate insulin signalling in 
metabolically active tissues by both IGF-dependent and IGF-independent mechanisms, 
thereby modulating insulin sensitivity (3).
 In middle aged adults, elderly and cancer patients, serum concentrations of IGFBP-2 
were inversely associated with insulin levels (4-7) and HOMA insulin resistance (5, 8). 
Also, IGFBP-2 was inversely associated with body mass index (BMI) (4, 6-8) and fat mass 
(6, 8). Studies in mice demonstrated that overexpression of IGFBP-2 results in diminished 
postnatal weight gain and reduced fasting glucose and insulin levels (9). Transgenic mice 
were protected from age-related development of glucose intolerance, insulin resistance 
and high blood pressure (10). Possibly, IGFBP-2 limits adipocyte expansion by inhibiting 
adipocyte differentiation (3, 10). IGFBP-2 knockout mice were heavier than controls but 
were not insulin resistant (11).  This suggests that the effect of IGFBP-2 on glucose 
homeostasis is independent of its effect on BMI.
 In subjects born small for gestational age (SGA), the association between 
IGFBP-2 levels and metabolic and cardiovascular risk factors has not yet been studied. 
Epidemiological studies have shown that low birth weight and postnatal catch-up in 
weight are associated with the development of type 2 DM and associated disorders 
such as hypertension, dyslipidemia, and cardiovascular disease in adults (12-14). Most 
children who were born SGA show spontaneous catch-up growth in height and weight but 
about 10% remains short through adult life. SGA infants were reported to have elevated 
IGFBP-2 levels (15, 16) and the only study that measured IGFBP-2 levels in short SGA 
children found also high levels (17). These studies, however, measured IGFBP-2 levels 
with another purpose and did not study the association with cardiovascular risk factors. 
For SGA young adults, serum IGFBP-2 levels have not been documented. 
 In this study, we measured serum IGFBP-2 levels in a cohort of young adults and 
children who were born SGA, and compared these levels to those found in age and 
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gender-matched controls with normal stature. We hypothesize that serum IGFBP-2 levels 
are a marker of metabolic and cardiovascular risk in subjects born SGA.  
SuBjeCtS And MetHodS
Subjects
The group of young adults born SGA (i.e. birth length < -2 SDS) (18) comprised 151 
subjects with either short stature (adult height adjusted for age and gender < - 2 SDS; 
n = 37) or a normal height (> - 2 SDS; n = 114) (19). Catch-up growth was defined as a 
height > -1 SDS (n = 67). They were recruited as part of the PROgramming factors for 
GRowth And Metabolism (PROGRAM) study (20). In addition, 147 children born SGA with 
short stature were studied. Inclusion and exclusion criteria for the short SGA children 
have been previously described (21). In brief: children were included when they were 
SGA at birth (birth length and/or birth weight SDS of below –2.0 for gestational age 
(18)), had short stature (height SDS for age and gender < – 2) (19), did not show catch-
up growth to a height > -2 SDS, and had no growth failure caused by other disorders. 
Birth characteristics were collected from hospital registries. The gestational age of the 
subjects was determined by ultrasound in the first trimester or otherwise calculated from 
the date of the last menstruation. None of the young adults and children studied was 
treated with growth hormone (GH). The Medical Ethics Committees of Erasmus Medical 
Center, Rotterdam, and of the participating centers approved all studies and written 
informed consent was obtained from all participants or their parents. 
Study design
Standing height and weight were measured as previously described (21) and expressed 
as SDS using Dutch reference data (19). Body mass index (BMI) was calculated as weight 
divided by height squared (kg/m2) and was expressed as SDS adjusting for age and 
gender (19). Systolic and diastolic blood pressure (BP) was measured twice on the left 
arm with an automated device and using an appropriate cuff size (Dinamap Critikon, 
southern Medical Corp., Baton Rouge, LA, USA). The mean of two measurements was 
used for analysis. As blood pressure is known to increase with height, BP was expressed 
as SDS adjusted for height and gender (22). Dual-energy X-ray Absorptiometry (DXA, type 
Lunar Prodigy, GE Healthcare, Chalfont St Giles, UK) was performed in all young adults 
and in 24 children. In which children a DXA was performed was determined by the date 
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of their inclusion in the study.  The intra-instrument reliability for lean and fat tissue was 
1.57-4.49% and 0.41-0.88%, respectively (23). Lean body mass (LBM) and fat mass 
(FM) were determined. FM and LBM were transformed into SD-scores for gender and 
chronological age using Dutch reference values, which were obtained using the same 
machine and software (24, 25). Since body composition is strongly related to height, 
LBM and FM expressed as SDS for age and gender may result in an underestimation 
in case of short stature. Therefore, LBM and FM were expressed as SDS for height and 
gender (26).
Glucose homeostasis
A modified, frequently sampled intravenous glucose tolerance test (FSIGT) with 
tolbutamide, was performed in a subgroup of 67 young adults and 22 children, 
as previously described (27, 28). In which children an FSIGT was performed was 
determined by the date of their inclusion in the study. Serum glucose and insulin levels 
were measured in one laboratory as previously described (29) and insulin sensitivity 
(Si), glucose effectiveness (Sg), acute insulin response (AIR) and disposition index (DI) 
were calculated using Bergman’s MINMOD MILENNIUM software (30). Si is defined as 
the capacity of insulin to promote glucose disposal. Sg reflects the capacity of glucose 
to mediate its own disposal. AIR is an estimate of the insulin secretory capacity, being 
represented by the area under the curve from zero to ten minutes corrected for baseline 
insulin levels. DI is an overall measure of the ability of the beta cells to secrete insulin 
in response to the degree of insulin resistance, i.e. the product of AIR and Si (DI = AIRg 
* SI) (30).
laboratory parameters
All blood samples were taken after an overnight fast. Serum IGFBP-2 levels were determined 
by a specific RIA, using an antiserum (WKZ35920) that was raised in a New Zealand 
rabbit against recombinant bovine IGFBP-2 (rbIGFBP-2; GroPep, Adelaide, Australia), in 
principle as described previously (31) with some slight modifications. In brief: the assay 
buffer was composed of 50 mM sodium phosphate (pH 7.4), 10 mM ethyleen-diamino-
tetra-acetaat (EDTA), 0.05% (w/v) Tween-20, 0.2% BSA and 0.02% NaN3. Recombinant 
hIGFBP-2 (GroPep, Adelaide, Australia) was used as a standard (range 0.02-15 ng/tube) 
and [125I]-rhIGFBP-2 as tracer. The RIA incubation mixture consisted of 100 μL standard 
or diluted sample, 100 μL antiserum (final dilution in assay buffer: 1:80.000), and 100 
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μL tracer (≈10.000 cpm). After equilibrium incubation for 17-20 hrs at room temperature 
in polystyrene tubes, 100 μL Sac-Cel solid phase anti-rabbit IgG- coated cellulose 
suspension (Immunodiagnostic Systems, Boldon, UK) was added. Complexation was 
complete after 30 min at room temperature, and 0.5 mL distilled phosphate buffered 
saline was added to the samples, which were subsequently centrifuged at 10,000 x g 
for 4 min. Pellets were counted in a t-counter (Packard Instrument Co.,Inc., Downers 
Grove, IL). ). Intra-assay variations (10 replicates) were 8.3, 4.9 and 4.5 % at mean serum 
levels of 73, 256, and 1205 μg/L, respectively. Inter-assay variations (n=8) were 12.1 
%, 8.9 % and 8.1 % at mean serum levels of 77, 246, 1268 μg/L, respectively. The 
sensitivity of the assay was 0.1 μg/L (absolute concentration). Serum levels of IGFBP-2 
were expressed as SDS, adjusting for age and gender, based on blood samples of 831 
healthy individuals being derived from sources described previously (32).
 Fasting glucose was measured on a Hitachi 917 analyzer and fasting insulin was 
measured by chemoluminescent assay on an Immulite 2000 analyzer (Diagnostic 
Products Corporation, Los Angeles, CA). HOMA insulin resistance index (HOMA-IR) was 
calculated (33). Serum cholesterol levels were measured as previously described (34). 
Triglycerides were measured on the Chem-I analyzer according to the manufacturer’s 
instructions (Technicon Instruments, Tarrytown, New York) and after 1998 on the 
Hitachi 917 analyser according to the manufacturer’s instructions (Roche Diagnostics, 
Mannheim, Germany). Both methods were comparable (y = x – 0.030).
 
Statistics
Due to a skewed distribution, serum values of IGFBP-2 SDS, glucose, insulin, and 
lipids, and HOMA-IR, Si, AIR, DI, were log-transformed before analyses. These data are 
presented as median (interquartile range). The various other parameters investigated 
are expressed as mean (SD). SD scores were compared with reference population means 
(zero SDS) using one-sample t tests. Results in young adults with short stature and young 
adults with catch-up growth to a height > -1 SDS were compared using independent 
samples t tests. After log-transformation, Pearson’s correlation coefficient was used for 
correlations. Associations of IGFBP-2 with metabolic and cardiovascular risk factors were 
investigated by multiple linear regression analysis. We entered age, gender, height SDS, 
birth length SDS, birth weight SDS, lean body mass SDSheight, and fat mass SDSheight to 
the model because these are determinants of evaluated cardiovascular risk (20). The 
interaction term birth length SDS * adult height SDS was added to all models because 
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the young adults were selected on birth length and adult height, in order to ensure that 
the effect of these variables was modelled correctly. IGFBP-2 SDS was added to the 
model in order to determine the effect of IGFBP-2 SDS on the outcome variable adjusted 
for other determinants. A p value < 0.05 was considered significant. Analyses were 
performed using the computer statistical package SPSS version 15 for Windows (SPSS 
Inc., Chicago, IL).
reSultS
Clinical data
Clinical characteristics are shown in Table 1. Young adults had a normal fat mass (FM) 
for age. However, on average, they exhibited a shorter stature than the population mean. 
As a consequence their FM for height SDS was significantly higher than zero SDS. In 
contrast, short SGA children, showed SDS values of both FM for age and FM for height 
that were significantly reduced (< -2 SDS).  
 Differences between young adults with a height SDS < -2 and young adults with a 
height SDS > -1 in BMI SDS, FM SDSage, FM SDSheight, Si, AIR, DI, and serum levels of total 
cholesterol and triglycerides did not reach significance.
 When the total group of SGA young adults was considered, diastolic blood pressure 
was elevated when compared to values of gender and height matched references. No 
differences were observed between short young adults and those with catch-up growth to 
a normal height. In the SGA children, both systolic and diastolic blood pressure appeared 
to be elevated. 
Serum IGFBP-2 levels
Serum IGFBP-2 levels in SGA young adults were significantly lower than in gender and 
age matched references. There was no significant difference in IGFBP-2 SDS between 
young adults with short stature and young adults with catch-up growth to a normal height 
(p = 0.95).  Short SGA children had similar IGFBP-2 levels as their peers (Table 1). In both 
young adults and children, IGFBP-2 SDS did not significantly correlate with birth weight 
SDS, birth length SDS, gestational age, or height SDS.
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Table 1. Clinical and laboratory characteristics in two cohorts of SGA born subjects
SGA young adults SGA children
n n
Male/female 64/87 151 81/66 147
Age 20.9 (1.7) 151 7.1 (2.8) 147
Gestational age (wk) 39.0 (38.0 to 40.0) 151 37.3 (32.3 to 39.3) 147
Birth weight SDS -2.3 (0.7)* 151 -2.4 (1.0)* 147
Birth length SDS -2.7 (1.0)* 151 -3.6 (1.5)* 110
Height SDS -1.2 (1.2)* 151 -3.0 (0.6)* 147
BMI 23.1 (4.1) 151 14.2 (1.5) 147
BMI SDS 0.2 (1.3) 151 -1.4 (1.0)* 147
Fat mass SDSage 0.2 (1.1) 147 -2.7 (1.7)* 24
Fat mass SDSheight 0.5 (1.0)* 147 -2.6 (1.8)* 24
Lean mass SDSage -1.0 (1.0)* 147 -2.6 (0.5)* 24
Lean mass SDSheight 0.3 (1.4)*** 147 -1.3 (1.7)** 24
Systolic bp SDS 0.0 (0.8) 99 0.9 (1.1)* 145
Diastolic bp SDS 0.3 (0.5)* 99 0.4 (1.0)* 145
IGFBP-2 (ng/ml) 122 (64 to 227) 151 262 (188 to 331) 147
IGFBP-2 SDS -0.86 (1.8)* 151 -0.16 (1.2) 147
F Insulin (pmol/l) 58.2 (45.9 to 85.8) 74 19.5 (14.0 to 36.0) 126
F Glucose (mmol/l) 4.9 (4.5 to 5.1) 135 4.4 (4.0 to 4.8) 131
HOMA-IR 1.1 (0.9 to 1.6) 74 0.3 (0.2 to 0.6) 124
Si*10-4/min-1 (μU/ml) 4.7 (2.9 to 8.3) 67 12.4 (7.1 to 18.3) 22
AIR (mU/L) 441 (302 to 774) 67 312 (205 to 515) 22
DI (AIR*Si) 2466 (1595 to 4015) 67 3130 (2362 to 4911) 22
Cholesterol (mmol/l) 4.5 (3.9 to 5.4) 145 4.3 (3.7 to 5.0) 77
Triglycerides (mmol/l) 0.9 (0.7 to 1.2) 145 0.8 (0.6 to 1.3) 59
Values are expressed as mean (SD) or as median (interquartile range). 
Gestational age was compared with a nonparametric test. Data with a skewed distribution were 
log transformed before analysis with t-tests.
SDS = standard deviation score F  = fasting; HOMA IR = insulin resistance index; Si = insulin 
sensitivity; AIR = acute insulin response; DI = disposition index
Compared with zero SDS: *p < 0.001; **p < 0.01; ***p < 0.05
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Associations between IGFBP-2 SDS and metabolic and cardiovascular risk 
factors
In the SGA young adults, IGFBP-2 SDS correlated negatively with BMI SDS, FM SDS, 
blood pressure SDS, fasting insulin, HOMA-IR, insulin secretion (AIR), cholesterol, and 
triglycerides (Table 2). There was a positive correlation between IGFBP-2 SDS and insulin 
sensitivity (Si). In the short SGA children, IGFBP-2 SDS did not correlate with any of the 
metabolic or cardiovascular risk factors studied.
 In addition, we evaluated the association of serum IGFBP-2 SDS with several 
metabolic and cardiovascular risk factors in the SGA young adults with multiple regression 
(MR) analyses (Table 3). These analyses revealed that IGFBP-2 SDS associated with Si, 
also after adjustment for known determinants of Si, including FM SDSheight. Notably, there 
was a significant association between Si and FM SDSheight  (β -0.39, p < 0.001) but when 
we added IGFBP-2 SDS to the model this association was no longer significant 
Table 2. Correlations between IGFBP-2 SDS and various metabolic and cardiovascular risk factors
SGA young adults (n = 151) SGA children (n = 147)
R p-value R p-value
BMI SDS -0.31 < 0.001 -0.04 0.66
Fat mass SDSage -0.48 < 0.001 -0.16 0.57
Fat mass SDSheight -0.45 < 0.001 0.12 0.58
Lean mass SDSage -0.15 0.08 -0.07 0.76
Lean mass SDSheight 0.05 0.52 0.04 0.86
Systolic bp SDS -0.27 0.007 0.04 0.60
Diastolic bp SDS -0.30 0.002 0.16 0.06
F insulin (pmol/l) -0.55 < 0.001 -0.15 0.09
F Glucose (mmol/l) 0.07 0.46 -0.01 0.88
HOMA-IR -0.55 < 0.001 -0.13 0.14
Si*10-4/min-1 (μU/ml) 0.54 < 0.001 0.18 0.44
AIR (mU/L) -0.45 < 0.001 -0.22 0.32
DI (AIR*Si) 0.03 0.82 0.02 0.95
Cholesterol (mmol/l) -0.40 < 0.001 -0.21 0.07
Triglycerides (mmol/l) -0.40 < 0.001 -0.05 0.73
R = Pearson’s correlation coeffi cient; SDS = standard deviation score F  = fasting; HOMA IR = insulin 
resistance index; Si = insulin sensitivity; AIR = acute insulin response; DI = disposition index
F insulin, HOMA-IR, Si, cholesterol and triglycerids were log-transformed for analysis.
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(Table 3). Thus, the association between Si and IGFBP-2 SDS was stronger than the 
association between Si and FM SDSheight. When instead of Si, systolic and diastolic blood 
pressure, total cholesterol and triglycerides levels were analyzed as dependent variable, 
similar results were found. After adjustment for age, gender, size at birth, height SDS, 
LBM SDSheight and FM SDSheight, IGFBP-2 SDS was not associated with HOMA-IR (β -0.04, 
p = 0.17). However, when we removed FM SDSheight from the model, there was a negative 
association between IGFBP-2 SDS and HOMA-IR (β -0.11, p < 0.001). This indicates that 
the association between IGFBP-2 and HOMA-IR is probably mediated through fat mass. 
When instead of HOMA-IR, fasting insulin levels and insulin secretion (AIR) were analyzed 
as dependent variable, similar results were found.  
diSCuSSion
In this study we show that serum IGFBP-2 levels in SGA young adults were significantly re-
duced, when compared to age and gender-matched references. To our knowledge, so far 
data on serum IGFBP-2 levels for SGA young adults did not exist. We found no association 
between size at birth or adult height SDS and serum IGFBP-2 SDS. In a study on disease-
free men (50-70 yrs of age), Gunnell et al. could also not find an association between 
circulating levels of IGFBP-2 and height (35). Our study shows that lower serum IGFBP-2 
levels in SGA young adults were neither associated with their relatively small size at birth 
nor with height SDS, but appeared to be related to their increased fat mass SDS. 
 The inverse correlation between serum IGFBP-2 levels and BMI has been 
consistently reported (4, 6-8), but only a few studies also examined body composition. 
We performed DXA scans in 147 young adults and found a significant inverse correlation 
between IGFBP-2 SDS and fat mass SDS. Two studies in elderly subjects yielded a similar 
result (6, 8). However, in contrast to these previous reports (6, 8), we did not find a 
significant relationship between serum IGFBP-2 SDS and lean mass SDS. There are 
several possible explanations for this apparent discrepancy. Besides the fact that we 
studied much younger individuals, in one study (8) body composition was determined by 
leg-to-leg bioimpedance which is less accurate than DXA. Furthermore, we adjusted lean 
body mass for height and gender while this was not performed in the other two studies 
referred to above. 
 Data on the association between serum IGFBP-2 and metabolic and cardiovascular 
risk factors were not available yet for subjects born SGA. In this study we found that serum 
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IGFBP-2 SDS is an independent cardiovascular risk marker in SGA young adults. Studies 
in subjects with other conditions found correlations between IGFBP-2 and cardiovascular 
risk factors in line with our results. In older adults with type 2 DM, IGFBP-2 correlated 
independently and negatively with fasting glucose, triglycerides and LDL cholesterol and 
positively with insulin sensitivity (36). In adults with a mean age of 55 years, IGFBP-2 
correlated inversely with insulin, triglycerides, fasting glucose levels, systolic and diastolic 
blood pressure (4) and in non-diabetic patients with chronic heart failure, IGFBP-2 
correlated inversely with insulin and HOMA-IR but not with insulin sensitivity measured 
by hyperinsulinemic-euglycemic clamp (5). As there is no marked prandial regulation of 
IGFBP-2, this IGF-binding protein is considered a robust biomarker for cardiovascular risk 
(36).
 In our cohort of short SGA children, with a mean age of seven years, serum IGFBP-2 
levels were comparable to reference values. Only one other study measured circulating 
IGFBP-2 levels in a much smaller cohort of 17 short SGA children (mean age 6 years) 
and reported higher IGFBP-2 levels than in age-matched references (17). Infants with 
intrauterine growth restriction are reported to exhibit decreased levels of IGF-I, IGF-2, 
IGFBP-3, and insulin, and elevated levels of IGFBP-I and IGFBP-2 (15, 16). It is, however, 
not known whether the increased IGFBP-2 levels in SGA infants do normalize during 
childhood. 
 In contrast to the SGA young adults, serum IGFBP-2 levels in short SGA children did 
not correlate with any of the metabolic and cardiovascular risk parameters investigated. 
This may be explained by the difference in BMI SDS between SGA young adults and 
children, more precisely, the difference in fat mass adjusted for height and gender. SGA 
children had a low fat mass for height SDS while young adults had a significantly higher 
fat mass for height SDS compared to the population mean. Since serum IGFBP-2 SDS 
negatively associate with fat mass SDS, a certain threshold level of fat mass may be 
required before serum IGFBP-2 levels correlate with other cardiovascular risk factors. 
However, it must be emphasized that the association of serum IGFBP-2 SDS with insulin 
sensitivity, blood pressure, cholesterol and triglycerides persisted after adjustment for fat 
mass SDS. Longitudinal studies, in which the same subjects are evaluated in childhood 
and at young adult age, will allow more definite conclusions.  
 For children, data on the relationships between serum IGFBP-2 levels and metabolic 
and cardiovascular risk factors are very scarce. Three studies on obese children reported 
decreased circulating IGFBP-2 levels compared to those in controls (37-39).  One of 
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these studies also reported an inverse association between serum levels of IGFBP-2 and 
insulin (37). Other metabolic risk factors were not investigated. 
 In conclusion, SGA birth per se is not associated with altered IGFBP-2 levels. In 
contrast to short SGA children, young adults born SGA have significantly lower serum 
IGFBP-2 levels than references, and these correlated inversely with systolic and diastolic 
blood pressure, total cholesterol levels and triglycerides and positively with insulin 
sensitivity, also after correction for possible confounders including fat mass SDS. Hence, 
for this particular group of subjects, serum IGFBP-2 levels could serve as an independent 
cardiovascular risk marker. 
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The present thesis describes the studies investigating the influence of family history, 
preterm birth, genetic polymorphisms, and growth hormone treatment on metabolic 
and cardiovascular risk factors in SGA children with short stature. In addition, thyroid 
hormone levels during GH treatment and the association between serum IGFBP-2 levels 
and cardiovascular risk factors were studied. 
 In this chapter, results from the studies described in this thesis are discussed, 
also in view of current literature. Subsequently, clinical implications and conclusions are 
presented and directions for future research are given.
fAMily HiStory
Concern has been expressed regarding the possible detrimental effects of GH treatment 
in children with a possible increased risk to develop type 2 DM or CVD in later life (1-3). 
Therefore, it would be very informative to know which children have the highest risk to 
develop such diseases. As determinants of metabolic and cardiovascular disease are 
known to cluster in families (4, 5), family history could be a valuable indicator of the risk 
of a child to develop disease.
 In a group of 286 short SGA children and 482 parents, we compared anthropometry, 
blood pressure, fasting serum lipid, glucose and insulin levels with age- and sex-matched 
references. We also investigated whether these parameters correlated between parents 
and their offspring. Children had significantly higher systolic and diastolic blood pressure 
than sex- and height-matched references. Mothers had higher systolic blood pressure, 
fathers a higher body mass index (BMI) and parents had more often high fasting glucose 
levels than age- and sex-matched references. Twenty-four percent of mothers and 10% 
of fathers were born SGA but these parents did not have more cardiovascular risk 
factors than those born appropriate for gestational age. Cardiovascular risk factors did 
not correlate between parents and children. We concluded that parents of short SGA 
children have a modest increase in some cardiovascular risk factors but that there is no 
correlation between risk factors in parents and in children.
 This is the first study evaluating anthropometry and cardiovascular risk factors 
in a large cohort of short SGA children and their parents. Previous studies regarding 
intergenerational associations focused either on cardiovascular risk factors (4, 5) or on 
low birth weight or SGA (6) but not on the combination. 
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Clinical implications and conclusions
Our data indicate that there is no association between cardiovascular risk factors in 
parents and short SGA children. However, the children were young at the time of the 
study (mean age 6.4 years). Possibly the association does not develop before the 
offspring has reached adult age. Therefore it is mandatory to keep monitoring GH-treated 
and untreated SGA children into adulthood. This is the best way to investigate whether 
a family history of DM or CVD will predict which SGA children have the highest risk to 
develop disease.
tHyroid HorMone leVelS
The secretion and action of thyroid hormones and those of the GH/IGF-I axis are 
interdependent (7). Disturbances in serum thyroid hormone levels were reported for 
SGA children but the association with spontaneous catch-up growth and prematurity 
was unclear (8-10). In addition, the effect of growth hormone (GH) treatment on thyroid 
function had not been studied in short SGA children. To clarify these issues we evaluated 
serum thyroid hormone levels in short SGA children, in comparison with those of age-
matched controls, and evaluated the influence of gestational age and GH treatment.  
 In our population of 264 short SGA children, we found similar free T4 (FT4) levels 
as those in age-matched references. TSH levels were within the normal range but 
significantly higher than in age-matched references. When preterm and term born short 
SGA children were analyzed separately, FT4 adjusted for age was significantly higher 
in preterm children than in term children but both groups had similar FT4 levels as 
age-matched references. TSH was significantly higher compared to controls in preterm 
born children but not in term children. Notably, TSH levels were all within the normal 
range. There was no correlation between TSH and gestational age, birth length SDS or 
birth weight SDS. Other studies in smaller cohorts, reported increased (11) or normal 
(8, 10) TSH levels in SGA children compared with AGA children. One study investigated 
the influence of gestational age and reported a negative correlation between TSH and 
gestational age, independently from birth weight or birth length (10). Since we included 
much more SGA children and found no correlation between TSH levels and gestational 
age or size at birth, we consider the association between size at birth or gestational age 
and TSH levels to be weak and not clinically relevant.
 During GH treatment we observed a significant decrease in FT4 levels during the 
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first 6 months of GH, but levels remained within the normal range. The change in FT4 
levels was not associated with a change in TSH levels and there was no effect on the 
2-year-growth response. None of the children developed hypothyroidism. In other patient 
groups, GH treatment was also associated with a decline in serum FT4 without a change 
in TSH level (12-14). 
Clinical implications and conclusions
We demonstrated that alterations in serum thyroid hormone levels in preterm and term 
born short SGA children are very subtle, and within the normal range. During GH treatment 
FT4 levels declined but remained within the normal range and the decline in FT4 was not 
associated with a change in TSH levels. We therefore conclude that frequent monitoring 
of thyroid function during GH therapy is not warranted in short SGA children. This is in 
contrast to the monitoring of children with multiple pituitary hormone deficiencies who 
may develop true hypothyroidism during GH therapy (12). 
preMAturity
Short SGA children comprise a heterogeneous group also with respect to their gestational 
age, as some are born at term and others are born preterm. Despite this important 
difference, GH treatment is the same for all SGA children. The prenatal environment and 
genetic background might be different when there is a shorter duration of pregnancy. 
Therefore, preterm birth might be associated with a smaller size for gestational age, 
a different post-natal growth pattern and a different cardiovascular risk profile. To 
investigate whether this is the case we performed two studies within our large population 
of short SGA children. In the first study we evaluated growth and in the second study we 
evaluated cardiovascular risk factors.
 In our population of 392 short SGA children prematurity was indeed associated with 
a smaller size for gestational age (more severe SGA), and a shorter height corrected for 
target height and leaner phenotype in childhood. However, the response to GH treatment 
was similar for preterm and term short SGA children. Therefore preterm short SGA 
children should not be excluded from GH treatment. Ours was the first study evaluating 
whether the response to GH treatment is different for preterm and term born SGA children. 
 Both prematurity and SGA birth have been associated with increased metabolic and 
cardiovascular risk factors (1, 2, 15-18), but the combination of SGA and preterm birth 
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probably does not result in an additional increase of all risk factors (19). The independent 
effect of prematurity on GH-induced changes in metabolic and cardiovascular risk factors 
had not been evaluated. We compared short SGA children born preterm with short SGA 
children born at term, with respect to the change in cardiovascular risk factors during 
4 years of GH treatment. We found that preterm birth did not have an independent 
influence on the effect of GH on blood pressure, insulin sensitivity, beta cell function and 
body composition. Therefore, we concluded that GH treatment has the same effect on 
cardiovascular risk factors in preterm as in term short SGA children.
 Willemsen et al. investigated whether preterm birth is associated with an 
independent adverse risk profile in short SGA children and reported a lower body fat 
percentage, a higher systolic and diastolic blood pressure and a higher insulin secretion 
in preterm children compared with term children, whereas insulin sensitivity and lipid 
levels were not different (19). Other studies investigated the influence of birth weight 
SDS and gestational age on metabolic and cardiovascular risk factors in the general 
population (17, 20) or in populations of preterm born or low-birth-weight subjects (21-
25), of which only a small proportion was born SGA. As a result, these studies were not 
suitable to investigate whether preterm birth has an additional detrimental effect on the 
cardiovascular risk profile of short SGA children.
Clinical implications and conclusions
We have shown that it is justified to make no difference between short SGA children 
born preterm and short SGA children born at term when treating them with GH. The 
GH-induced catch-up growth and change in serum IGF-I and IGFBP-3 levels were similar 
for preterm and term short SGA children and GH treatment had the same effect on 
cardiovascular risk factors in preterm and term short SGA children.
GenetiC polyMorpHiSMS
Recent genome-wide association studies found various single nucleotide polymorphisms 
(SNPs) that associated with the risk to develop type 2 DM including PPAR-γ Pro12Ala 
and TCF7L2 rs7903146 (26-30). We studied associations between these genetic 
polymorphisms and metabolic and cardiovascular risk factors and growth in short SGA 
children.
 Short SGA children usually have a lean phenotype with a relatively low insulin 
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sensitivity and high blood pressure (1, 2, 15). GH treatment of short SGA children results 
in a decrease in blood pressure and insulin sensitivity, and an increase in BMI and 
insulin secretion (15, 31). However, not all GH-treated short SGA children demonstrate 
the same change in these determinants of cardiovascular disease, suggesting additional 
influencing factors such as genetic variations. When genetic variations would predict the 
change of important determinants of the risk for type 2 DM and cardiovascular disease 
during GH treatment, we might be able to predict how children would respond to GH 
treatment. Children who are less able to compensate for the GH-induced reduction in 
insulin sensitivity because they have a certain genetic variant, could then be monitored 
more closely during and after GH treatment.
 During GH treatment some SGA children remain lean while others demonstrate 
catch-up in BMI SDS. As the PPAR-γ gene is involved in lipid metabolism and adipocyte 
differentiation (32) it might be a response modifier to a triggering factor such as GH 
treatment. Other studies indicated that the effect of PPAR-γ on BMI is different in 
various phenotypes, which suggests gene-environment interactions (32, 33). We found a 
significantly higher increase in BMI SDS in carriers of the Ala12 allele but the frequency 
of the Ala12 allele was not different in subjects with catch-up in BMI SDS and subjects 
without catch-up in BMI SDS. The Ala12 allele was not associated with changes in 
determinants of metabolic and cardiovascular diseases. 
 In large populations of adults the T-variant of TCF7L2 rs7903146 was associated 
with reduced insulin secretion and a higher risk for type 2 DM (34-39). Insulin is the 
most important fetal growth factor and insulin-mediated fetal growth might therefore 
be affected by genetic factors that regulate fetal insulin sensitivity or insulin secretion 
before and after birth (40). In line with two other studies (41, 42) we found, however, no 
association between fetal TCF7L2 genotype and birth size. We extended the research 
on the association between TCF7L2 genotype and early growth by demonstrating 
that longitudinal growth patterns were also not associated with TCF7L2 genotype. We 
therefore concluded that, despite its supposed effect on insulin secretion, TCF7L2 does 
not influence fetal and postnatal growth. 
 As the TCF7L2 rs7903146 SNP was associated with insulin sensitivity and insulin 
secretion (34-38), it could be a marker predicting how well short SGA children are able to 
increase their insulin production during GH treatment. Children with less insulin secretion 
during GH-treatment might be more at risk to develop DM in later life. We demonstrated 
that presence of the TCF7L2 rs7903146 T allele was not associated with the increase 
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in insulin secretion during GH treatment. The decrease in insulin sensitivity compared 
to values at start was significant in the CT/TT group and not in the CC group, but the 
difference between the groups in decrease of insulin sensitivity was not significant. This 
merits further study. We concluded that TCF7L2 rs7903146 genotype does not predict 
how well a short SGA child can produce extra insulin during GH treatment. 
 
Clinical implications and conclusions
Our data show that the PPARγ Pro12Ala polymorphism was not associated with changes 
in the metabolic and cardiovascular risk profile and thus does not predict the response 
to GH treatment with regard to determinants for DM and CVD. Although we did not find 
an association with cardiovascular risk factors, there was a positive association of the 
Ala12 allele with weight gain during GH treatment. As this might be clinically relevant 
this finding warrants further investigation. The TCF7L2 rs7903146 T-variant was neither 
associated with spontaneous growth during the first years of life nor with the GH-induced 
changes in insulin secretion. The TCF7L2 rs7903146 T-variant was associated with a 
larger GH-induced decrease in insulin sensitivity but not significantly. When the T-variant 
indeed predicts a stronger decrease in insulin sensitivity it would be very interesting to 
investigate what happens with insulin sensitivity after discontinuation of GH treatment in 
subjects carrying this variant.
IGFBP-2 lEVElS AnD CARDIOVASCulAR RISK FACTORS
In a study population of 147 SGA children with short stature, we found similar IGFBP-2 
levels as in age and gender matched references. However in 151 SGA young adults 
with various heights (37 with a height SDS < -2), we found significantly lower IGFBP-2 
levels compared to age and gender matched references. Further analysis revealed that 
IGFBP-2 levels did not correlate with height SDS, birth weight SDS or birth length SDS but 
that there was a strong negative correlation with fat mass SDS. Since short SGA children 
had a low fat mass and SGA young adults had a higher fat mass, this might explain 
the observed difference in IGFBP-2 levels. There was no significant correlation between 
IGFBP-2 levels in short SGA children and metabolic and cardiovascular risk factors. In 
contrast, in the SGA young adults there were strong correlations between IGFBP-2 SDS 
and blood pressure, serum lipids and insulin sensitivity. These correlations persisted 
after adjustment for other covariates including fat mass SDS.
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 In SGA infants, IGFBP-2 levels have been reported to be higher than in references 
(43, 44) but data about IGFBP-2 levels in childhood are very scarce. Only one study 
compared IGFBP-2 levels in a small cohort of short SGA children with age-matched 
references and found high levels (45). IGFBP-2 levels in SGA young adults were unknown. 
IGFBP-2 levels are particularly interesting in subjects born SGA because they associate 
inversely with several cardiovascular risk factors in middle aged and older adults and in 
cancer patients (46-49). Subjects who were SGA at birth might have an increased risk to 
develop type 2 DM or CVD in adulthood, especially when there is catch-up in weight and 
fat accumulation (50-53). The association between IGFBP-2 levels and metabolic and 
cardiovascular risk factors had not yet been studied in subjects born SGA.
 The direction and degree of the associations between IGFBP-2 levels and estimates 
of glucose homeostasis, blood pressure and serum lipids in our study was in line with the 
associations found in other populations (46-49, 54, 55). IGFBP-2 levels adjusted for age 
and gender did not correlate with size at birth or height SDS. Serum levels of IGFBP-2 
show little diurnal variation and do not vary in response to meals or glucose infusions (56, 
57). We therefore hypothesize that IGFBP-2 levels might be an independent marker of 
cardiovascular risk in all patients. To confirm this hypothesis, DXA scans, FSIGTs, serum 
lipids, blood pressure and IGFBP-2 levels should be measured in a large population of 
healthy young adults.
Clinical implications and conclusions 
Our data show that IGFBP-2 levels are not associated with SGA birth or height SDS but 
strongly associate with fat mass. In short SGA children with a low fat mass SDS, there 
is no association between IGFBP-2 levels and blood pressure, glucose homeostasis 
and serum lipids but in SGA young adults with a higher fat mass IGFBP-2 is inversely 
associated with the metabolic risk profile. Higher IGFBP-2 levels are independently 
associated with a lower blood pressure, better insulin sensitivity and lower serum lipids. 
Serum IGFBP-2 level is an independent cardiovascular risk marker in young adults who 
were born SGA and possibly also in all adults.
GenerAl ConCluSionS
The observation by Barker et al. that men with the lowest birth weights had the highest risk 
to die from a myocardial infarction, has led to the initiation of many studies investigating 
Proefschrift Sandra W.K de Kort 20-08-09.indd   204 13-09-2009   16:59:02
204 205
chapter 
10
G
en
er
al
 D
is
cu
ss
io
n
the association between low birth weight and metabolic and cardiovascular disease in 
later life. Since GH treatment was approved for short SGA children, they comprise a large 
group of GH-treated children. Because of the metabolic effects of GH treatment, it is 
important to know which SGA children have the highest risk to develop type 2 DM or 
CVD in adulthood and to predict the effect of GH treatment on this risk. In this thesis we 
investigated the influence of family history, prematurity, genetic polymorphisms, serum 
IGFBP-2 levels, and GH treatment on several metabolic risk determinants in short SGA 
children. Table 1 summarizes the most important recent findings from trials in SGA 
subjects performed by our research group.
 In summary, our results do not provide evidence that determinants of metabolic 
and cardiovascular disease or the change in those determinants during long-term GH 
treatment associates with a family history of type 2 DM or CVD, preterm birth or TCF7L2 
genotype. PPARγ genotype possibly predicts weight gain during GH treatment but this 
needs to be confirmed in other cohorts. Serum IGFBP-2 levels associate with several 
determinants of metabolic and cardiovascular disease but only in SGA young adults and 
not in childhood. 
direCtionS for future reSeArCH
Growth hormone has well-known anti-insulinemic effects, such as a reduction in insulin 
sensitivity. TCF7L2 has repeatedly been found to associate with insulin secretion 
(34-38). We had the opportunity to accurately measure insulin sensitivity and insulin 
secretion in a sample of short SGA children by means of FSIGT. We found no association 
between TCF7L2 genotype and the change in insulin secretion but there seemed to be 
an association with the decrease in insulin sensitivity. Because of our sample size we 
could only detect large effects. It would be very interesting to perform FSIGT tests during 
GH treatment in a larger group of short SGA children to provide a definitive answer to the 
question whether the decrease in insulin sensitivity associates with TCF7L2 rs7903146 
genotype. 
 As the PPAR-γ Pro12Ala polymorphism is reported to associate with BMI and 
weight gain (33, 58-60) and we also observed an association with weight gain during 
GH treatment, it would be very interesting to investigate whether this polymorphism also 
associates with postnatal spontaneous catch-up growth in weight in SGA children. 
 Serum IGFBP-2 levels were not only associated with determinants of the risk for 
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cardiovascular disease and DM (54) but also with bone growth and metabolism (61) 
(62). Size at birth and during childhood may affect bone mineral density (BMD) and the 
risk of osteoporotic fracture in adulthood (63). In short SGA children, lumbar spine BMD 
adjusted for height was reported to be significantly lower than normal (64). Therefore it 
will be interesting to investigate IGFBP-2 levels in subjects born SGA in association with 
BMD. 
 In addition it remains important to perform long-term follow-up studies at regular 
intervals in SGA cohorts after discontinuation of GH treatment. When we know which 
subjects may eventually develop adult diseases we could investigate whether GH 
treatment improves or worsens this risk. It will be very interesting to investigate previously 
GH treated SGA subjects at an age when type 2 DM and CVD develop in the general 
population. The majority of the children benefits from GH treatment with an increase in 
height but since GH treatment was only licensed in 2001 long-term follow up data are not 
yet available. These are important research question for future studies. 
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Table 1. What have we learned about cardiovascular risk factors in Dutch children and young adults born SGA? 
Name author/researcher
Catch-up in weight
- Fat accumulation during childhood is associated with reduced insulin 
sensitivity and increased serum lipids and blood pressure in early adult-
hood, independent of size at birth. 
- Weight gain relative to height gain in the fi rst three months of life is 
associated with an unfavourable cardiovascular and metabolic profi le in 
early adulthood.
R.W.J. Leunissen (53, 65, 66)
Family history 
- Parents of short SGA children have a modest increase in some cardio-
vascular risk factors but there is no correlation between blood pressure, 
lipid levels and glucose homeostasis in parents and their children.
S.W.K. de Kort (this thesis)(67)
Prematurity
- preterm short SGA children have a lower body fat percentage, higher 
blood pressure and higher insulin secretion than term short SGA children, 
whereas insulin sensitivity and lipid levels are comparable.
- GH treatment has the same effect on cardiovascular risk factors in 
preterm as in term short SGA children.
R.H. Willemsen (19) 
S.W.K. de Kort (this thesis)(68)
Genetic polymorphisms
- The rs7903146 polymorphism of TCF7L2 is not associated with the 
increase in insulin secretion during GH treatment.
- The Pro12Ala polymorphism of PPAR-γ positively associates with weight 
gain during GH treatment but not with the change in other cardiovascular 
risk factors.
S.W.K. de Kort (this thesis)(69)
IGFBPs
- Both IGFBP-1 and IGFBP-2 were similar to controls in short SGA chil-
dren with a low fat mass and lower than controls in young SGA adults with 
a normal or increased fat mass.
- IGFBP-1 correlated inversely with systolic blood pressure, insulin and 
triglycerides and positively with HDL-cholesterol.
- In young SGA adults, IGFBP-2 levels associated independently and 
inversely with blood pressure, cholesterol and triglycerides and positively 
with insulin sensitivity.
- IGFBP-1 and IGFBP-2 might serve as markers to identify subjects with 
an adverse metabolic outcome.
D.C.M. van der Kaay (70)
S.W.K. de Kort (this thesis)
Growth hormone treatment
- GH treatment in short SGA children did not negatively infl uence glucose 
levels.
- GH treatment induced higher insulin levels and lower insulin sensitivity, 
but these effects were completely reversible after discontinuation of GH 
treatment.
- GH treatment associated with a decrease of blood pressure and serum 
cholesterol levels and these effects remained until 6.5 years after discon-
tinuation of GH.
- GH treatment induced a decrease in body fat percentage.
- After stop of GH treatment, body fat percentage increases and lean body 
mass decreases but values remain well within the normal range.
M.van Dijk (71)
R.H. Willemsen (72)
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Chapter 1
This chapter provides an introduction in the definitions, prevalence and possible causes 
of SGA birth. Furthermore, clinical and endocrinological aspects associated with SGA are 
described, such as short stature, the GH-IGF-IGFBP axis, the limited available data on 
thyroid hormones, the association with cardiovascular disease (CVD) and type 2 diabetes 
mellitus (type 2 DM), family history for CVD and type 2 DM and genetic polymorphisms. 
This chapter also gives a summary of previously reported effects of GH treatment on 
growth and the GH-IGF-IGFBP axis in short SGA children. Finally, the aims and outline of 
this thesis are presented.
Chapter 2
An increased prevalence of cardiovascular risk factors at a young age had been 
described in SGA children with short stature. It was not known whether this increased 
risk is caused by their size at birth, a familial predisposition for cardiovascular disease 
or smallness at birth or a combination of these factors. The cardiovascular risk profile 
of parents of SGA children had never been investigated. We compared anthropometry, 
blood pressure, fasting serum lipid, glucose, and insulin levels of 482 parents and 286 
short SGA children with age-and gender-matched references. In addition, we investigated 
whether these parameters correlated between parents and their children. We found a 
higher blood pressure in mothers, a higher BMI in fathers and more frequently high 
fasting glucose levels than age- and gender matched references in both mothers and 
fathers. The short SGA children had significantly higher systolic and diastolic blood 
pressure than gender- and height-matched references. Twenty-four percent (mothers) 
and 10% (fathers) were born SGA but they did not have more cardiovascular risk factors 
than parents born AGA. Cardiovascular risk factors did not correlate between parents 
and children. In conclusion, our study shows that parents of short SGA children have a 
modest increase in some cardiovascular risk factors but there is no correlation between 
risk factors in parents and children.
Chapter 3
Disturbances in thyroid function had been described in SGA children but the influence 
of prematurity was unclear. As normal thyroid function is necessary for growth and 
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development, it is important to know whether GH treatment alters thyroid function. 
Studies concerning thyroid hormone levels in SGA children were very limited and the 
effect of GH administration on thyroid function in these children had not been studied 
yet. We measured TSH and free T4 (FT4) levels before and during 2 years of GH treatment 
in 264 short SGA children who were divided in those born preterm and those born at 
term. We found higher, though normal TSH levels in preterm born short SGA children 
compared with age-matched controls. TSH levels in term short SGA children were not 
different than in controls. Mean FT4 at baseline was not different between short SGA 
children and controls. TSH and FT4 levels did not correlate with gestational age, birth 
weight SDS or birth length SDS. During GH treatment, FT4 decreased but was neither 
associated with an increase in TSH nor did it affect the growth response to GH treatment. 
Because these mild alterations in thyroid function do not appear clinically relevant, we 
conclude that frequent monitoring of thyroid function during GH therapy is not warranted 
in short SGA children.
Chapter 4
Short SGA children comprise a heterogeneous group, also because some are born at 
term and others are born preterm. Despite this important difference, all SGA children are 
treated with the same dose of growth hormone. Prematurity might have a detrimental 
effect on spontaneous postnatal growth. When preterm short SGA children suffer 
from extra growth impairment during their neonatal period, this may result in a height 
significantly below the genetic height potential of the child. This could lead to a smaller 
GH-induced catch-up growth in preterm born short SGA children than in those born at 
term. We investigated in a longitudinal 3-year GH study, whether prematurity has an 
independent influence on the response to GH treatment in short SGA children. Adjusted 
for gestational age, preterm short SGA children were lighter and smaller at birth than term 
short SGA children. Preterm children also had a shorter height adjusted for target height 
and a leaner phenotype than children born at term. Despite the differences in body size, 
there were no significant differences in age- and sex-adjusted IGF-I and IGFBP-3 levels. 
The response to GH treatment was similar for preterm and term born short SGA children. 
Therefore, preterm short SGA children should not be excluded from GH treatment. 
Chapter 5
Both SGA and preterm birth had been associated with increased incidence of adult 
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cardiovascular disease and type 2 DM. Short SGA children who were born preterm 
have a lower body fat percentage and a higher blood pressure, insulin secretion and 
disposition index than short SGA children born at term. It was unknown whether preterm 
birth also influences these parameters during GH treatment. We compared blood 
pressure, insulin sensitivity, beta-cell function and body composition during 4 years of 
GH treatment between 143 preterm and 261 term short SGA children. We demonstrate 
that GH treatment resulted in a similar decrease in systolic and diastolic blood pressure, 
body fat percentage, limb fat/total fat ratio and insulin sensitivity, and a similar increase 
in insulin secretion and disposition index. Lean body mass adjusted for gender and 
height increased in term children while it did not change in preterm children but multiple 
regression analysis revealed that this difference in change of lean body mass was not 
associated with gestational age. We conclude that the effect of GH treatment on metabolic 
and cardiovascular risk factors is similar in preterm and term short SGA children.
Chapter 6
The Pro12Ala polymorphism of the PPAR-γ gene had been inversely associated with BMI, 
changes in BMI and the risk to develop type 2 DM. Short SGA children are lean and have 
a lower insulin sensitivity and higher blood pressure. GH treatment results in weight gain, 
and a decrease in blood pressure and insulin sensitivity. However, not all children respond 
in the same way. We analyzed the contribution of the PPARγ Pro12Ala polymorphism 
to GH induced changes in determinants of metabolic and cardiovascular disease in 
238 Caucasian short SGA children. We found no association between the Ala12 allele 
and baseline anthropometry, blood pressure, serum lipids, insulin sensitivity, insulin 
secretion and disposition index. However, after 4 years of GH-treatment, the increase 
in weight for height SDS and BMI SDS was significantly greater in carriers of an Ala12 
allele than in non-carriers. The change in all other parameters was not associated with 
Pro12Ala genotype. In conclusion, the Ala12 variant of PPARγ might be associated with 
higher weight gain during GH-treatment but this variant is not associated with changes in 
determinants of metabolic and cardiovascular diseases in subjects born SGA.
Chapter 7
Since insulin is the most important growth factor in fetal life, the reported inverse 
association between birth weight and the risk to develop type 2 DM in adulthood might 
be explained by common genetic variants related to insulin secretion and resistance. 
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TCF7L2 rs7903146 had been shown to have a genetic effect on the risk to develop type 
2 DM and this result had been replicated in several studies. In this study we investigated 
whether the TCF7L2 rs7903146 polymorphism is associated with growth patterns from 
fetal life until infancy in a population-based cohort and in a cohort of subjects born SGA. 
We found a similar minor allele frequency in the SGA cohort as in the general population, 
so the polymorphism was not associated with an increased risk of SGA birth. In both the 
SGA cohort and the general population, there were no differences between the genotypes 
in gestational age or size at birth and the TCF7L2 rs7903146 polymorphism was also not 
associated with growth in fetal and early postnatal life. 
Chapter 8
The TCF7L2 rs7903146 polymorphism might increase the risk to develop type 2 DM 
by decreasing insulin secretion. SGA birth has been associated with type 2 DM in later 
life while GH treatment reduces insulin sensitivity and increases insulin secretion. 
This makes GH-treated SGA children an ideal group to investigate whether TCF7L2 
rs7903146 genotype is associated with changes in glucose homeostasis. In a cohort of 
246 Caucasian short SGA children, we found no association between TCF7L2 rs7903146 
genotype and insulin sensitivity or insulin secretion at baseline. After adjustment for 
possible confounders, insulin secretion was higher in carriers of a T-allele than in non-
carriers. During 4 years of GH treatment, the increase in insulin secretion was, however, 
not associated with TCF7L2 rs7903146 genotype. The decrease in insulin sensitivity was 
only significant in carriers of the T-allele, but the difference between genotype groups 
did not reach significance. In conclusion, the TCF7L2 rs7903146 polymorphism does 
not predict how well a child is capable of producing extra insulin to compensate for the 
reduced insulin sensitivity induced by GH treatment. With regard to the effect of this 
polymorphism on the decrease in insulin sensitivity a larger sample size will allow more 
definite conclusions.
Chapter 9
IGFBP-2 levels might protect against cardiovascular disease. In several adult populations, 
serum concentrations of IGFBP-2 were inversely associated with insulin levels, HOMA 
insulin resistance, BMI, and fat mass. In subjects born SGA, the association between 
IGFBP-2 levels and metabolic and cardiovascular risk factors had not yet been studied. 
Our aim was to determine circulating IGFBP-2 levels in subjects born SGA, compare 
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these levels to those found in age and gender-matched controls with normal stature, 
and to investigate the association with metabolic and cardiovascular risk factors. We 
found significantly decreased IGFBP-2 levels in SGA young adults only. Fat mass SDS 
was higher than average in young adults and reduced (< -2 SDS) in short children. Serum 
IGFBP-2 SDS values for SGA young adults correlated positively with insulin sensitivity 
(Si), and negatively with fat mass SDS, insulin secretion (AIR), fasting insulin, HOMA-IR, 
blood pressure SDS, total cholesterol, and triglycerides. The association between serum 
IGFBP-2 SDS and Si, blood pressure, total cholesterol and triglycerides levels remained 
significant after adjustment for fat mass SDS and other known covariates. In short SGA 
children, IGFBP-2 SDS did not correlate with any of the cardiovascular risk factors. In 
conclusion, serum IGFBP-2 SDS is an independent cardiovascular risk marker in young 
adults who were born SGA but not in short SGA children. 
Chapter 10
In the general discussion, we discuss our findings in a broader context. The chapter ends 
with general conclusions and suggestions for further research.
Proefschrift Sandra W.K de Kort 20-08-09.indd   222 13-09-2009   16:59:04
222 223
chapter 
11
Su
m
m
ar
y
Proefschrift Sandra W.K de Kort 20-08-09.indd   223 13-09-2009   16:59:04
Proefschrift Sandra W.K de Kort 20-08-09.indd   224 13-09-2009   16:59:04
Summary in Dutch
Acknowledgments
Curriculum Vitae
list of publications
chapter 12
Proefschrift Sandra W.K de Kort 20-08-09.indd   225 13-09-2009   16:59:04
226
chapter 
12
Su
m
m
ar
y 
in
 D
ut
ch
227
SAMenVAttinG
Hoofdstuk 1
Dit hoofdstuk beschrijft de definities, prevalentie en verschillende oorzaken van SGA. 
Ook wordt er een overzicht gegeven van klinische en endocrinologische aspecten van 
SGA, zoals een te kleine lichaamslengte, de GH-IGF-IGFBP-as, mogelijke veranderingen 
in schildklierhormoon concentraties, de gerapporteerde associatie met het krijgen 
van hart- en vaatziekten en type 2 Diabetes Mellitus (type 2 DM) op latere leeftijd, 
prevalentie van hart- en vaatziekten in de familie en variaties in het DNA. Dit hoofdstuk 
geeft ook een samenvatting van eerder gerapporteerde effecten van groeihormoon 
(GH)-behandeling op de groei en GH-IGF-IGFBP-as van te kleine SGA kinderen. Aan het 
eind van dit hoofdstuk worden de doelstellingen van de studies en de indeling van dit 
proefschrift besproken.
Hoofdstuk 2
Te kleine SGA kinderen hebben mogelijk al op vrij jonge leeftijd risicofactoren voor 
het op latere leeftijd krijgen van hart- en vaatziekten of type 2 DM. Het was echter 
nog niet bekend of het hebben van risicofactoren voor deze ziekten veroorzaakt wordt 
doordat deze kinderen te klein waren bij de geboorte (SGA), door het vaker voorkomen 
van hart- en vaatziekten, type 2 DM of SGA in de familie, of door een combinatie van 
deze factoren. Er was nog nooit onderzocht of de ouders van te kleine SGA kinderen 
cardiovasculaire risicofactoren hebben. Wij vergeleken lichaamsmetingen, bloeddruk, 
nuchtere vetspiegels, glucoseconcentraties en insulineconcentraties van 482 ouders en 
286 te kleine SGA kinderen met een controlegroep met dezelfde leeftijd en geslacht. 
Ook onderzochten we of er een verband was tussen deze parameters bij ouders en 
hun kinderen. Vergeleken met de controlegroep hadden de moeders een hogere 
bloeddruk, de vaders een hogere BMI en moeders en vaders vaker hoge nuchtere 
glucose spiegels. De te kleine SGA kinderen hadden een significant hogere systolische 
en diastolische bloeddruk dan andere kinderen met dezelfde lengte en van hetzelfde 
geslacht. Vierentwintig procent van de moeders en 10% van de vaders was zelf SGA bij 
de geboorte maar deze ouders hadden niet meer cardiovasculaire risicofactoren dan 
ouders met een normale grootte (AGA) bij de geboorte. Er was geen verband tussen de 
aanwezigheid van risicofactoren bij ouders en hun kinderen. Wij concluderen daarom 
dat ouders van te kleine SGA kinderen iets meer risicofactoren voor hart- en vaatziekten 
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tussen ouders en kinderen.
Hoofdstuk 3
Het zou kunnen dat SGA geboorte geassocieerd is met een veranderde schildklierfunctie 
maar of prematuriteit hier iets mee te maken heeft was nog niet duidelijk. Voor groei 
en ontwikkeling is een goed werkende schildklier nodig en daarom is het belangrijk om 
te weten of GH-behandeling de werking van de schildklier beïnvloedt. Er was echter 
nog maar heel weinig onderzoek gedaan naar de schildklierhormoon spiegels bij SGA 
kinderen en het effect van GH-behandeling was helemaal nog niet onderzocht. Wij 
hebben bij 264 te kleine SGA kinderen TSH en vrij T4 spiegels gemeten voor aanvang van 
de GH-behandeling en gedurende de twee jaar daarna. Een deel van de kinderen was 
prematuur geboren en een deel aterm waardoor we ook het effect van vroeggeboorte 
konden onderzoeken. We vonden hoger dan gemiddelde (maar wel normale) TSH 
spiegels bij prematuur geboren SGA kinderen en gemiddelde TSH spiegels bij aterm 
geboren SGA kinderen. Voor aanvang van de GH-behandeling hadden te kleine SGA 
kinderen een normale vrij T4 spiegel. Er was geen verband tussen de TSH en vrij T4 
spiegels en zwangerschapsduur, geboortegewicht SDS of geboortelengte SDS. Tijdens 
de GH-behandeling daalde de vrij T4 concentratie maar deze daling ging niet samen 
met een stijging van de TSH concentratie en had ook geen invloed op de groei. Omdat 
deze milde veranderingen in schildklierfunctie geen klinische relevantie lijken te hebben, 
concluderen wij dat het bij GH-behandeling van te kleine SGA kinderen voldoende is om 
één keer per jaar de schildklierfunctie te controleren.
Hoofdstuk 4
De groep te kleine SGA kinderen is heterogeen, ook omdat sommige kinderen te vroeg 
geboren zijn en andere aterm. Ondanks dit belangrijke verschil worden alle SGA kinderen 
met dezelfde dosis groeihormoon behandeld. Prematuriteit kan een negatieve invloed 
hebben op de spontane groei na de geboorte. Als te vroeg geboren SGA kinderen een 
extra groeiafbuiging na de geboorte hebben zou het kunnen dat hun lengte nog verder 
onder de voor hun genetisch normale lengte uitkomt. Hierdoor zou de inhaalgroei van 
prematuur geboren SGA kinderen tijdens GH-behandeling minder kunnen zijn dan bij 
aterme SGA kinderen. Wij onderzochten of prematuriteit een onafhankelijke invloed 
heeft op het effect van 3 jaar GH-behandeling bij te kleine SGA kinderen. Na correctie 
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voor de zwangerschapsduur, waren de premature kleine SGA kinderen lichter en 
kleiner bij de geboorte dan de aterme kinderen. Bij aanvang van de GH-behandeling 
hadden de premature kinderen na correctie voor de lengte van de ouders, een kleinere 
lengte en slankere lichaamsbouw dan aterme kinderen. Ondanks deze verschillen in 
lichaamsgrootte was er geen verschil in voor leeftijd en geslacht gecorrigeerde IGF-I en 
IGFBP-3 spiegels. Ook de veranderingen in lichaamsgrootte en –samenstelling en in 
IGF-I en IGFBP-3 spiegels waren vergelijkbaar voor premature en aterme SGA kinderen. 
De conclusie is daarom dat prematuur geboren SGA kinderen met een te kleine lengte 
baat hebben bij GH-behandeling, vergelijkbaar met aterm geboren SGA kinderen.
Hoofdstuk 5
In sommige studies werd gevonden dat zowel SGA als prematuriteit geassocieerd zijn 
met een grotere kans om op latere leeftijd hart- en vaatziekten of type 2 DM te krijgen. 
Premature SGA kinderen hebben een lager vetpercentage en een hogere bloeddruk, 
insuline secretie en dispositie index dan aterme SGA kinderen. Het was echter nog niet 
bekend of prematuriteit ook een onafhankelijk effect heeft op de verandering van deze 
parameters tijdens GH-behandeling. Wij hebben gedurende 4 jaar GH-behandeling 
143 premature SGA kinderen vergeleken met 261 aterme SGA kinderen wat betreft 
hun bloeddruk, insuline gevoeligheid, bèta cel functie en lichaamssamenstelling. In 
dit onderzoek tonen we aan dat tijdens GH-behandeling de systolische en diastolische 
bloeddruk, het percentage lichaamsvet, de verhouding perifeer vet / totaal vet en de 
insulinegevoeligheid evenveel daalt bij premature als aterme SGA kinderen. Ook de 
toename in insuline secretie en dispositie index was vergelijkbaar. De spiermassa 
gecorrigeerd voor lengte en geslacht nam toe bij de aterme kinderen en bleef onveranderd 
laag bij de prematuur geborenen. Dit verschil in verandering van spiermassa bleek 
echter niet samen te hangen met het verschil in zwangerschapsduur. De conclusie is 
daarom dat het effect van GH-behandeling op risicofactoren voor hart- en vaatziekten en 
type 2 DM hetzelfde is bij prematuur geboren SGA kinderen als bij aterm geboren SGA 
kinderen.
Hoofdstuk 6
Het Pro12Ala polymorfisme van het PPAR-γ gen vertoont een negatieve associatie 
met BMI, veranderingen in BMI en de kans op het ontwikkelen van type 2 DM. Te 
kleine SGA kinderen zijn slank en hebben vergeleken met het gemiddelde een lagere 
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insulinegevoeligheid en hogere bloeddruk. GH-behandeling zorgt voor een toename in 
gewicht en een afname van de insulinegevoeligheid en bloeddruk. Deze veranderingen 
zijn echter niet bij alle kinderen even groot. Wij hebben bij 238 te kleine SGA kinderen 
onderzocht wat de bijdrage is van het PPARγ Pro12Ala polymorfisme aan de veranderingen 
in risicofactoren voor hart- en vaatziekten en type 2 DM tijdens GH-behandeling. Voor 
aanvang van de GH-behandeling was er geen verband tussen het hebben van het Ala12 
allel en lichaamsafmetingen, bloeddruk, serumspiegels lipiden, insulinegevoeligheid, 
insulinesecretie en dispositie index. Na vier jaar GH-behandeling was de toename in 
gewicht SDS en in BMI SDS significant groter bij dragers van een Ala12 allel dan bij 
niet-dragers. De verandering in alle andere risicofactoren tijdens de 4 jaar behandeling 
was niet geassocieerd met het Pro12Ala genotype. Wij concluderen dat bij SGA geboren 
kinderen de Ala12 variant van PPARγ mogelijk geassocieerd is met gewichtstoename 
tijdens GH-behandeling, maar dat deze variant bij SGA geborenen niet geassocieerd is 
met risicofactoren voor hart- en vaatziekten of type 2 DM.
Hoofdstuk 7
Voor een foetus is insuline de belangrijkste groeifactor. Het omgekeerde verband tussen 
geboortegewicht en het risico om als volwassene type 2 DM te krijgen zou daarom 
verklaard kunnen worden door variaties in het DNA die iets te maken hebben met 
insulinesecretie en insulineresistentie. Meerdere studies hebben aangetoond dat de 
T-variant van TCF7L2 rs7903146 effect heeft op de kans om type 2 DM te krijgen. In dit 
onderzoek hebben wij onderzocht of het TCF7L2 rs7903146 T-allel geassocieerd is met 
groeipatronen van de foetale periode tot de leeftijd van 2 jaar. Wij hebben dit onderzocht 
in een cohort dat een afspiegeling is van de algemene populatie en in een cohort van 
SGA geboren kinderen. Het T-allel bleek even vaak voor te komen in het SGA cohort 
als in de algemene populatie dus deze variant leek niet geassocieerd te zijn met een 
grotere kans om SGA geboren te worden. In beide populaties was er geen verschil in 
zwangerschapsduur of grootte bij de geboorte tussen dragers van het T-allel en niet-
dragers. Het T-allel was ook niet geassocieerd met groei in de foetale periode en in de 
eerste twee levensjaren.
Hoofdstuk 8
Mogelijk verhoogt het TCF7L2 rs7903146 polymorfisme de kans om type 2 DM te 
krijgen doordat het de insulinesecretie doet afnemen. SGA geboorte is geassocieerd 
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met een grotere kans op het ontstaan van type 2 DM. Van GH-behandeling is bekend 
dat het de insulinegevoeligheid verlaagt en de insulinesecretie doet toenemen. SGA 
kinderen die met GH behandeld worden zijn daarom een zeer geschikte groep om te 
onderzoeken of het TCF7L2 rs7903146 genotype geassocieerd is met veranderingen 
in de glucosehuishouding. Wij vonden, in een groep van 246 te kleine SGA kinderen, 
geen verband tussen het TCF7L2 rs7903146 genotype en insulinegevoeligheid of 
insulinesecretie. Wanneer er gecorrigeerd werd voor mogelijk beïnvloedende factoren 
dan was de insulinesecretie hoger bij kinderen met een TCF7L2 rs7903146 T-allel 
dan bij kinderen zonder T-allel. Tijdens 4 jaar GH-behandeling was de toename in 
insulinesecretie vergelijkbaar bij kinderen met en kinderen zonder T-allel. Er was alleen 
een significante afname van de insulinegevoeligheid bij kinderen met een T-allel, maar 
het verschil in daling van de insulinesecretie tussen de groep met een T-allel en de 
groep zonder T-allel was niet significant. De conclusie is daarom dat variatie in TCF7L2 
rs7903146 niet voorspelt hoe goed een kind zijn insulinesecretie kan verhogen om te 
compenseren voor de afgenomen insulinegevoeligheid als gevolg van GH-behandeling. 
Een grotere groep kinderen zal onderzocht moeten worden om erachter te komen of dit 
polymorfisme invloed heeft op de afname in insulinegevoeligheid.
Hoofdstuk 9
Het zou kunnen dat hogere IGFBP-2 spiegels beschermen tegen het krijgen van hart- 
en vaatziekten. Bij volwassenen is de IGFBP-2 concentratie omgekeerd geassocieerd 
met insulinespiegels, HOMA insulineresistentie, BMI en vetmassa. Bij mensen die SGA 
geboren zijn was het verband tussen IGFBP-2 spiegels en risicofactoren voor hart- en 
vaatziekten en type 2 DM nog niet onderzocht. Wij hebben de IGFBP-2 concentratie 
gemeten bij kinderen met een te kleine lengte en jongvolwassenen met een normale of 
te kleine lengte die SGA waren bij de geboorte. Wij hebben deze concentraties vergeleken 
met die van controlepersonen met dezelfde leeftijd en geslacht en een normale lengte. 
Ook onderzochten we het verband tussen de IGFBP-2 concentratie en cardiovasculaire 
risicofactoren. Alleen bij de jongvolwassenen was de IGFBP-2 concentratie significant 
lager dan in de controlegroep. De vetmassa was hoger dan gemiddeld bij de 
jongvolwassenen en lager dan gemiddeld bij de kinderen. Wij vonden een positieve 
relatie tussen IGFBP-2 en insulinegevoeligheid en een negatieve relatie tussen IGFBP-2 
en vetmassa, insulinesecretie, nuchtere insuline spiegels, HOMA-IR, bloeddruk, totale 
cholesterol concentratie en triglyceriden concentratie. Het verband tussen IGFBP-2 
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en insulinegevoeligheid, bloeddruk, cholesterol en triglyceriden bleef ook bestaan als 
we corrigeerden voor vetmassa en andere beïnvloedende factoren. Bij de te kleine 
SGA kinderen was er geen verband tussen IGFBP-2 en cardiovasculaire risicofactoren. 
Onze resultaten laten zien dat laag IGFBP-2 bij SGA geboren jongvolwassenen een 
onafhankelijke risicofactor voor het krijgen van hart- en vaatziekten is.   
Hoofdstuk 10
In de algemene discussie worden de resultaten van de verschillende studies besproken 
en vergeleken met de literatuur. Wij sluiten dit hoofdstuk af met algemene overwegingen 
en suggesties voor toekomstig onderzoek.
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